Herbert Kim Lyerly
George Barth Geller Distinguished Professor of Immunology
Current Appointments & Affiliations
- George Barth Geller Distinguished Professor of Immunology, Surgery, Surgical Sciences, Surgery 2004
- Professor of Surgery, Surgery, Surgical Sciences, Surgery 2011
- Professor in Immunology, Integrative Immunobiology, Basic Science Departments 2017
- Professor of Pathology, Pathology, Clinical Science Departments 2018
- Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 1983
- Affiliate, Duke Global Health Institute, Duke Global Health Institute, University Institutes and Centers 2014
- Core Faculty Member, Duke-Margolis Center for Health Policy, Duke - Margolis Center For Health Policy, Initiatives 2020
- Affiliate of the Duke Regeneration Center, Regeneration Next Initiative, Basic Science Departments 2021
Contact Information
- 203 Research Drive, Rm 433B, Box 2606, Durham, NC 27710
- Box 2606 Med Ctr, Durham, NC 27710
-
lyerl001@mc.duke.edu
(919) 681-8350
- Background
-
Education, Training, & Certifications
- M.D., University of California - Los Angeles 1983
-
Previous Appointments & Affiliations
- Associate Professor of Pathology, Pathology, Clinical Science Departments 1998 - 2018
- Assistant Professor in Immunology, Integrative Immunobiology, Basic Science Departments 1995 - 2016
- Director, Duke Comprehensive Cancer Center in the School of Medicine, School of Medicine, Duke University 2003 - 2013
- Professor of Surgery, Surgical Oncology, Surgery 1997 - 2011
- Assistant Professor of Pathology, Pathology, Clinical Science Departments 1994 - 1998
- Associate Professor of Surgery with Tenure, Surgery, Clinical Science Departments 1994 - 1997
- Assistant Professor of Surgery, Surgery, Clinical Science Departments 1990 - 1994
-
Academic Positions Outside Duke
- Visiting Fellow, Cambridge University. 2022
- Commisioner, North Carolina Environmental Management Commission. 2022 - 2025
- Life Member, Cambridge University, Clare Hall. 2022 - 2030
- Visiting Fellow, Cambridge University. 2019
- Recognition
-
In the News
-
JUL 13, 2021 Duke Health News -
APR 20, 2020 Reuters -
DEC 2, 2019 Duke Health News -
AUG 19, 2019 TheHill.com -
MAR 11, 2019 Duke Health News -
SEP 24, 2018 -
SEP 18, 2018 Duke Health News -
SEP 18, 2018 Duke Health News -
SEP 17, 2014 NPR’s “All Things Considered -
JUN 25, 2014 WUNC -
JUN 23, 2014 -
JUN 23, 2014 CBC News -
JUN 23, 2014 The News & Observer
-
-
Awards & Honors
- Visiting Fellow. Cambridge University. 2019
- National Cancer Institute Directors Service Award. National Cancer Institute. 2014
- National Cancer Advisory Board. National Cancer Institute. 2013
- National Cancer Advisory Board. National Cancer Institute. 2012
- National Cancer Advisory Board. National Cancer Institute. 2011
- National Cancer Advisory Board. National Cancer Institute. 2010
- National Cancer Advisory Board. National Cancer Institute. 2009
- National Cancer Advisory Board. National Cancer Institute. 2008
- Expertise
-
Global Scholarship
- Research
-
Selected Grants
- Visualizing tumor heterogeneity in an immune intact and autochthonous mouse model of breast cancer awarded by National Institutes of Health 2021 - 2026
- Therapeutic targeting of breast cancer and host immune responses at inflection points in the disease trajectory awarded by Department of Defense 2021 - 2025
- Mouse Paint: A massively combinatorial approach for illuminating tumor heterogeneity in True Color awarded by National Institutes of Health 2022 - 2025
- Enabling effective anti-tumor immunity from targeted antibodies through dual innate and adaptive immune checkpoint blockade in non-immunogenic cancers awarded by National Institutes of Health 2019 - 2024
- Duke University Program in Environmental Health awarded by National Institutes of Health 2019 - 2024
- Viral Oncology Training Grant awarded by National Institutes of Health 1980 - 2024
- Beyond PD1: An immunotherapeutic strategy to stimulate and enable both T-cell and B-cell responses in immunosuppressive and non-mutated metastatic breast cancer awarded by Department of Defense 2020 - 2024
- Determinants of geographic disparities in mortality and multimorbidity in the U.S. awarded by National Institutes of Health 2019 - 2024
- Hebei Bio-High Technology Visiting Researcher Training awarded by Hebei Bio-High Technology Development CO. LTD 2020 - 2022
- Defining the Rules of Breast Cancer Cell Traffic Through Bone awarded by National Institutes of Health 2017 - 2022
- Detection and Elimination of Oncogenic Signaling Networks in Pre-malignant and Malignant Cells with Magnetic Resonance Imaging awarded by Department of Defense 2012 - 2022
- Developing a HER3 Vaccine to Prevent Resistance to Endocrine Therapy awarded by Department of Defense 2012 - 2022
- Translational Research in Surgical Oncology awarded by National Institutes of Health 2002 - 2022
- A Molecular Framework for Understanding DCIS awarded by Department of Defense 2014 - 2022
- Establishing the molecular and cellular mechanisms of Lgr5 signaling for controlling cancer stem cell behavior awarded by National Institutes of Health 2017 - 2021
- Mechanisms of Action and Resistance to PD-1 Immunotherapies in Breast Cancer awarded by Merck 2017 - 2020
- Immunotherapeutic Targeting of a Therapy Resistant Oncogenic HER2 Isoform awarded by Susan G. Komen Breast Cancer Foundation 2017 - 2020
- Investigating Adaptive Immune Recognition of Dormant Disseminated Tumor Cells awarded by Fred Hutchinson Cancer Research Center 2017 - 2019
- Inhibition of Wnt/B-Catenin Signaling in Colorectal Cancer Therapy awarded by National Institutes of Health 2013 - 2019
- Duke University Program in Environmental Health awarded by National Institute of Environmental Health Sciences 2013 - 2019
- 3D Biology Signatures defined by Nanostring Max System awarded by North Carolina Biotechnology Center 2018 - 2019
- Duke-Komen Fundamentals Training for Patient Advocates - AAADV awarded by Susan G. Komen Breast Cancer Foundation 2018
- A Cancer Rainbow Mouse for Simultaneous Assessment of Multiple Oncogenes awarded by National Institutes of Health 2015 - 2018
- AAADV Fundamentals awarded by Susan G. Komen Breast Cancer Foundation 2017
- Advancing Immunology in Dogs with Naturally-occurring Invasive Bladder Cancer, a Relevant Model to Improve Immunotherapy Across Molecular Cancer Subtypes in Humans awarded by Purdue University 2016 - 2017
- A Simple System for Early Detection of Breast Cancer awarded by Arizona State University 2014 - 2017
- AAADV Scholars awarded by Millennium Pharmaceuticals, Inc. 2016 - 2017
- AAADV Scholars awarded by Genentech, Inc. 2016
- AAADV Scholars awarded by Pfizer, Inc. 2016
- AAADV Workshop awarded by Susan G Komen for the Cure 2015 - 2016
- Cancer Biology Training Grant awarded by National Cancer Institute 1993 - 2016
- Integrating Population and Basic Science in Cancer Research awarded by National Institutes of Health 2009 - 2015
- Clinical Oncology Research Career Development Program awarded by National Institutes of Health 2009 - 2015
- 2015 Accelerating Anticancer Agent Development and Validation Workshop awarded by Susan G Komen for the Cure 2015
- A Cancer Rainbow Mouse for the Simultaneous Assessment of Multiple Oncogenes awarded by National Institutes of Health 2012 - 2015
- Administrative Supplement for Recruitment of New Faculty awarded by National Cancer Institute 2009 - 2011
- Immunotherapy with High Frequency, CEA Specific awarded by National Institutes of Health 2000 - 2011
- SPORE in Breast Cancer awarded by National Institutes of Health 1998 - 2010
- Cancer Center Core Grant Supplement - Accelerating Anticancer Agent Development Workshop awarded by National Institutes of Health 2006 - 2009
- Cancer Center Core Grant Supplement - Accelerating Anticancer Agent Dev Workshop awarded by National Institutes of Health 2005 - 2009
- Targeting hCG-beta for Breast Cancer Immunotherapy awarded by National Institutes of Health 2004 - 2009
- Developing Biomarker-Based Prognostics in Breast Cancer awarded by National Institutes of Health 2004 - 2009
- Vaccination with Regulatory T Cell Depletion awarded by National Institutes of Health 2006 - 2008
- Markers of short term breast cancer risk in FNA awarded by National Institutes of Health 1995 - 2008
- Novel Biomarkers for Aromatase Inhibitor Therapy awarded by National Institutes of Health 1995 - 2008
- Phase II trial of Cetuximab & Carboplatin in Basal-like Breast Cancer awarded by National Institutes of Health 1995 - 2008
- Biomarker Studies for Novel Anti-Cancer Agents awarded by National Institutes of Health 2003 - 2008
- Dendritic Cell Based Immunotherapy awarded by National Institutes of Health 2002 - 2007
- Immunotherapy using peptide MHC tetramer isolated Tcells awarded by National Institutes of Health 2002 - 2007
- Dendritic Cell Mobilization and Active Immunotherapy awarded by National Institutes of Health 2001 - 2007
- Immunologic Correlates of Effective Immunizations for Cancer Vaccines awarded by National Institutes of Health 2001 - 2006
- Planning a Duke Academic Public Private Partnership Program (AP4) Center awarded by National Cancer Institute 2004 - 2006
- Phase II Trial of Estradiol Therapy for Advanced Breast Cancer awarded by National Institutes of Health 2003 - 2005
- Mentored Oriented Research Career Development Award awarded by National Institutes of Health 2000 - 2005
- Cancer Center Core Grant - CURE Supplment awarded by National Institutes of Health 2003 - 2004
- Immunotherapy of Prostate Cancer with Tumor Vaccines awarded by National Institutes of Health 1999 - 2004
- RNA Transfected Dendritic Cells for Cancer Immunotherapy awarded by National Institutes of Health 1999 - 2004
- Dexasome Based Immunotherapy of Lung Cancer awarded by National Institutes of Health 2001 - 2004
- Immunotherapy with TRICOM Modified Dendritic Cells awarded by National Institutes of Health 2001 - 2003
- Cytomation MoFlo High Performance Flow Cytometer awarded by National Institutes of Health 2002 - 2003
- Dendritic Cell Immunotherapy For Breast Cancer awarded by National Institutes of Health 1998 - 2000
- Cancer Immunotherapy With Rna Pulsed Dendritic Cells awarded by National Institutes of Health 1998 - 1999
- Immunotherapy With Peptide Pulsed Dendritic Cells awarded by National Institutes of Health 1996 - 1999
- Immunotherapy with peptide pulsed dendritic cell awarded by National Institutes of Health 1996 - 1999
- Viral Control And Immune Reconstitution In Hiv Infection awarded by National Institutes of Health 1996 - 1999
- Viral Control & Immune Reconstitution In Hiv Infection awarded by National Institutes of Health 1995 - 1999
- Immunotherapy Of Breast Cance5 With Gene Modified Tumor awarded by National Institutes of Health 1995 - 1999
- Immunotherapy Of Breast Cancer With Gene Modified Tumor awarded by National Institutes of Health 1995 - 1999
- Immunotherapy of Breast Cancer with Gene Modified Tumors awarded by National Institutes of Health 1995 - 1999
- DUMC AIDS Malignancy Program awarded by National Institutes of Health 1995 - 1999
- Dumc Aids Malignancy Program awarded by National Institutes of Health 1995 - 1999
- Spore In Breast Cancer awarded by National Institutes of Health 1995 - 1998
- Spore In Breast Cancer awarded by National Institutes of Health 1995 - 1998
- Surrogate Markers Of Tumor Specific Immunity awarded by National Institutes of Health 1994 - 1998
- Preclinical Development Of Rna Decoys awarded by National Institutes of Health 1994 - 1998
- Adoptive Immunotherapy For Aids Lymphoma awarded by National Institutes of Health 1993 - 1996
- Cellular Immunity Against Post-Transplant Lymphoma awarded by National Institutes of Health 1992 - 1994
- missing activity
-
External Relationships
- AlphaVax
- Biologic Response Laboratories
- HuaDong Pharmaceutical Company
- ImmunityBio
- Oncosec
- Replicate
- Sonokine Bioscience
- State of North Carolina Environmental Management Commission
- TRIO Biopharma
- Publications & Artistic Works
-
Selected Publications
-
Books
-
Morse, Michael A., Timothy M. Clay, and H Kim Lyerly. Handbook of Cancer Vaccines. Springer Science & Business Media, 2004.
-
Mosca, Paul J., Lisa A. Clark, and H Kim Lyerly. Pocket Surgery. Lippincott Williams & Wilkins, 2002.
-
Sabiston, David C., and H Kim Lyerly. Sabiston Textbook of Surgery The Biological Basis of Modern Surgical Practice, 1999.
-
Sabiston, David C., and H Kim Lyerly. Textbook of Surgery Pocket Companion. W B Saunders Company, 1997.
-
Sabiston, David C. Sabiston Essentials of Surgery. Saunders, 1994.
-
Lyerly, H Kim, and J William Gaynor. The Handbook of Surgical Intensive Care Practices of the Surgical Residents at the Duke University Medical Center. Mosby Incorporated, 1992.
-
-
Academic Articles
-
Lyerly, Herbert Kim. “Self-replicating messenger RNA based cancer immunotherapy.” Cancer Gene Ther, May 5, 2023, 1–2. https://doi.org/10.1038/s41417-023-00619-w.Full Text Link to Item
-
Morse, Michael A., Erika J. Crosby, Jeremy Force, Takuya Osada, Amy C. Hobeika, Zachary C. Hartman, Peter Berglund, Jonathan Smith, and H Kim Lyerly. “Clinical trials of self-replicating RNA-based cancer vaccines.” Cancer Gene Ther, February 10, 2023, 1–9. https://doi.org/10.1038/s41417-023-00587-1.Full Text Link to Item
-
Kaneko, Kensuke, Hiroshi Nagata, Xiao-Yi Yang, Joshua Ginzel, Zachary Hartman, Jeffrey Everitt, Philip Hughes, et al. “A Non-Invasive Deep Photoablation Technique to Inhibit DCIS Progression and Induce Antitumor Immunity.” Cancers (Basel) 14, no. 23 (November 23, 2022). https://doi.org/10.3390/cancers14235762.Full Text Link to Item
-
Kaneko, Kensuke, Chaitanya R. Acharya, Hiroshi Nagata, Xiao Yang, Zachary Conrad Hartman, Amy Hobeika, Philip F. Hughes, et al. “Combination of a novel heat shock protein 90-targeted photodynamic therapy with PD-1/PD-L1 blockade induces potent systemic antitumor efficacy and abscopal effect against breast cancers.” J Immunother Cancer 10, no. 9 (September 2022). https://doi.org/10.1136/jitc-2022-004793.Full Text Link to Item
-
Yu, Bin, Igor Akushevich, Arseniy P. Yashkin, Anatoliy I. Yashin, H Kim Lyerly, and Julia Kravchenko. “Epidemiology of geographic disparities in heart failure among US older adults: a Medicare-based analysis.” Bmc Public Health 22, no. 1 (July 1, 2022): 1280. https://doi.org/10.1186/s12889-022-13639-2.Full Text Open Access Copy Link to Item
-
Lee, Jack Y., Bianca Nguyen, Anandaroop Mukhopadhyay, Mia Han, Jun Zhang, Ravindra Gujar, Jon Salazar, et al. “Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of plasmid CXCL9 synergizes with plasmid IL-12 therapy to elicit robust anti-tumor immunity.” Mol Ther Oncolytics 25 (June 16, 2022): 174–88. https://doi.org/10.1016/j.omto.2022.04.005.Full Text Link to Item
-
Rebbeck, Clare A., Jian Xian, Susanne Bornelöv, Joseph Geradts, Amy Hobeika, Heather Geiger, Jose Franco Alvarez, et al. “Gene expression signatures of individual ductal carcinoma in situ lesions identify processes and biomarkers associated with progression towards invasive ductal carcinoma.” Nat Commun 13, no. 1 (June 13, 2022): 3399. https://doi.org/10.1038/s41467-022-30573-4.Full Text Link to Item
-
Schiller, John T., Douglas R. Lowy, Ian H. Frazer, Olivera J. Finn, Eduardo Vilar, H Kim Lyerly, Sacha Gnjatic, et al. “Cancer vaccines.” Cancer Cell 40, no. 6 (June 13, 2022): 559–64. https://doi.org/10.1016/j.ccell.2022.05.015.Full Text Link to Item
-
Kizub, Darya, Cathyryne K. Manner, Katy Graef, Bello Abubakar, Jackson Orem, Folakemi Odedina, Mojisola Christianah Adeyeye, et al. “Action for Increasing Diversity, Market Access, and Capacity in Oncology Registration Trials-Is Africa the Answer? Report From a Satellite Session of the Accelerating Anti-Cancer Agent Development and Validation Workshop.” Jco Glob Oncol 8 (June 2022): e2200117. https://doi.org/10.1200/GO.22.00117.Full Text Link to Item
-
Tsao, Li-Chung, Erika J. Crosby, Timothy N. Trotter, Junping Wei, Tao Wang, Xiao Yang, Amanda N. Summers, et al. “Trastuzumab/pertuzumab combination therapy stimulates antitumor responses through complement-dependent cytotoxicity and phagocytosis.” Jci Insight 7, no. 6 (March 22, 2022). https://doi.org/10.1172/jci.insight.155636.Full Text Link to Item
-
Hwang, Bin-Jin, Li-Chung Tsao, Chaitanya R. Acharya, Timothy Trotter, Pankaj Agarwal, Junping Wei, Tao Wang, et al. “Sensitizing immune unresponsive colorectal cancers to immune checkpoint inhibitors through MAVS overexpression.” J Immunother Cancer 10, no. 3 (March 2022). https://doi.org/10.1136/jitc-2021-003721.Full Text Link to Item
-
Abe, Shinya, Hiroshi Nagata, Erika J. Crosby, Yoshiyuki Inoue, Kensuke Kaneko, Cong-Xiao Liu, Xiao Yang, et al. “Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity.” J Immunother Cancer 10, no. 1 (January 2022). https://doi.org/10.1136/jitc-2021-003717.Full Text Link to Item
-
Osada, Takuya, Erika J. Crosby, Kensuke Kaneko, Joshua C. Snyder, Joshua D. Ginzel, Chaitanya R. Acharya, Xiao-Yi Yang, et al. “HSP90-Specific nIR Probe Identifies Aggressive Prostate Cancers: Translation from Preclinical Models to a Human Phase I Study.” Mol Cancer Ther 21, no. 1 (January 2022): 217–26. https://doi.org/10.1158/1535-7163.MCT-21-0334.Full Text Link to Item
-
Von Hoff, Daniel D., Gary M. Clark, Charles A. Coltman, Mary L. Disis, S. G. Eckhardt, Lee M. Ellis, Margaret Foti, et al. “A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop.” Clin Cancer Res 27, no. 20 (October 15, 2021): 5472–81. https://doi.org/10.1158/1078-0432.CCR-21-1799.Full Text Link to Item
-
Ginzel, Joshua D., Chaitanya R. Acharya, Veronica Lubkov, Hidetoshi Mori, Peter G. Boone, Lauren K. Rochelle, Wendy L. Roberts, et al. “HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase.” Molecular Cancer Research : Mcr 19, no. 10 (October 2021): 1699–1711. https://doi.org/10.1158/1541-7786.mcr-21-0215.Full Text
-
Song, Linan, Shuo Wang, Tong Fang, Xiaoguang Qiu, Xiaoli Wang, Xinna Zhou, Michael A. Morse, et al. “Changes in Peripheral Blood Regulatory T Cells and IL-6 and IL-10 Levels Predict Response of Pediatric Medulloblastoma and Germ Cell Tumors With Residual or Disseminated Disease to Craniospinal Irradiation.” Int J Radiat Oncol Biol Phys 111, no. 2 (October 1, 2021): 479–90. https://doi.org/10.1016/j.ijrobp.2021.04.041.Full Text Link to Item
-
Wang, Jie, Takuya Osada, Michael A. Morse, Frank Calzone, Hai Yan, Dung Thai, and H Kim Lyerly. “Targeting the glucagon receptor signaling pathway as a novel strategy to counteract PI3K inhibitor induced hyperglycemia while sustaining tumor PI3K inhibition.” Leuk Lymphoma 62, no. 7 (July 2021): 1761–64. https://doi.org/10.1080/10428194.2021.1881504.Full Text Link to Item
-
Telli, Melinda L., Hiroshi Nagata, Irene Wapnir, Chaitanya R. Acharya, Kaitlin Zablotsky, Bernard A. Fox, Carlo B. Bifulco, et al. “Intratumoral Plasmid IL12 Expands CD8+ T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti-PD-1 Therapy.” Clin Cancer Res 27, no. 9 (May 1, 2021): 2481–93. https://doi.org/10.1158/1078-0432.CCR-20-3944.Full Text Link to Item
-
Crosby, Erika J., H Kim Lyerly, and Zachary C. Hartman. “Cancer vaccines: the importance of targeting oncogenic drivers and the utility of combinations with immune checkpoint inhibitors.” Oncotarget 12, no. 1 (January 5, 2021): 1–3. https://doi.org/10.18632/oncotarget.27861.Full Text Link to Item
-
Rhew, Sung Han, Julia Kravchenko, and H Kim Lyerly. “Exposure to low-dose ambient fine particulate matter PM2.5 and Alzheimer's disease, non-Alzheimer's dementia, and Parkinson's disease in North Carolina.” Plos One 16, no. 7 (2021): e0253253. https://doi.org/10.1371/journal.pone.0253253.Full Text Link to Item
-
Wang, Xiaoli, Guoliang Qiao, Ni Jiang, Michael A. Morse, Xinna Zhou, Shuo Wang, Jiangping Wu, et al. “Serial assessment of circulating T lymphocyte phenotype and receptor repertoire during treatment of non-muscle invasive bladder cancer with adoptive T cell immunotherapy.” Am J Cancer Res 11, no. 4 (2021): 1709–18.Link to Item
-
Yang, Duo, Xiaoli Wang, Xinna Zhou, Jing Zhao, Huabing Yang, Shuo Wang, Michael A. Morse, et al. “Blood microbiota diversity determines response of advanced colorectal cancer to chemotherapy combined with adoptive T cell immunotherapy.” Oncoimmunology 10, no. 1 (2021): 1976953. https://doi.org/10.1080/2162402X.2021.1976953.Full Text Link to Item
-
Crosby, Erika J., Amy C. Hobeika, Donna Niedzwiecki, Christel Rushing, David Hsu, Peter Berglund, Jonathan Smith, et al. “Long-term survival of patients with stage III colon cancer treated with VRP-CEA(6D), an alphavirus vector that increases the CD8+ effector memory T cell to Treg ratio.” J Immunother Cancer 8, no. 2 (November 2020). https://doi.org/10.1136/jitc-2020-001662.Full Text Link to Item
-
Bhatnagar, Vishal, Stacie Hudgens, Elisabeth Piault-Louis, Lee Jones, Julia A. Beaver, H Kim Lyerly, Gregory Reaman, Thomas Fleming, and Paul G. Kluetz. “Patient-Reported Outcomes in Oncology Clinical Trials: Stakeholder Perspectives from the Accelerating Anticancer Agent Development and Validation Workshop 2019.” Oncologist 25, no. 10 (October 2020): 819–21. https://doi.org/10.1634/theoncologist.2020-0062.Full Text Link to Item
-
Schrott, Rose, Maya Rajavel, Kelly Acharya, Zhiqing Huang, Chaitanya Acharya, Andrew Hawkey, Erica Pippen, H Kim Lyerly, Edward D. Levin, and Susan K. Murphy. “Sperm DNA methylation altered by THC and nicotine: Vulnerability of neurodevelopmental genes with bivalent chromatin.” Sci Rep 10, no. 1 (September 29, 2020): 16022. https://doi.org/10.1038/s41598-020-72783-0.Full Text Link to Item
-
Hafez, Navid, Hope S. Rugo, Margaret A. Tempero, Elizabeth Fox, Gregory H. Reaman, Herbert Kim Lyerly, Desiree Walker, and Patricia M. LoRusso. “Novel Therapeutic Interventions Early in the Disease Trajectory: Drug Development Beyond the Refractory Setting.” Clin Cancer Res 26, no. 18 (September 15, 2020): 4743–47. https://doi.org/10.1158/1078-0432.CCR-19-4035.Full Text Link to Item
-
Crosby, Erika J., Chaitanya R. Acharya, Anthony-Fayez Haddad, Christopher A. Rabiola, Gangjun Lei, Jun-Ping Wei, Xiao-Yi Yang, et al. “Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer.” Clin Cancer Res 26, no. 17 (September 1, 2020): 4670–81. https://doi.org/10.1158/1078-0432.CCR-20-0389.Full Text Link to Item
-
Trotter, Timothy N., Casey W. Shuptrine, Li-Chung Tsao, Robert D. Marek, Chaitanya Acharya, Jun-Ping Wei, Xiao-Yi Yang, et al. “IL26, a Noncanonical Mediator of DNA Inflammatory Stimulation, Promotes TNBC Engraftment and Progression in Association with Neutrophils.” Cancer Res 80, no. 15 (August 1, 2020): 3088–3100. https://doi.org/10.1158/0008-5472.CAN-18-3825.Full Text Link to Item
-
Kim, Howuk, Huaiyu Wu, Namwoo Cho, Pei Zhong, Kamran Mahmood, Herbert Kim Lyerly, and Xiaoning Jiang. “Miniaturized Intracavitary Forward-Looking Ultrasound Transducer for Tissue Ablation.” Ieee Trans Biomed Eng 67, no. 7 (July 2020): 2084–93. https://doi.org/10.1109/TBME.2019.2954524.Full Text Link to Item
-
Chen, Alan Chen, Renhuan Xu, Tao Wang, Junping Wei, Xiao-Yi Yang, Cong-Xiao Liu, Gangjun Lei, Herbert Kim Lyerly, Teri Heiland, and Zachary Conrad Hartman. “HER2-LAMP vaccines effectively traffic to endolysosomal compartments and generate enhanced polyfunctional T cell responses that induce complete tumor regression.” J Immunother Cancer 8, no. 1 (June 2020). https://doi.org/10.1136/jitc-2019-000258.Full Text Link to Item
-
Wang, Shuo, Xiaoli Wang, Xinna Zhou, Herbert Kim Lyerly, Michael A. Morse, and Jun Ren. “DC-CIK as a widely applicable cancer immunotherapy.” Expert Opin Biol Ther 20, no. 6 (June 2020): 601–7. https://doi.org/10.1080/14712598.2020.1728250.Full Text Link to Item
-
Kaneko, Kensuke, Takuya Osada, Michael A. Morse, William R. Gwin, Joshua D. Ginzel, Joshua C. Snyder, Xiao-Yi Yang, et al. “Heat shock protein 90-targeted photodynamic therapy enables treatment of subcutaneous and visceral tumors.” Commun Biol 3, no. 1 (May 8, 2020): 226. https://doi.org/10.1038/s42003-020-0956-7.Full Text Link to Item
-
He, Zixuan, Shuo Wang, Guoliang Qiao, Xiaoli Wang, Xinna Zhou, Siyu Zhu, Yanhua Yuan, et al. “Clinical efficacy of intra-cavitary infusions of autologous dendritic cell/cytokine-induced killer cell products for the treatment of refractory malignant pleural effusions and ascites.” Am J Transl Res 12, no. 7 (2020): 3940–52.Link to Item
-
Kravchenko, Julia, Igor Akushevich, Sung Han Rhew, Pankaj Agarwal, and H Kim Lyerly. “Uterine Cancer Mortality in White and African American Females in Southeastern North Carolina.” J Environ Public Health 2020 (2020): 6734031. https://doi.org/10.1155/2020/6734031.Full Text Link to Item
-
Shaw, Brian I., Daniel K. Cheng, Chaitanya R. Acharya, Robert B. Ettenger, Herbert Kim Lyerly, Qing Cheng, Allan D. Kirk, and Eileen T. Chambers. “An age-independent gene signature for monitoring acute rejection in kidney transplantation.” Theranostics 10, no. 15 (2020): 6977–86. https://doi.org/10.7150/thno.42110.Full Text Open Access Copy Link to Item
-
Wang, Shuo, Yuguang Song, Michael A. Morse, Pingping Sun, Guoliang Qiao, Xiaoli Wang, Xinna Zhou, Amy Hobeika, Jun Ren, and Herbert Kim Lyerly. “Infiltration of metastatic lymph nodes with PD-1+ T cells is associated with improved disease-free and overall survival in resected N+ NSCLC.” Am J Cancer Res 10, no. 12 (2020): 4435–49.Link to Item
-
Zhou, Xinna, Guoliang Qiao, Jun Ren, Xiaoli Wang, Shuo Wang, Siyu Zhu, Yanhua Yuan, Michael A. Morse, Amy Hobeika, and Herbert Kim Lyerly. “Adoptive immunotherapy with autologous T-cell infusions reduces opioid requirements in advanced cancer patients.” Pain 161, no. 1 (January 2020): 127–34. https://doi.org/10.1097/j.pain.0000000000001702.Full Text Link to Item
-
Tsao, Li-Chung, Erika J. Crosby, Timothy N. Trotter, Pankaj Agarwal, Bin-Jin Hwang, Chaitanya Acharya, Casey W. Shuptrine, et al. “CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis.” Jci Insight 4, no. 24 (December 19, 2019). https://doi.org/10.1172/jci.insight.131882.Full Text Link to Item
-
Boone, Peter G., Lauren K. Rochelle, Joshua D. Ginzel, Veronica Lubkov, Wendy L. Roberts, P. J. Nicholls, Cheryl Bock, et al. “A cancer rainbow mouse for visualizing the functional genomics of oncogenic clonal expansion.” Nat Commun 10, no. 1 (December 2, 2019): 5490. https://doi.org/10.1038/s41467-019-13330-y.Full Text Link to Item
-
Huang, Lefu, Guoliang Qiao, Michael A. Morse, Xiaoli Wang, Xinna Zhou, Jiangping Wu, Amy Hobeika, Jun Ren, and Herbert K. Lyerly. “Predictive significance of T cell subset changes during ex vivo generation of adoptive cellular therapy products for the treatment of advanced non-small cell lung cancer.” Oncol Lett 18, no. 6 (December 2019): 5717–24. https://doi.org/10.3892/ol.2019.10964.Full Text Open Access Copy Link to Item
-
Kravchenko, Julia, and H Kim Lyerly. “GEOGRAPHIC DISPARITIES IN LIFE EXPECTANCY AND MORTALITY IN THE U.S.” Innovation in Aging 3, no. Suppl 1 (November 8, 2019): S427–S427. https://doi.org/10.1093/geroni/igz038.1597.Full Text
-
Qiao, Guoliang, Xiaoli Wang, Xinna Zhou, Michael A. Morse, Jiangping Wu, Shuo Wang, Yuguang Song, et al. “Immune correlates of clinical benefit in a phase I study of hyperthermia with adoptive T cell immunotherapy in patients with solid tumors.” Int J Hyperthermia 36, no. sup1 (November 2019): 74–82. https://doi.org/10.1080/02656736.2019.1647350.Full Text Link to Item
-
Lv, Shuzhen, Shuo Wang, Guoliang Qiao, Xiaoli Wang, Xinna Zhou, Fengcai Yan, Yanping Li, et al. “Functional CD3+CD8+PD1- T Cell Accumulation and PD-L1 Expression Increases During Tumor Invasion in DCIS of the Breast.” Clin Breast Cancer 19, no. 5 (October 2019): e617–23. https://doi.org/10.1016/j.clbc.2019.04.001.Full Text Link to Item
-
Kula, Tomasz, Mohammad H. Dezfulian, Charlotte I. Wang, Nouran S. Abdelfattah, Zachary C. Hartman, Kai W. Wucherpfennig, Herbert Kim Lyerly, and Stephen J. Elledge. “T-Scan: A Genome-wide Method for the Systematic Discovery of T Cell Epitopes.” Cell 178, no. 4 (August 8, 2019): 1016-1028.e13. https://doi.org/10.1016/j.cell.2019.07.009.Full Text Link to Item
-
Sun, Yuanyuan, Suya Wang, Hainan Yang, Jiangping Wu, Sha Li, Guoliang Qiao, Shuo Wang, et al. “Impact of synchronized anti-PD-1 with Ad-CEA vaccination on inhibition of colon cancer growth.” Immunotherapy 11, no. 11 (August 2019): 953–66. https://doi.org/10.2217/imt-2019-0055.Full Text Link to Item
-
Salgado, Roberto, David B. Solit, David L. Rimm, Jan Bogaerts, Renzo Canetta, Tracy Lively, Kim Lyerly, et al. “Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology.” Eur J Cancer 114 (June 2019): 128–36. https://doi.org/10.1016/j.ejca.2019.03.025.Full Text Link to Item
-
Zhao, Y., G. Qiao, X. Wang, Y. Song, X. Zhou, N. Jiang, L. Zhou, et al. “Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients' preference-based study (PPPS).” Clin Transl Oncol 21, no. 6 (June 2019): 721–28. https://doi.org/10.1007/s12094-018-1968-3.Full Text Link to Item
-
Crosby, Erika J., William Gwin, Kimberly Blackwell, Paul K. Marcom, Serena Chang, Holden T. Maecker, Gloria Broadwater, et al. “Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study.” Clin Cancer Res 25, no. 9 (May 1, 2019): 2725–36. https://doi.org/10.1158/1078-0432.CCR-18-3102.Full Text Open Access Copy Link to Item
-
Wang, Xiaoli, Shuo Wang, Michael A. Morse, Ni Jiang, Yanjie Zhao, Yuguang Song, Lei Zhou, et al. “Prospective randomized comparative study on rivaroxaban and LMWH for prophylaxis of post-apheresis thrombosis in adoptive T cell immunotherapy cancer patients.” J Thromb Thrombolysis 47, no. 4 (May 2019): 505–11. https://doi.org/10.1007/s11239-019-01844-7.Full Text Link to Item
-
Cecchini, Michael, Eric H. Rubin, Gideon M. Blumenthal, Kassa Ayalew, Howard A. Burris, Michele Russell-Einhorn, Hildy Dillon, et al. “Challenges with Novel Clinical Trial Designs: Master Protocols.” Clin Cancer Res 25, no. 7 (April 1, 2019): 2049–57. https://doi.org/10.1158/1078-0432.CCR-18-3544.Full Text Link to Item
-
Qiao, Guoliang, Xiaoli Wang, Lei Zhou, Xinna Zhou, Yuguang Song, Shuo Wang, Lei Zhao, et al. “Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer: A Prospective Study.” Clin Cancer Res 25, no. 5 (March 1, 2019): 1494–1504. https://doi.org/10.1158/1078-0432.CCR-18-2360.Full Text Link to Item
-
Wang, Jiangbo, Xiu-Rong Ren, Hailan Piao, Shengli Zhao, Takuya Osada, Richard T. Premont, Robert A. Mook, Michael A. Morse, Herbert Kim Lyerly, and Wei Chen. “Niclosamide-induced Wnt signaling inhibition in colorectal cancer is mediated by autophagy.” Biochem J 476, no. 3 (February 8, 2019): 535–46. https://doi.org/10.1042/BCJ20180385.Full Text Link to Item
-
Mook, Robert A., Jiangbo Wang, Xiu-Rong Ren, Hailan Piao, H Kim Lyerly, and Wei Chen. “Identification of novel triazole inhibitors of Wnt/β-catenin signaling based on the Niclosamide chemotype.” Bioorg Med Chem Lett 29, no. 2 (January 15, 2019): 317–21. https://doi.org/10.1016/j.bmcl.2018.11.022.Full Text Link to Item
-
Lyerly, H Kim, Takuya Osada, and Zachary C. Hartman. “Right Time and Place for IL12: Targeted Delivery Stimulates Immune Therapy.” Clin Cancer Res 25, no. 1 (January 1, 2019): 9–11. https://doi.org/10.1158/1078-0432.CCR-18-2819.Full Text Link to Item
-
Lyerly, H Kim, Jun Ren, Renzo Canetta, Gi Hyun Kim, Sumimasa Nagai, Tomohiro Yamaguchi, Ken Hatogai, et al. “Global Development of Anticancer Therapies for Rare Cancers, Pediatric Cancers, and Molecular Subtypes of Common Cancers.” J Glob Oncol 4 (December 2018): 1–11. https://doi.org/10.1200/JGO.18.00092.Full Text Link to Item
-
Wang, Jiangbo, Robert A. Mook, Xiu-Rong Ren, Qingfu Zhang, Genevieve Jing, Min Lu, Ivan Spasojevic, H Kim Lyerly, David Hsu, and Wei Chen. “Identification of DK419, a potent inhibitor of Wnt/β-catenin signaling and colorectal cancer growth.” Bioorg Med Chem 26, no. 20 (November 1, 2018): 5435–42. https://doi.org/10.1016/j.bmc.2018.09.016.Full Text Link to Item
-
Osada, Takuya, Zachary C. Hartman, Junping Wei, Gangjun Lei, Amy C. Hobeika, William R. Gwin, Marcio A. Diniz, et al. “Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers.” Breast Cancer Res 20, no. 1 (August 9, 2018): 90. https://doi.org/10.1186/s13058-018-1023-x.Full Text Link to Item
-
Forbes, Neil S., Robert S. Coffin, Liang Deng, Laura Evgin, Steve Fiering, Matthew Giacalone, Claudia Gravekamp, et al. “White paper on microbial anti-cancer therapy and prevention.” J Immunother Cancer 6, no. 1 (August 6, 2018): 78. https://doi.org/10.1186/s40425-018-0381-3.Full Text Link to Item
-
Zhou, Xinna, Guoliang Qiao, Xiaoli Wang, Qingkun Song, Michael A. Morse, Amy Hobeika, William R. Gwin, Jun Ren, and H Kim Lyerly. “CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine.” Cancer Chemother Pharmacol 81, no. 2 (February 2018): 365–72. https://doi.org/10.1007/s00280-017-3500-9.Full Text Link to Item
-
Blotnick, June, and H Kim Lyerly. “Philanthropy Profile: Protecting North Carolina's Health by Investing in a Healthy Environment.” N C Med J 79, no. 5 (2018): 337–38. https://doi.org/10.18043/ncm.79.5.337.Full Text Link to Item
-
Crosby, Erika J., Junping Wei, Xiao Yi Yang, Gangjun Lei, Tao Wang, Cong-Xiao Liu, Pankaj Agarwal, et al. “Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors.” Oncoimmunology 7, no. 5 (2018): e1421891. https://doi.org/10.1080/2162402X.2017.1421891.Full Text Link to Item
-
Kravchenko, Julia, H Kim Lyerly, and William Ross. “The Health Impacts of Environmental Policy: The North Carolina Clean Smokestacks Act.” N C Med J 79, no. 5 (2018): 329–33. https://doi.org/10.18043/ncm.79.5.329.Full Text Link to Item
-
Kravchenko, Julia, Sung Han Rhew, Igor Akushevich, Pankaj Agarwal, and H Kim Lyerly. “Mortality and Health Outcomes in North Carolina Communities Located in Close Proximity to Hog Concentrated Animal Feeding Operations.” N C Med J 79, no. 5 (2018): 278–88. https://doi.org/10.18043/ncm.79.5.278.Full Text Link to Item
-
Kravchenko, Julia, and H Kim Lyerly. “The Impact of Coal-Powered Electrical Plants and Coal Ash Impoundments on the Health of Residential Communities.” N C Med J 79, no. 5 (2018): 289–300. https://doi.org/10.18043/ncm.79.5.289.Full Text Link to Item
-
Lyerly, H Kim, and David B. Peden. “Health and the Environment in North Carolina.” N C Med J 79, no. 5 (2018): 302–5. https://doi.org/10.18043/ncm.79.5.302.Full Text Link to Item
-
Song, Qingkun, Jun Ren, Xinna Zhou, Xiaoli Wang, Guohong Song, Amy Hobeika, Yanhua Yuan, and Herbert Kim Lyerly. “Circulating CD8+CD28- suppressor T cells tied to poorer prognosis among metastatic breast cancer patients receiving adoptive T-cell therapy: A cohort study.” Cytotherapy 20, no. 1 (January 2018): 126–33. https://doi.org/10.1016/j.jcyt.2017.08.018.Full Text
-
Osada, Takuya, Kensuke Kaneko, William R. Gwin, Michael A. Morse, Amy Hobeika, Brian W. Pogue, Zachary C. Hartman, Philip F. Hughes, Timothy Haystead, and H Kim Lyerly. “In Vivo Detection of HSP90 Identifies Breast Cancers with Aggressive Behavior.” Clin Cancer Res 23, no. 24 (December 15, 2017): 7531–42. https://doi.org/10.1158/1078-0432.CCR-17-1453.Full Text Link to Item
-
Shuptrine, Casey W., Reham Ajina, Elana J. Fertig, Sandra A. Jablonski, H. Kim Lyerly, Zachary C. Hartman, and Louis M. Weiner. “An unbiased in vivo functional genomics screening approach in mice identifies novel tumor cell-based regulators of immune rejection.” Cancer Immunol Immunother 66, no. 12 (December 2017): 1529–44. https://doi.org/10.1007/s00262-017-2047-2.Full Text Link to Item
-
Jiang, Ni, Guoliang Qiao, Xiaoli Wang, Michael A. Morse, William R. Gwin, Lei Zhou, Yuguang Song, et al. “Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study.” Clin Cancer Res 23, no. 17 (September 1, 2017): 5066–73. https://doi.org/10.1158/1078-0432.CCR-17-0492.Full Text Link to Item
-
Snyder, Joshua C., Lauren K. Rochelle, Caroline Ray, Thomas F. Pack, Cheryl B. Bock, Veronica Lubkov, H Kim Lyerly, Alan S. Waggoner, Larry S. Barak, and Marc G. Caron. “Inhibiting clathrin-mediated endocytosis of the leucine-rich G protein-coupled receptor-5 diminishes cell fitness.” J Biol Chem 292, no. 17 (April 28, 2017): 7208–22. https://doi.org/10.1074/jbc.M116.756635.Full Text Link to Item
-
Crowe, Lauren B., Philip F. Hughes, David A. Alcorta, Takuya Osada, Aaron P. Smith, Juliane Totzke, David R. Loiselle, et al. “A Fluorescent Hsp90 Probe Demonstrates the Unique Association between Extracellular Hsp90 and Malignancy in Vivo.” Acs Chem Biol 12, no. 4 (April 21, 2017): 1047–55. https://doi.org/10.1021/acschembio.7b00006.Full Text Link to Item
-
Mook, Robert A., Xiu-Rong Ren, Jiangbo Wang, Hailan Piao, Larry S. Barak, H. Kim Lyerly, and Wei Chen. “Benzimidazole inhibitors from the Niclosamide chemotype inhibit Wnt/β-catenin signaling with selectivity over effects on ATP homeostasis.” Bioorg Med Chem 25, no. 6 (March 15, 2017): 1804–16. https://doi.org/10.1016/j.bmc.2017.01.046.Full Text Link to Item
-
Sauer, Scott J., Michael Tarpley, Imran Shah, Akshay V. Save, H Kim Lyerly, Steven R. Patierno, Kevin P. Williams, and Gayathri R. Devi. “Bisphenol A activates EGFR and ERK promoting proliferation, tumor spheroid formation and resistance to EGFR pathway inhibition in estrogen receptor-negative inflammatory breast cancer cells.” Carcinogenesis 38, no. 3 (March 1, 2017): 252–60. https://doi.org/10.1093/carcin/bgx003.Full Text Link to Item
-
Osada, Takuya, Michael A. Morse, Amy Hobeika, Marcio A. Diniz, William R. Gwin, Zachary Hartman, Junping Wei, et al. “Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibition.” Oncoimmunology 6, no. 6 (2017): e1315495. https://doi.org/10.1080/2162402X.2017.1315495.Full Text Link to Item
-
Ren, Jun, William R. Gwin, Xinna Zhou, Xiaoli Wang, Hongyan Huang, Ni Jiang, Lei Zhou, et al. “Adaptive T cell responses induced by oncolytic Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapy.” Oncoimmunology 6, no. 4 (2017): e1264563. https://doi.org/10.1080/2162402X.2016.1264563.Full Text Link to Item
-
Quiroga, Dionisia, H Kim Lyerly, and Michael A. Morse. “Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer.” Curr Treat Options Oncol 17, no. 8 (August 2016): 41. https://doi.org/10.1007/s11864-016-0414-4.Full Text Link to Item
-
Oldham, M., S. Yoon, B. Meng, Z. Fathi, W. Beyer, J. Adamson, D. Alcorta, et al. “WE-FG-BRA-01: Cancer Treatment Utilizing Photo-Activation of Psoralen with KV X-Rays.” Med Phys 43, no. 6 (June 2016): 3823. https://doi.org/10.1118/1.4957901.Full Text Link to Item
-
Vaidyanathan, Ganesan, Darryl McDougald, Jaeyeon Choi, Eftychia Koumarianou, Douglas Weitzel, Takuya Osada, H Kim Lyerly, and Michael R. Zalutsky. “Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET.” J Nucl Med 57, no. 6 (June 2016): 967–73. https://doi.org/10.2967/jnumed.115.171306.Full Text Link to Item
-
Price, Trevor T., Monika L. Burness, Ayelet Sivan, Matthew J. Warner, Renee Cheng, Clara H. Lee, Lindsey Olivere, et al. “Dormant breast cancer micrometastases reside in specific bone marrow niches that regulate their transit to and from bone.” Sci Transl Med 8, no. 340 (May 25, 2016): 340ra73. https://doi.org/10.1126/scitranslmed.aad4059.Full Text Link to Item
-
Kohrt, Holbrook E., Paul C. Tumeh, Don Benson, Nina Bhardwaj, Joshua Brody, Silvia Formenti, Bernard A. Fox, et al. “Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials.” J Immunother Cancer 4 (2016): 15. https://doi.org/10.1186/s40425-016-0118-0.Full Text Link to Item
-
Oldham, Mark, Paul Yoon, Zak Fathi, Wayne F. Beyer, Justus Adamson, Leihua Liu, David Alcorta, et al. “X-Ray Psoralen Activated Cancer Therapy (X-PACT).” Plos One 11, no. 9 (2016): e0162078. https://doi.org/10.1371/journal.pone.0162078.Full Text Open Access Copy Link to Item
-
Wang, X., J. Ren, J. Zhang, Y. Yan, N. Jiang, J. Yu, L. Di, et al. “Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45).” Clin Transl Oncol 18, no. 1 (January 2016): 82–87. https://doi.org/10.1007/s12094-015-1339-2.Full Text Link to Item
-
Morse, Michael A., and H Kim Lyerly. “Checkpoint blockade in combination with cancer vaccines.” Vaccine 33, no. 51 (December 16, 2015): 7377–85. https://doi.org/10.1016/j.vaccine.2015.10.057.Full Text Link to Item
-
Song, Qing-Kun, Jun Ren, Xin-Na Zhou, Xiao-Li Wang, Guo-Hong Song, Li-Jun Di, Jing Yu, et al. “The prognostic value of peripheral CD4+CD25+ T lymphocytes among early stage and triple negative breast cancer patients receiving dendritic cells-cytokine induced killer cells infusion.” Oncotarget 6, no. 38 (December 1, 2015): 41350–59. https://doi.org/10.18632/oncotarget.5534.Full Text Link to Item
-
Song, Qingkun, Xinna Zhou, Jing Yu, Ningning Dong, Xiaoli Wang, Huabing Yang, Jun Ren, and H Kim Lyerly. “The prognostic values of CYP2B6 genetic polymorphisms and metastatic sites for advanced breast cancer patients treated with docetaxel and thiotepa.” Sci Rep 5 (November 25, 2015): 16775. https://doi.org/10.1038/srep16775.Full Text Link to Item
-
Zhou, Xinna, Xiaoli Wang, Qingkun Song, Huabing Yang, Xishan Zhu, Jing Yu, Guohong Song, et al. “Transformation of alkylating regimen of thiotepa into tepa determines the disease progression through GSTP1 gene polymorphism for metastatic breast cancer patients receiving thiotepa containing salvage chemotherapy.” Int J Clin Pharmacol Ther 53, no. 11 (November 2015): 914–22. https://doi.org/10.5414/CP202391.Full Text Link to Item
-
“IMPACTS OF CEREBROVASCULAR AND NEURODEGENERATIVE DISEASES ON SURVIVAL OF LUNG CANCER PATIENTS.” The Gerontologist 55, no. Suppl_2 (November 2015): 496–496. https://doi.org/10.1093/geront/gnv214.03.Full Text Open Access Copy
-
“LONG-TERM DYNAMICS OF RESPIRATORY, CARDIO- AND CEREBROVASCULAR DEATH RATES AMONG OLDER ADULTS AND IMPROVING AIR QUALITY.” The Gerontologist 55, no. Suppl_2 (November 2015): 282–282. https://doi.org/10.1093/geront/gnv581.06.Full Text
-
Mook, Robert A., Jiangbo Wang, Xiu-Rong Ren, Minyong Chen, Ivan Spasojevic, Larry S. Barak, H Kim Lyerly, and Wei Chen. “Structure-activity studies of Wnt/β-catenin inhibition in the Niclosamide chemotype: Identification of derivatives with improved drug exposure.” Bioorg Med Chem 23, no. 17 (September 1, 2015): 5829–38. https://doi.org/10.1016/j.bmc.2015.07.001.Full Text Link to Item
-
Song, Qing-Kun, Xiao-Li Wang, Xin-Na Zhou, Hua-Bing Yang, Yu-Chen Li, Jiang-Ping Wu, Jun Ren, and Herbert Kim Lyerly. “Breast Cancer Challenges and Screening in China: Lessons From Current Registry Data and Population Screening Studies.” Oncologist 20, no. 7 (July 2015): 773–79. https://doi.org/10.1634/theoncologist.2014-0351.Full Text Link to Item
-
Goodson, William H., Leroy Lowe, David O. Carpenter, Michael Gilbertson, Abdul Manaf Ali, Adela Lopez de Cerain Salsamendi, Ahmed Lasfar, et al. “Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead.” Carcinogenesis 36 Suppl 1, no. Suppl 1 (June 2015): S254–96. https://doi.org/10.1093/carcin/bgv039.Full Text Link to Item
-
Kravchenko, Julia, Emanuela Corsini, Marc A. Williams, William Decker, Masoud H. Manjili, Takemi Otsuki, Neetu Singh, et al. “Chemical compounds from anthropogenic environment and immune evasion mechanisms: potential interactions.” Carcinogenesis 36 Suppl 1, no. Suppl 1 (June 2015): S111–27. https://doi.org/10.1093/carcin/bgv033.Full Text Link to Item
-
Osada, Takuya, Sandip P. Patel, Scott A. Hammond, Koya Osada, Michael A. Morse, and H Kim Lyerly. “CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1.” Cancer Immunol Immunother 64, no. 6 (June 2015): 677–88. https://doi.org/10.1007/s00262-015-1671-y.Full Text Link to Item
-
Lyerly, H Kim, Maria R. Fawzy, Zeba Aziz, Reena Nair, C. S. Pramesh, Vani Parmar, Purvish M. Parikh, et al. “Regional variation in identified cancer care needs of early-career oncologists in China, India, and Pakistan.” Oncologist 20, no. 5 (May 2015): 532–38. https://doi.org/10.1634/theoncologist.2014-0213.Full Text Link to Item
-
Osada, Takuya, Koji Nagaoka, Masashi Takahara, Xiao Yi Yang, Cong-Xiao Liu, Hongtao Guo, Kingshuk Roy Choudhury, et al. “Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors.” J Immunother 38, no. 4 (May 2015): 155–64. https://doi.org/10.1097/CJI.0000000000000075.Full Text Link to Item
-
Kravchenko, Julia, Mark Berry, Konstantin Arbeev, H Kim Lyerly, Anatoly Yashin, and Igor Akushevich. “Cardiovascular comorbidities and survival of lung cancer patients: Medicare data based analysis.” Lung Cancer 88, no. 1 (April 2015): 85–93. https://doi.org/10.1016/j.lungcan.2015.01.006.Full Text Open Access Copy Link to Item
-
Snyder, Joshua C., Lauren K. Rochelle, Sébastien Marion, H Kim Lyerly, Larry S. Barak, and Marc G. Caron. “Lgr4 and Lgr5 drive the formation of long actin-rich cytoneme-like membrane protrusions.” J Cell Sci 128, no. 6 (March 15, 2015): 1230–40. https://doi.org/10.1242/jcs.166322.Full Text Link to Item
-
Ren, Xiu-Rong, Jiangbo Wang, Takuya Osada, Robert A. Mook, Michael A. Morse, Larry S. Barak, Herbert Kim Lyerly, and Wei Chen. “Perhexiline promotes HER3 ablation through receptor internalization and inhibits tumor growth.” Breast Cancer Res 17, no. 1 (February 15, 2015): 20. https://doi.org/10.1186/s13058-015-0528-9.Full Text Link to Item
-
Gray, Michael, Jian Gong, Van Nguyen, Takuya Osada, Zachary Hartman, Jeff Hutchins, Bruce Freimark, and Kim Lyerly. “Targeting of phosphatidylserine by monoclonal antibodies augments the activity of paclitaxel and anti-PD1/PD-L1 therapy in the murine breast model E0771.” Journal for Immunotherapy of Cancer 3, no. Suppl 2 (January 2015): P357–P357. https://doi.org/10.1186/2051-1426-3-s2-p357.Full Text
-
Morse, Michael A., Amy Hobeika, William Gwin, Takuya Osada, Jonathan Gelles, Christel Rushing, Donna Niedzwiecki, and H Kim Lyerly. “Phase I study of alphaviral vector (AVX701) in colorectal cancer patients: comparison of immune responses in stage III and stage IV patients.” Journal for Immunotherapy of Cancer 3, no. Suppl 2 (January 2015): P444–P444. https://doi.org/10.1186/2051-1426-3-s2-p444.Full Text
-
Zhao, Yan-Jie, Ni Jiang, Qing-Kun Song, Jiang-Ping Wu, Yu-Guang Song, Hong-Mei Zhang, Feng Chen, et al. “Continuous DC-CIK infusions restore CD8+ cellular immunity, physical activity and improve clinical efficacy in advanced cancer patients unresponsive to conventional treatments.” Asian Pac J Cancer Prev 16, no. 6 (2015): 2419–23. https://doi.org/10.7314/apjcp.2015.16.6.2419.Full Text Link to Item
-
Kravchenko, Julia, Thomas H. Darrah, Richard K. Miller, H Kim Lyerly, and Avner Vengosh. “A review of the health impacts of barium from natural and anthropogenic exposure.” Environ Geochem Health 36, no. 4 (August 2014): 797–814. https://doi.org/10.1007/s10653-014-9622-7.Full Text Link to Item
-
Cheng, Qing, Jeffrey T. Chang, William R. Gwin, Jun Zhu, Stefan Ambs, Joseph Geradts, and H Kim Lyerly. “A signature of epithelial-mesenchymal plasticity and stromal activation in primary tumor modulates late recurrence in breast cancer independent of disease subtype.” Breast Cancer Res 16, no. 4 (July 25, 2014): 407. https://doi.org/10.1186/s13058-014-0407-9.Full Text Link to Item
-
Sauer, Scott Jeffrey, John B. Davis, H Kim Lyerly, Imran Shah, Kevin P. Williams, and Gayathri R. Devi. “Bisphenol a Interacts with Gper, Activates EGFR and ERK Signaling and Antagonizes Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Breast Cancer Cells.” Endocrine Reviews 35, no. 3 (June 1, 2014).Link to Item
-
Palena, Claudia, Mario Roselli, Mary T. Litzinger, Patrizia Ferroni, Leopoldo Costarelli, Antonella Spila, Francesco Cavaliere, et al. “Overexpression of the EMT driver brachyury in breast carcinomas: association with poor prognosis.” J Natl Cancer Inst 106, no. 5 (May 9, 2014). https://doi.org/10.1093/jnci/dju054.Full Text Link to Item
-
Pruszynski, Marek, Eftychia Koumarianou, Ganesan Vaidyanathan, Hilde Revets, Nick Devoogdt, Tony Lahoutte, H Kim Lyerly, and Michael R. Zalutsky. “Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling.” J Nucl Med 55, no. 4 (April 2014): 650–56. https://doi.org/10.2967/jnumed.113.127100.Full Text Link to Item
-
Kravchenko, Julia, Igor Akushevich, Amy P. Abernethy, Sheila Holman, William G. Ross, and H Kim Lyerly. “Long-term dynamics of death rates of emphysema, asthma, and pneumonia and improving air quality.” Int J Chron Obstruct Pulmon Dis 9 (2014): 613–27. https://doi.org/10.2147/COPD.S59995.Full Text Open Access Copy Link to Item
-
Palena, C., M. Roselli, M. T. Litzinger, P. Ferroni, L. Costarelli, A. Spila, F. Cavaliere, et al. “Overexpression of the EMT driver brachyury in breast carcinomas: association with poor prognosis.” Journal of the National Cancer Institute 106, no. 5 (January 1, 2014).
-
Patel, Sandip P., Takuya Osada, H Kim Lyerly, and Michael A. Morse. “Designing effective vaccines for colorectal cancer.” Immunotherapy 6, no. 8 (2014): 913–26. https://doi.org/10.2217/imt.14.61.Full Text Link to Item
-
Patel, S. P., T. Osada, K. Osada, H. Hurwitz, H. K. Lyerly, and M. A. Morse. “Modulation of immune system inhibitory checkpoints in colorectal cancer.” Current Colorectal Cancer Reports 9, no. 4 (December 1, 2013): 391–97. https://doi.org/10.1007/s11888-013-0184-3.Full Text
-
Barrott, Jared J., Philip F. Hughes, Takuya Osada, Xiao-Yi Yang, Zachary C. Hartman, David R. Loiselle, Neil L. Spector, et al. “Optical and radioiodinated tethered Hsp90 inhibitors reveal selective internalization of ectopic Hsp90 in malignant breast tumor cells.” Chem Biol 20, no. 9 (September 19, 2013): 1187–97. https://doi.org/10.1016/j.chembiol.2013.08.004.Full Text Link to Item
-
Hanks, Brent A., Alisha Holtzhausen, Katherine S. Evans, Rebekah Jamieson, Petra Gimpel, Olivia M. Campbell, Melissa Hector-Greene, et al. “Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment.” J Clin Invest 123, no. 9 (September 2013): 3925–40. https://doi.org/10.1172/JCI65745.Full Text Open Access Copy Link to Item
-
Morse, Michael A., Takuya Osada, Amy Hobeika, Sandip Patel, and H Kim Lyerly. “Biomarkers and Correlative Endpoints for Immunotherapy Trials: What Can We Learn in Lung Cancer from Other Tumor Types?” American Society of Clinical Oncology Educational Book, no. 33 (May 2013): e287–93. https://doi.org/10.14694/edbook_am.2013.33.e287.Full Text
-
Snyder, Joshua C., Lauren K. Rochelle, H Kim Lyerly, Marc G. Caron, and Lawrence S. Barak. “Constitutive internalization of the leucine-rich G protein-coupled receptor-5 (LGR5) to the trans-Golgi network.” J Biol Chem 288, no. 15 (April 12, 2013): 10286–97. https://doi.org/10.1074/jbc.M112.447540.Full Text Link to Item
-
Mook, Robert A., Minyong Chen, Jiuyi Lu, Larry S. Barak, H Kim Lyerly, and Wei Chen. “Small molecule modulators of Wnt/β-catenin signaling.” Bioorg Med Chem Lett 23, no. 7 (April 1, 2013): 2187–91. https://doi.org/10.1016/j.bmcl.2013.01.101.Full Text Link to Item
-
Kravchenko, Julia, Amy P. Abernethy, Maria Fawzy, and H Kim Lyerly. “Minimization of heatwave morbidity and mortality.” Am J Prev Med 44, no. 3 (March 2013): 274–82. https://doi.org/10.1016/j.amepre.2012.11.015.Full Text Link to Item
-
Kearney, Gregory D., Mina Shehee, and H Kim Lyerly. “Bridging the information gap between health and the environment in North Carolina.” J Public Health Manag Pract 19, no. 5 (2013): 475–78. https://doi.org/10.1097/PHH.0b013e318280010e.Full Text Link to Item
-
Lu, Jiuyi, Minyong Chen, Xiu-Rong Ren, Jiangbo Wang, H Kim Lyerly, Larry Barak, and Wei Chen. “Regulation of hedgehog signaling by Myc-interacting zinc finger protein 1, Miz1.” Plos One 8, no. 5 (2013): e63353. https://doi.org/10.1371/journal.pone.0063353.Full Text Link to Item
-
Morse, Michael A., Takuya Osada, Amy Hobeika, Sandip Patel, and H Kim Lyerly. “Biomarkers and correlative endpoints for immunotherapy trials.” Am Soc Clin Oncol Educ Book, 2013. https://doi.org/10.14694/EdBook_AM.2013.33.e287.Full Text Link to Item
-
Morse, Michael, Elizabeth Gabitzsch, Joseph P. Balint, Younong Xu, H. K. Lyerly, and Frank Jones. “Novel adenoviral serotype 5 based immunotherapeutic induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients.” Journal for Immunotherapy of Cancer 1, no. Suppl 1 (January 2013): P129–P129. https://doi.org/10.1186/2051-1426-1-s1-p129.Full Text
-
Nair, Smita, Amy J. Aldrich, Eoin McDonnell, Qing Cheng, Anshu Aggarwal, Pujan Patel, Monique M. Williams, et al. “Immunologic targeting of FOXP3 in inflammatory breast cancer cells.” Plos One 8, no. 1 (2013): e53150. https://doi.org/10.1371/journal.pone.0053150.Full Text Link to Item
-
Patel, S. P., T. Osada, K. Osada, H. Hurwitz, H. K. Lyerly, and M. A. Morse. “Modulation of Immune System Inhibitory Checkpoints in Colorectal Cancer.” Current Colorectal Cancer Reports, 2013, 1–7.
-
Xia, Wenle, Emanual F. Petricoin, Sumin Zhao, Leihua Liu, Takuya Osada, Qing Cheng, Julia D. Wulfkuhle, et al. “An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.” Breast Cancer Res 15, no. 5 (2013): R85. https://doi.org/10.1186/bcr3480.Full Text Link to Item
-
Piede, J. A., S. Zhao, L. Liu, H. K. Lyerly, T. Osada, T. Wang, W. Xia, and N. Spector. “Abstract P4-08-07: Novel insight into the tumor “flare” phenomenon and lapatinib resistance.” Cancer Research 72, no. 24_Supplement (December 15, 2012). https://doi.org/10.1158/0008-5472.sabcs12-p4-08-07.Full Text
-
Wang, Jiangbo, Robert A. Mook, Jiuyi Lu, David M. Gooden, Anthony Ribeiro, Anchen Guo, Larry S. Barak, H Kim Lyerly, and Wei Chen. “Identification of a novel Smoothened antagonist that potently suppresses Hedgehog signaling.” Bioorg Med Chem 20, no. 22 (November 15, 2012): 6751–57. https://doi.org/10.1016/j.bmc.2012.09.030.Full Text Link to Item
-
Osada, Takuya, Peter Berglund, Michael A. Morse, Bolyn Hubby, Whitney Lewis, Donna Niedzwiecki, Xiao Yi Yang, et al. “Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effects.” Cancer Immunol Immunother 61, no. 11 (November 2012): 1941–51. https://doi.org/10.1007/s00262-012-1248-y.Full Text Link to Item
-
Morse, M., A. Hobeika, Y. Xu, J. Balint, S. Balcaitis, H. K. Lyerly, and F. R. Jones. “Ad5 immunity after multiple safe, homologous immunizations against tumor-associated antigens with new recombinant Ad5 vector.” J Clin Oncol 30, no. 30_suppl (October 20, 2012): 85. https://doi.org/10.1200/jco.2012.30.30_suppl.85.Full Text Link to Item
-
Rangwala, Fatima, Kevin P. Williams, Ginger R. Smith, Zainab Thomas, Jennifer L. Allensworth, H Kim Lyerly, Anna Mae Diehl, Michael A. Morse, and Gayathri R. Devi. “Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines.” Bmc Cancer 12 (September 10, 2012): 402. https://doi.org/10.1186/1471-2407-12-402.Full Text Link to Item
-
Cao, Baoshan, Jun Jia, Liwen Ma, Lijun Di, Guohong Song, Yanhua Yuan, Bo Ma, et al. “Recombinant human endostatin could eliminate the pro-angiogenesis priority of SP cells sorted from non-small cell lung cancer cells.” Clin Transl Oncol 14, no. 8 (August 2012): 575–85. https://doi.org/10.1007/s12094-012-0844-9.Full Text Link to Item
-
Wang, Jiangbo, Jiuyi Lu, Robert A. Mook, Min Zhang, Shengli Zhao, Larry S. Barak, Jonathan H. Freedman, H Kim Lyerly, and Wei Chen. “The insecticide synergist piperonyl butoxide inhibits hedgehog signaling: assessing chemical risks.” Toxicol Sci 128, no. 2 (August 2012): 517–23. https://doi.org/10.1093/toxsci/kfs165.Full Text Link to Item
-
Wang, Zheng, Xu Liang, Jing Yu, Xiaohui Zheng, Yulin Zhu, Ying Yan, Ningning Dong, et al. “Non-genetic risk factors and predicting efficacy for docetaxel--drug-induced liver injury among metastatic breast cancer patients.” J Gastroenterol Hepatol 27, no. 8 (August 2012): 1348–52. https://doi.org/10.1111/j.1440-1746.2012.07131.x.Full Text Link to Item
-
Kim, Mickey K., Takuya Osada, William T. Barry, Xiao Yi Yang, Jennifer A. Freedman, Katherine A. Tsamis, Michael Datto, et al. “Characterization of an oxaliplatin sensitivity predictor in a preclinical murine model of colorectal cancer.” Mol Cancer Ther 11, no. 7 (July 2012): 1500–1509. https://doi.org/10.1158/1535-7163.MCT-11-0937.Full Text Link to Item
-
Ren, Xiu-Rong, Junping Wei, Gangjun Lei, Jiangbo Wang, Jiuyi Lu, Wenle Xia, Neil Spector, et al. “Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells.” Breast Cancer Res 14, no. 3 (June 7, 2012): R89. https://doi.org/10.1186/bcr3204.Full Text Link to Item
-
Osada, Takuya, Michael A. Morse, Amy Hobeika, and H Kim Lyerly. “Novel recombinant alphaviral and adenoviral vectors for cancer immunotherapy.” Semin Oncol 39, no. 3 (June 2012): 305–10. https://doi.org/10.1053/j.seminoncol.2012.02.013.Full Text Link to Item
-
Cheng, Qing, Jeffrey T. Chang, Joseph Geradts, Leonard M. Neckers, Timothy Haystead, Neil L. Spector, and H Kim Lyerly. “Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer.” Breast Cancer Res 14, no. 2 (April 17, 2012): R62. https://doi.org/10.1186/bcr3168.Full Text Link to Item
-
Hamilton, Erika, Kimberly Blackwell, Amy C. Hobeika, Timothy M. Clay, Gloria Broadwater, Xiu-Rong Ren, Wei Chen, et al. “Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected].” J Transl Med 10 (February 10, 2012): 28. https://doi.org/10.1186/1479-5876-10-28.Full Text Link to Item
-
Aird, Katherine M., Jennifer L. Allensworth, Ines Batinic-Haberle, H Kim Lyerly, Mark W. Dewhirst, and Gayathri R. Devi. “ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells.” Breast Cancer Res Treat 132, no. 1 (February 2012): 109–19. https://doi.org/10.1007/s10549-011-1568-1.Full Text Link to Item
-
Rhodes, T. D., M. Morse, H. K. Lyerly, J. R. Nevins, B. M. Clary, and S. D. Hsu. “Discovering pathways in the tumor microenvironment important for recurrence-free survival in patients with colorectal liver metastasis.” J Clin Oncol 30, no. 4_suppl (February 2012): 480.Link to Item
-
Rhodes, Terence Duane, Michael Morse, H Kim Lyerly, Joseph R. Nevins, Bryan M. Clary, and Shiaowen David Hsu. “Discovering pathways in the tumor microenvironment important for recurrence-free survival in patients with colorectal liver metastasis.” Journal of Clinical Oncology 30, no. 4_suppl (February 1, 2012): 480–480. https://doi.org/10.1200/jco.2012.30.4_suppl.480.Full Text
-
VanDeusen, J. B., J. Uronis, M. Morse, M. L. Gatza, M. B. Datto, C. Mantyh, H. K. Lyerly, J. R. Nevins, B. M. Clary, and S. D. Hsu. “Predictive and prognostic markers of recurrence after resection of primary or metastatic colorectal cancer.” J Clin Oncol 30, no. 4_suppl (February 2012): 447.Link to Item
-
VanDeusen, Jeffrey Bryan, Joshua Uronis, Michael Morse, Michael L. Gatza, Michael B. Datto, Christopher Mantyh, H Kim Lyerly, Joseph R. Nevins, Bryan M. Clary, and Shiaowen David Hsu. “Predictive and prognostic markers of recurrence after resection of primary or metastatic colorectal cancer.” Journal of Clinical Oncology 30, no. 4_suppl (February 1, 2012): 447–447. https://doi.org/10.1200/jco.2012.30.4_suppl.447.Full Text
-
CHEN WEI, Kim, Kim BARAK LAWRENCE, Kim LYERLY H KIM, and Kim WANG JIANGBO. “SMOOTHENED RECEPTOR MODULATORS,” 2012.
-
Kravchenko, Julia, Igor Akushevich, Amy P. Abernethy, and H Kim Lyerly. “Evaluating the number of stages in development of squamous cell and adenocarcinomas across cancer sites using human population-based cancer modeling.” Plos One 7, no. 5 (2012): e37430. https://doi.org/10.1371/journal.pone.0037430.Full Text Open Access Copy Link to Item
-
Morse, M. A., A. Hobeika, D. Serra, K. Aird, M. McKinney, A. Aldrich, T. Clay, et al. “Depleting regulatory T cells with arginine-rich, cell-penetrating, peptide-conjugated morpholino oligomer targeting FOXP3 inhibits regulatory T-cell function.” Cancer Gene Ther 19, no. 1 (January 2012): 30–37. https://doi.org/10.1038/cgt.2011.63.Full Text Link to Item
-
Uronis, Joshua M., Takuya Osada, Shannon McCall, Xiao Yi Yang, Christopher Mantyh, Michael A. Morse, H Kim Lyerly, Bryan M. Clary, and David S. Hsu. “Histological and molecular evaluation of patient-derived colorectal cancer explants.” Plos One 7, no. 6 (2012): e38422. https://doi.org/10.1371/journal.pone.0038422.Full Text Link to Item
-
Hamilton, E. P., A. C. Hobeika, H. K. Lyerly, K. Owzar, G. Rocha, G. G. Kimmick, P. K. Marcom, J. M. Peppercorn, M. A. Morse, and K. L. Blackwell. “P1-13-03: Zoledronic Acid Induces an Immune Response in Breast Cancer Patients through Stimulation of Central Memory and Effector Memory gamma/delta T-Cells.” Cancer Research 71, no. 24_Supplement (December 15, 2011). https://doi.org/10.1158/0008-5472.sabcs11-p1-13-03.Full Text
-
Hartman, Zachary C., Junping Wei, Oliver K. Glass, Hongtao Guo, Gangjun Lei, Xiao-Yi Yang, Takuya Osada, et al. “Increasing vaccine potency through exosome antigen targeting.” Vaccine 29, no. 50 (November 21, 2011): 9361–67. https://doi.org/10.1016/j.vaccine.2011.09.133.Full Text Link to Item
-
Lyerly, H Kim, Amy P. Abernethy, Martin R. Stockler, Bogda Koczwara, Zeba Aziz, Reena Nair, and Lesley Seymour. “Need for global partnership in cancer care: perceptions of cancer care researchers attending the 2010 australia and Asia pacific clinical oncology research development workshop.” J Oncol Pract 7, no. 5 (September 2011): 324–29. https://doi.org/10.1200/JOP.2011.000230.Full Text Link to Item
-
Xia, Wenle, Zuguo Liu, Rongrong Zong, Leihua Liu, Sumin Zhao, Sarah S. Bacus, Yubin Mao, et al. “Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors.” Mol Cancer Ther 10, no. 8 (August 2011): 1367–74. https://doi.org/10.1158/1535-7163.MCT-10-0991.Full Text Link to Item
-
Morse, Michael A., Robert Chapman, John Powderly, Kimberly Blackwell, Tibor Keler, Jennifer Green, Renee Riggs, et al. “Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients.” Clin Cancer Res 17, no. 14 (July 15, 2011): 4844–53. https://doi.org/10.1158/1078-0432.CCR-11-0891.Full Text Link to Item
-
Hartman, Zachary C., Xiao-Yi Yang, Oliver Glass, Gangjun Lei, Takuya Osada, Sandeep S. Dave, Michael A. Morse, Timothy M. Clay, and Herbert K. Lyerly. “HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis.” Cancer Res 71, no. 13 (July 1, 2011): 4380–91. https://doi.org/10.1158/0008-5472.CAN-11-0308.Full Text Link to Item
-
Kravchenko, Julia, Igor Akushevich, Victoria L. Seewaldt, Amy P. Abernethy, and H Kim Lyerly. “Breast cancer as heterogeneous disease: contributing factors and carcinogenesis mechanisms.” Breast Cancer Res Treat 128, no. 2 (July 2011): 483–93. https://doi.org/10.1007/s10549-011-1347-z.Full Text Open Access Copy Link to Item
-
Osada, Takuya, Minyong Chen, Xiao Yi Yang, Ivan Spasojevic, Jeffrey B. Vandeusen, David Hsu, Bryan M. Clary, et al. “Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations.” Cancer Res 71, no. 12 (June 15, 2011): 4172–82. https://doi.org/10.1158/0008-5472.CAN-10-3978.Full Text Link to Item
-
Hanks, B. A., O. M. Campbell, J. D. Lee, M. Morse, T. M. Clay, H. K. Lyerly, and G. C. Blobe. “Role of the type III TGF-β receptor in modulating antitumor immunity during breast cancer progression.” J Clin Oncol 29, no. 15_suppl (May 20, 2011): 10540.Link to Item
-
Lyerly, H. K., A. Hobeika, D. Niedzwiecki, T. Osada, J. Marshall, C. R. Garrett, D. Z. Chang, et al. “A dendritic cell-based vaccine effects on T-cell responses compared with a viral vector vaccine when administered to patients following resection of colorectal metastases in a randomized phase II study.” J Clin Oncol 29, no. 15_suppl (May 20, 2011): 2533.Link to Item
-
Morse, M., D. Niedzwiecki, J. Marshall, C. R. Garrett, D. Z. Chang, M. Aklilu, T. S. Crocenzi, et al. “Survival rates among patients vaccinated following resection of colorectal cancer metastases in a phase II randomized study compared with contemporary controls.” J Clin Oncol 29, no. 15_suppl (May 20, 2011): 3557.Link to Item
-
Morse, Michael A., Angeles A. Secord, Kimberly Blackwell, Amy C. Hobeika, Gomathinayagam Sinnathamby, Takuya Osada, Julie Hafner, et al. “MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer.” Clin Cancer Res 17, no. 10 (May 15, 2011): 3408–19. https://doi.org/10.1158/1078-0432.CCR-10-2614.Full Text Link to Item
-
Thomas, Z. I., W. Gibson, J. Z. Sexton, K. M. Aird, S. M. Ingram, A. Aldrich, H. K. Lyerly, G. R. Devi, and K. P. Williams. “Targeting GLI1 expression in human inflammatory breast cancer cells enhances apoptosis and attenuates migration.” Br J Cancer 104, no. 10 (May 10, 2011): 1575–86. https://doi.org/10.1038/bjc.2011.133.Full Text Link to Item
-
Shetty, Vivekananda, Gomathinayagam Sinnathamby, Zacharie Nickens, Punit Shah, Julie Hafner, Lisa Mariello, Shivali Kamal, et al. “MHC class I-presented lung cancer-associated tumor antigens identified by immunoproteomics analysis are targets for cancer-specific T cell response.” J Proteomics 74, no. 5 (May 1, 2011): 728–43. https://doi.org/10.1016/j.jprot.2011.02.020.Full Text Link to Item
-
Smith, Sophia K., James E. Herndon, H Kim Lyerly, April Coan, Jane L. Wheeler, Tina Staley, and Amy P. Abernethy. “Correlates of quality of life-related outcomes in breast cancer patients participating in the Pathfinders pilot study.” Psychooncology 20, no. 5 (May 2011): 559–64. https://doi.org/10.1002/pon.1770.Full Text Link to Item
-
Clay, Timothy M., Takuya Osada, Zachary C. Hartman, Amy Hobeika, Gayathri Devi, Michael A. Morse, and H Kim Lyerly. “Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines.” Immunol Res 49, no. 1–3 (April 2011): 235–47. https://doi.org/10.1007/s12026-010-8186-6.Full Text Link to Item
-
Sinnathamby, G., J. Zerfass, J. Hafner, P. Block, Z. Nickens, A. Hobeika, A. A. Secord, H. K. Lyerly, M. A. Morse, and R. Philip. “ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers.” Clin Exp Immunol 163, no. 3 (March 2011): 324–32. https://doi.org/10.1111/j.1365-2249.2010.04298.x.Full Text Link to Item
-
Freedman, J. A., T. Osada, K. A. Tsamis, M. Morse, B. M. Clary, H. K. Lyerly, J. R. Nevins, T. M. Clay, and S. D. Hsu. “Development of an assay to predict oxaliplatin sensitivity from formalin-fixed, paraffin-embedded (FFPE) colorectal cancer tissues.” J Clin Oncol 29, no. 4_suppl (February 2011): 429.Link to Item
-
CHEN WEI, Kim, Kim BARAK LAWRENCE, Kim LYERLY H KIM, and Kim WANG JIANGBO. “SMOOTHENED RECEPTOR MODULATORS,” 2011.
-
CHEN WEI, Kim, Kim CHEN MINYONG, Kim LYERLY H KIM, Kim BARAK LAWRENCE S, Kim MOOK ROBERT, Kim OSADA TAYUKA, and Kim MORSE MICHAEL A. “TREATMENT OF WNT/FRIZZLED-RELATED DISEASES,” 2011.
-
Hobeika, Amy C., Michael A. Morse, Takuya Osada, Sharon Peplinski, H Kim Lyerly, and Timothy M. Clay. “Depletion of human regulatory T cells.” Methods Mol Biol 707 (2011): 219–31. https://doi.org/10.1007/978-1-61737-979-6_14.Full Text Link to Item
-
“Proceedings of the 2nd meeting of the asian cellular therapy organization.” J Stem Cells Regen Med 7, no. 3 (2011): 98–148. https://doi.org/10.46582/jsrm.0703016.Full Text Link to Item
-
Wang, Xinhui, Takuya Osada, Yangyang Wang, Ling Yu, Koichi Sakakura, Akihiro Katayama, James B. McCarthy, et al. “CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer.” J Natl Cancer Inst 102, no. 19 (October 6, 2010): 1496–1512. https://doi.org/10.1093/jnci/djq343.Full Text Link to Item
-
Hartman, Zachary C., Takuya Osada, Oliver Glass, Xiao Y. Yang, Gang-Jun Lei, H Kim Lyerly, and Timothy M. Clay. “Ligand-independent toll-like receptor signals generated by ectopic overexpression of MyD88 generate local and systemic antitumor immunity.” Cancer Res 70, no. 18 (September 15, 2010): 7209–20. https://doi.org/10.1158/0008-5472.CAN-10-0905.Full Text Link to Item
-
Morse, Michael A., Amy C. Hobeika, Takuya Osada, Peter Berglund, Bolyn Hubby, Sarah Negri, Donna Niedzwiecki, et al. “An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer.” J Clin Invest 120, no. 9 (September 2010): 3234–41. https://doi.org/10.1172/JCI42672.Full Text Open Access Copy Link to Item
-
Hsu, David S., Mickey K. Kim, Bala S. Balakumaran, Chaitanya R. Acharya, Carey K. Anders, Tim Clay, H Kim Lyerly, Charles G. Drake, Michael A. Morse, and Phillip G. Febbo. “Immune signatures predict prognosis in localized cancer.” Cancer Invest 28, no. 7 (August 2010): 765–73. https://doi.org/10.3109/07357900903095755.Full Text Link to Item
-
Abernethy, Amy P., James E. Herndon, April Coan, Tina Staley, Jane L. Wheeler, Krista Rowe, Sophia K. Smith, H. Shaw, and H Kim Lyerly. “Phase 2 pilot study of Pathfinders: a psychosocial intervention for cancer patients.” Support Care Cancer 18, no. 7 (July 2010): 893–98. https://doi.org/10.1007/s00520-010-0823-z.Full Text Link to Item
-
Gabitzsch, Elizabeth S., Younong Xu, Joseph P. Balint, Zachary C. Hartman, H Kim Lyerly, and Frank R. Jones. “Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA.” Cancer Immunol Immunother 59, no. 7 (July 2010): 1131–35. https://doi.org/10.1007/s00262-010-0847-8.Full Text Link to Item
-
Morse, Michael A., Junping Wei, Zachary Hartman, Wenle Xia, Xiu-Rong Ren, Gangjun Lei, William T. Barry, et al. “Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo.” Int J Cancer 126, no. 12 (June 15, 2010): 2893–2903. https://doi.org/10.1002/ijc.24995.Full Text Link to Item
-
Abernethy, Amy P., Asif Ahmad, S Yousuf Zafar, Jane L. Wheeler, Jennifer Barsky Reese, and H Kim Lyerly. “Electronic patient-reported data capture as a foundation of rapid learning cancer care.” Med Care 48, no. 6 Suppl (June 2010): S32–38. https://doi.org/10.1097/MLR.0b013e3181db53a4.Full Text Link to Item
-
Clarke, Jeffrey M., Michael A. Morse, H Kim Lyerly, Timothy Clay, and Tayuka Osada. “Adenovirus vaccine immunotherapy targeting WT1-expressing tumors.” Expert Opin Biol Ther 10, no. 6 (June 2010): 875–83. https://doi.org/10.1517/14712591003798278.Full Text Link to Item
-
Hsu, S. D., M. K. Kim, A. Foye, A. Silvestri, H. K. Lyerly, M. Morse, E. Petricoin, and P. G. Febbo. “Use of gene expression signatures to identify origin of primary and therapeutic strategies for patients with advanced solid tumors.” Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): 10504–10504. https://doi.org/10.1200/jco.2010.28.15_suppl.10504.Full Text
-
Wang, Jiangbo, Jiuyi Lu, Michael C. Bond, Minyong Chen, Xiu-Rong Ren, H Kim Lyerly, Larry S. Barak, and Wei Chen. “Identification of select glucocorticoids as Smoothened agonists: potential utility for regenerative medicine.” Proc Natl Acad Sci U S A 107, no. 20 (May 18, 2010): 9323–28. https://doi.org/10.1073/pnas.0910712107.Full Text Open Access Copy Link to Item
-
Aird, Katherine M., Rami B. Ghanayem, Sharon Peplinski, Herbert K. Lyerly, and Gayathri R. Devi. “X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor.” Mol Cancer Ther 9, no. 5 (May 2010): 1432–42. https://doi.org/10.1158/1535-7163.MCT-10-0160.Full Text Link to Item
-
Osada, Takuya, David Hsu, Scott Hammond, Amy Hobeika, Gayathri Devi, Timothy M. Clay, H Kim Lyerly, and Michael A. Morse. “Abstract 5338: Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T cell killing mediated by CEA/CD3-bispecific T cell-engaging BiTE antibody.” Cancer Research 70, no. 8_Supplement (April 15, 2010): 5338–5338. https://doi.org/10.1158/1538-7445.am10-5338.Full Text
-
Hartman, Zachary C., Junping Wei, Takuya Osada, Oliver Glass, Gangjun Lei, Xiao-Yi Yang, Sharon Peplinski, et al. “An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity.” Clin Cancer Res 16, no. 5 (March 1, 2010): 1466–77. https://doi.org/10.1158/1078-0432.CCR-09-2549.Full Text Link to Item
-
Osada, T., D. Hsu, S. Hammond, A. Hobeika, G. Devi, T. M. Clay, H. K. Lyerly, and M. A. Morse. “Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody.” Br J Cancer 102, no. 1 (January 5, 2010): 124–33. https://doi.org/10.1038/sj.bjc.6605364.Full Text Link to Item
-
Chen, Minyong, Jiangbo Wang, Jiuyi Lu, Michael C. Bond, Xiu-Rong Ren, H Kim Lyerly, Larry S. Barak, and Wei Chen. “The anti-helminthic niclosamide inhibits Wnt/Frizzled1 signaling.” Biochemistry 48, no. 43 (November 3, 2009): 10267–74. https://doi.org/10.1021/bi9009677.Full Text Link to Item
-
Wooten, D. R., D. P. I. I. I. Livingston, H. J. Lyerly, J. B. Holland, E. N. Jellen, D. S. Marshall, and J. P. Murphy. “Quantitative Trait Loci and Epistasis for Oat Winter-Hardiness Component Traits.” Crop Science. 49, no. 6 (November 2009): 1989–98. https://doi.org/10.2135/cropsci2008.10.0612.Full Text
-
Osada, T., X. Y. Yang, Z. C. Hartman, O. Glass, B. L. Hodges, D. Niedzwiecki, M. A. Morse, H. K. Lyerly, A. Amalfitano, and T. M. Clay. “Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity.” Cancer Gene Ther 16, no. 9 (September 2009): 673–82. https://doi.org/10.1038/cgt.2009.17.Full Text Link to Item
-
Johnson, Benjamin, Takuya Osada, Timothy Clay, Herbert Lyerly, and Michael Morse. “Physiology and therapeutics of vascular endothelial growth factor in tumor immunosuppression.” Curr Mol Med 9, no. 6 (August 2009): 702–7. https://doi.org/10.2174/156652409788970634.Full Text Link to Item
-
Ding, X., A. B. Mohd, Z. Huang, T. Baba, M. Q. Bernardini, H. K. Lyerly, A. Berchuck, S. K. Murphy, A. B. Buermeyer, and G. R. Devi. “MLH1 expression sensitises ovarian cancer cells to cell death mediated by XIAP inhibition.” Br J Cancer 101, no. 2 (July 21, 2009): 269–77. https://doi.org/10.1038/sj.bjc.6605180.Full Text Link to Item
-
Abernethy, Amy P., James E. Herndon, Jane L. Wheeler, Jeannette M. Day, Linda Hood, Meenal Patwardhan, Heather Shaw, and Herbert Kim Lyerly. “Feasibility and acceptability to patients of a longitudinal system for evaluating cancer-related symptoms and quality of life: pilot study of an e/Tablet data-collection system in academic oncology.” J Pain Symptom Manage 37, no. 6 (June 2009): 1027–38. https://doi.org/10.1016/j.jpainsymman.2008.07.011.Full Text Link to Item
-
Abernethy, A. P., S. Y. Zafar, R. Coeytaux, K. Rowe, J. L. Wheeler, and H. K. Lyerly. “Electronic patient-reported data capture as the foundation of a learning health care system.” J Clin Oncol 27, no. 15_suppl (May 20, 2009): 6522.Link to Item
-
Lyerly, H. K., T. Staley, J. E. Herndon, A. Coan, J. L. Wheeler, K. Rowe, B. Horne, and A. P. Abernethy. “Impact of a psychosocial intervention on performance status and coping.” J Clin Oncol 27, no. 15_suppl (May 20, 2009): 9611.Link to Item
-
Osada, Takuya, Christopher Y. Woo, Matthew McKinney, Xiao Yi Yang, Gangjun Lei, Heather G. Labreche, Zachary C. Hartman, et al. “Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine.” Clin Cancer Res 15, no. 8 (April 15, 2009): 2789–96. https://doi.org/10.1158/1078-0432.CCR-08-2589.Full Text Link to Item
-
CHEN WEI, Kim, Kim BARAK LAWRENCE, Kim LYERLY H KIM, and Kim WANG JIANGBO. “SMOOTHENED RECEPTOR MODULATORS,” 2009.
-
Dupont, Alexandra, Jane Wheeler, James E. Herndon, April Coan, S Yousuf Zafar, Linda Hood, Meenal Patwardhan, Heather S. Shaw, H Kim Lyerly, and Amy P. Abernethy. “Use of tablet personal computers for sensitive patient-reported information.” J Support Oncol 7, no. 3 (2009): 91–97.Link to Item
-
FERRONE SOLDANO, Kim, Kim WANG XINHUI, Kim CLAY TIM, Kim LYERLY H KIM, Kim MORSE MICHAEL A, Kim DEVI GAY, and Kim OSADA TAKUYA. “INHIBITION OF BREAST CARCINOMA STEM CELL GROWTH AND METASTASIS,” 2009.
-
Abernethy, Amy P., James E. Herndon, Jane L. Wheeler, Meenal Patwardhan, Heather Shaw, H Kim Lyerly, and Kevin Weinfurt. “Improving health care efficiency and quality using tablet personal computers to collect research-quality, patient-reported data.” Health Serv Res 43, no. 6 (December 2008): 1975–91. https://doi.org/10.1111/j.1475-6773.2008.00887.x.Full Text Link to Item
-
Cheever, Martin A., Jeffrey Schlom, Louis M. Weiner, H Kim Lyerly, Mary L. Disis, Addison Greenwood, Oren Grad, William G. Nelson, and William G. Translational Research Working Group. “Translational Research Working Group developmental pathway for immune response modifiers.” Clin Cancer Res 14, no. 18 (September 15, 2008): 5692–99. https://doi.org/10.1158/1078-0432.CCR-08-1266.Full Text Link to Item
-
Morse, Michael A., Amy C. Hobeika, Takuya Osada, Delila Serra, Donna Niedzwiecki, H Kim Lyerly, and Timothy M. Clay. “Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines.” Blood 112, no. 3 (August 1, 2008): 610–18. https://doi.org/10.1182/blood-2008-01-135319.Full Text Link to Item
-
Osada, Takuya, Gabriel Chong, Robert Tansik, Timothy Hong, Neil Spector, Rakesh Kumar, Herbert I. Hurwitz, et al. “The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients.” Cancer Immunol Immunother 57, no. 8 (August 2008): 1115–24. https://doi.org/10.1007/s00262-007-0441-x.Full Text Link to Item
-
Clay, T. M., A. Hobeika, T. Osada, D. Serra, D. Niedzwiecki, H. K. Lyerly, and M. A. Morse. “Depletion of human regulatory T cells (Treg) and antigen-specific immune responses to cancer vaccines.” J Clin Oncol 26, no. 15_suppl (May 20, 2008): 3010.Link to Item
-
Uronis, H. E., J. E. Herndon, A. Coan, K. Bronson, J. Wheeler, H. K. Lyerly, M. A. Morse, and A. P. Abernethy. “E/Tablets to collect research-quality, patient-reported data.” J Clin Oncol 26, no. 15_suppl (May 20, 2008): 17528.Link to Item
-
Maecker, Holden T., Jeffrey Hassler, Janice K. Payne, Amanda Summers, Karrie Comatas, Manar Ghanayem, Michael A. Morse, et al. “Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides.” Bmc Immunol 9 (March 17, 2008): 9. https://doi.org/10.1186/1471-2172-9-9.Full Text Link to Item
-
Aird, Katherine M., Xiuyun Ding, Aris Baras, Junping Wei, Michael A. Morse, Timothy Clay, Herbert K. Lyerly, and Gayathri R. Devi. “Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression.” Mol Cancer Ther 7, no. 1 (January 2008): 38–47. https://doi.org/10.1158/1535-7163.MCT-07-0370.Full Text Link to Item
-
FERRONE SOLDANO, Frank, Frank WANG XIANHUI, Frank CLAY TIM, Frank LYERLY KIM H, Frank MORSE MICHAEL A, Frank DEVI GAY, and Frank OSADA TAKUYA. “INHIBITION OF BREAST CARCINOMA STEM CELL GROWTH AND METASTASIS.,” 2008.
-
FERRONE SOLDANO, Kim, Kim WANG XINHUI, Kim CLAY TIM, Kim LYERLY KIM H, Kim MORSE MICHAEL A, Kim DEVI GAY, and Kim OSADA TAKUYA. “INHIBITION OF BREAST CARCINOMA STEM CELL GROWTH AND METASTASIS,” 2008.
-
Hobeika, Ac, T. Osada, D. Serra, S. Peplinski, K. Hanson, Y. Tanaka, D. Niedzwiecki, et al. “Detailed analysis of cytomegalovirus (CMV)-specific T cells expanded for adoptive immunotherapy of CMV infection following allogeneic stem cell transplantation for malignant disease.” Cytotherapy 10, no. 3 (2008): 289–302. https://doi.org/10.1080/14653240801927040.Full Text Link to Item
-
Morse, Michael, Lee Langer, Alexander Starodub, Amy Hobeika, Timothy Clay, and H Kim Lyerly. “Current immunotherapeutic strategies in colon cancer.” Surg Oncol Clin N Am 16, no. 4 (October 2007): 873–x. https://doi.org/10.1016/j.soc.2007.07.005.Full Text Link to Item
-
Morse, Michael A., Amy Hobeika, Takuya Osada, Donna Niedzwiecki, Paul Kelly Marcom, Kimberly L. Blackwell, Carey Anders, Gayathri R. Devi, H Kim Lyerly, and Timothy M. Clay. “Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2.” J Transl Med 5 (September 6, 2007): 42. https://doi.org/10.1186/1479-5876-5-42.Full Text Link to Item
-
Osada, T., T. M. Clay, C. Y. Woo, M. A. Morse, and H. Kim Lyerly. “Natural killer cell activation and dendritic cell-based vaccines.” Minerva Biotecnologica 19, no. 3 (September 1, 2007): 91–104.
-
Jing, Yu, Stefan Gravenstein, N Rao Chaganty, Nianyong Chen, Kim Herbert Lyerly, Sebastian Joyce, and Yuping Deng. “Aging is associated with a rapid decline in frequency, alterations in subset composition, and enhanced Th2 response in CD1d-restricted NKT cells from human peripheral blood.” Exp Gerontol 42, no. 8 (August 2007): 719–32. https://doi.org/10.1016/j.exger.2007.01.009.Full Text Link to Item
-
Murad, Yanal M., Timothy M. Clay, H Kim Lyerly, and Michael A. Morse. “CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy.” Expert Opin Biol Ther 7, no. 8 (August 2007): 1257–66. https://doi.org/10.1517/14712598.7.8.1257.Full Text Link to Item
-
Hu, Zhenlin, Xiao Yi Yang, Yunbo Liu, Georgy N. Sankin, Eric C. Pua, Michael A. Morse, H Kim Lyerly, Timothy M. Clay, and Pei Zhong. “Investigation of HIFU-induced anti-tumor immunity in a murine tumor model.” J Transl Med 5 (July 11, 2007): 34. https://doi.org/10.1186/1479-5876-5-34.Full Text Link to Item
-
Mosca, Paul J., H Kim Lyerly, Timothy M. Clay, and Michael A. Morse. “Dendritic cell vaccines.” Front Biosci 12 (May 1, 2007): 4050–60. https://doi.org/10.2741/2371.Full Text Link to Item
-
Hartman, Zachary, Daniel Appledorn, Todd Mendelson, Herbert Kim Lyerly, Tim Clay, and Andrea Amalfitano. “A New Human Adenoviral Type 4 viral vector system displays highly enhanced immunogenicity that is complement-dependent and correlates with altered adaptive responses.” Journal of Immunology 178 (April 1, 2007).Link to Item
-
Hartman, Zachary, Xiao Yi Yang, Gangjun Lei, Andrea Amalfitano, Michael Morse, Herbert Kim Lyerly, and Tim Clay. “Modulation of adenoviral vector immune responses through the over-expression of immune adaptor and viral immuno-modulatory genes.” Journal of Immunology 178 (April 1, 2007).Link to Item
-
Johnson, Benjamin F., Timothy M. Clay, Amy C. Hobeika, H Kim Lyerly, and Michael A. Morse. “Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy.” Expert Opin Biol Ther 7, no. 4 (April 2007): 449–60. https://doi.org/10.1517/14712598.7.4.449.Full Text Link to Item
-
Wei, Junping, Zachary Hartman, Takuya Osada, Xiao Yi Yang, Gangjun Lei, Haixiang Jiang, Gabriel Chong, et al. “Adenovirus-human HER2 vaccine inhibits breast cancer growth and vaccine induced antibodies (VIA) are efficacious against Herceptin-refractory human breast cancer.” Journal of Immunology 178 (April 1, 2007).Link to Item
-
Hutchings, Yalonda, Takuya Osada, Christopher Y. Woo, Timothy M. Clay, H Kim Lyerly, and Michael A. Morse. “Immunotherapeutic targeting of Wilms' tumor protein.” Curr Opin Mol Ther 9, no. 1 (February 2007): 62–69.Link to Item
-
FERRONE SOLDANO, Frank, Frank WANG XINHUI, Frank CLAY TIM, Frank LYERLY KIM H, Frank MORSE MICHAEL A, Frank DEVI GAY, and Frank OSADA TAKUYA. “Inhibition of breast carcinoma stem cell growth and metastasis,” 2007.
-
FERRONE SOLDANO, Kim, Kim WANG XINHUI, Kim CLAY TIM, Kim LYERLY KIM H, Kim MORSE MICHAEL A, Kim DEVI GAY, and Kim OSADA TAKUYA. “INHIBITION OF BREAST CARCINOMA STEM CELL GROWTH AND METASTASIS,” 2007.
-
Woo, Christopher Y., Takuya Osada, Timothy M. Clay, H Kim Lyerly, and Michael A. Morse. “Recent clinical progress in virus-based therapies for cancer.” Expert Opin Biol Ther 6, no. 11 (November 2006): 1123–34. https://doi.org/10.1517/14712598.6.11.1123.Full Text Link to Item
-
Osada, Takuya, Timothy Clay, Amy Hobeika, H Kim Lyerly, and Michael A. Morse. “NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity.” Cancer Immunol Immunother 55, no. 9 (September 2006): 1122–31. https://doi.org/10.1007/s00262-005-0089-3.Full Text Link to Item
-
Toloza, Eric M., Michael A. Morse, and H Kim Lyerly. “Gene therapy for lung cancer.” J Cell Biochem 99, no. 1 (September 1, 2006): 1–22. https://doi.org/10.1002/jcb.20851.Full Text Link to Item
-
Hu, Z., X. Y. Yang, Y. Liu, M. A. Morse, H. K. Lyerly, T. M. Clay, and P. Zhong. “Investigation of HIFU-induced anti-tumor immunity in a murine tumor model.” Aip Conference Proceedings 829 (May 8, 2006): 241–45. https://doi.org/10.1063/1.2205474.Full Text
-
Woo, Christopher Y., Timothy M. Clay, H Kim Lyerly, Michael A. Morse, and Takuya Osada. “Role of natural killer cell function in dendritic cell-based vaccines.” Expert Rev Vaccines 5, no. 1 (February 2006): 55–65. https://doi.org/10.1586/14760584.5.1.55.Full Text Link to Item
-
Disis, Mary L., Corazon dela Rosa, Vivian Goodell, Ling-Yu Kuan, Jennie C. C. Chang, Kristina Kuus-Reichel, Timothy M. Clay, et al. “Maximizing the retention of antigen specific lymphocyte function after cryopreservation.” J Immunol Methods 308, no. 1–2 (January 20, 2006): 13–18. https://doi.org/10.1016/j.jim.2005.09.011.Full Text Link to Item
-
Osada, Takuya, Timothy M. Clay, Christopher Y. Woo, Michael A. Morse, and H Kim Lyerly. “Dendritic cell-based immunotherapy.” Int Rev Immunol 25, no. 5–6 (2006): 377–413. https://doi.org/10.1080/08830180600992456.Full Text Link to Item
-
Disis, Mary L., and H Kim Lyerly. “Global role of the immune system in identifying cancer initiation and limiting disease progression.” J Clin Oncol 23, no. 35 (December 10, 2005): 8923–25. https://doi.org/10.1200/JCO.2005.10.007.Full Text Link to Item
-
Hu, Zhenlin, Xiao Yi Yang, Yunbo Liu, Michael A. Morse, H Kim Lyerly, Timothy M. Clay, and Pei Zhong. “Release of endogenous danger signals from HIFU-treated tumor cells and their stimulatory effects on APCs.” Biochem Biophys Res Commun 335, no. 1 (September 16, 2005): 124–31. https://doi.org/10.1016/j.bbrc.2005.07.071.Full Text Link to Item
-
Osada, Takuya, Michael A. Morse, H Kim Lyerly, and Timothy M. Clay. “Ex vivo expanded human CD4+ regulatory NKT cells suppress expansion of tumor antigen-specific CTLs.” Int Immunol 17, no. 9 (September 2005): 1143–55. https://doi.org/10.1093/intimm/dxh292.Full Text Link to Item
-
Chui, Stephen Y., Timothy M. Clay, H Kim Lyerly, and Michael A. Morse. “The development of therapeutic and preventive vaccines for gastric cancer and Helicobacter pylori.” Cancer Epidemiol Biomarkers Prev 14, no. 8 (August 2005): 1883–89. https://doi.org/10.1158/1055-9965.EPI-04-0775.Full Text Link to Item
-
Maecker, Holden T., James Moon, Sonny Bhatia, Smita A. Ghanekar, Vernon C. Maino, Janice K. Payne, Kristine Kuus-Reichel, et al. “Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT.” Bmc Immunol 6 (July 18, 2005): 17. https://doi.org/10.1186/1471-2172-6-17.Full Text Link to Item
-
Morse, M., T. Osada, A. Hobeika, S. Chui, T. Clay, and H. K. Lyerly. “Correlation of clinical outcome with natural killer (NK) response to an anti-cancer, dendritic cell-based vaccine.” J Clin Oncol 23, no. 16_suppl (June 2005): 2585.Link to Item
-
Morse, Michael A., Timothy M. Clay, Amy C. Hobeika, Takuya Osada, Shubi Khan, Stephen Chui, Donna Niedzwiecki, Dennis Panicali, Jeffrey Schlom, and H Kim Lyerly. “Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules.” Clin Cancer Res 11, no. 8 (April 15, 2005): 3017–24. https://doi.org/10.1158/1078-0432.CCR-04-2172.Full Text Link to Item
-
Morse, Michael A., Jennifer Garst, Takuya Osada, Shubi Khan, Amy Hobeika, Timothy M. Clay, Nancy Valente, et al. “A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer.” J Transl Med 3, no. 1 (February 21, 2005): 9. https://doi.org/10.1186/1479-5876-3-9.Full Text Link to Item
-
Morse, Michael A., Stephen Chui, Amy Hobeika, H Kim Lyerly, and Timothy Clay. “Recent developments in therapeutic cancer vaccines.” Nat Clin Pract Oncol 2, no. 2 (February 2005): 108–13. https://doi.org/10.1038/ncponc0098.Full Text Link to Item
-
Hobeika, Amy C., Michael A. Morse, Takuya Osada, Manar Ghanayem, Donna Niedzwiecki, Robert Barrier, H Kim Lyerly, and Timothy M. Clay. “Enumerating antigen-specific T-cell responses in peripheral blood: a comparison of peptide MHC Tetramer, ELISpot, and intracellular cytokine analysis.” J Immunother 28, no. 1 (2005): 63–72. https://doi.org/10.1097/00002371-200501000-00008.Full Text Link to Item
-
Mosca, Paul J., Timothy M. Clay, Michael A. Morse, and H Kim Lyerly. “Immune monitoring.” Cancer Treat Res 123 (2005): 369–88. https://doi.org/10.1007/0-387-27545-2_16.Full Text Link to Item
-
Chui, S., T. M. Clay, P. J. Mosca, A. C. Hobeika, T. Osada, L. Galibert, D. Caron, H. K. Lyerly, and M. A. Morse. “Flt3-ligand as a vaccine adjuvant: Results in a study of Flt3-ligand plus tetanus toxoid immunization.” Journal of Applied Research 4, no. 4 (December 1, 2004): 536–49.
-
Morse, M. A., T. M. Clay, A. C. Hobeika, S. Chui, P. J. Mosca, D. Caron, and H. K. Lyerly. “Active immunotherapy with Flt3-ligand mobilized peripheral blood dendritic cells loaded with carcinoembryonic antigen peptide in patients with metastatic malignancies.” Journal of Applied Research 4, no. 4 (December 1, 2004): 554–69.
-
Lyerly, H Kim. “Your Ad here: optimizing adenoviral vector-based vaccines.” Blood 104, no. 9 (November 1, 2004): 2612–13. https://doi.org/10.1182/blood-2004-08-3082.Full Text
-
Chui, S. Y., M. A. Morse, T. Doldo, T. Osada, T. M. Clay, H. K. Lyerly, S. Khan, A. Gattis, and A. C. Hobeika. “Regulatory and effector T cell subsets and dendritic cells in breast cancer.” J Clin Oncol 22, no. 14_suppl (July 15, 2004): 9697.Link to Item
-
Kaufman, H. L., R. Dipaola, M. Von Mehren, J. Marshall, H. K. Lyerly, H. Streicher, J. Schlom, D. Panicali, and T. Schuetz. “Safety profile of therapeutic pox virus-based vaccines for cancer.” J Clin Oncol 22, no. 14_suppl (July 15, 2004): 2513.Link to Item
-
Morse, M., T. Clay, A. Hobeika, T. Osada, D. Panicali, and H. K. Lyerly. “Phase I study of immunization with dendritic cells (DC) modified with recombinant fowlpox encoding carcinoembryonic antigen (CEA) and the triad of costimulatory molecules CD54, CD58, and CD80 (rF-CEA(6D)-TRICOM) in patients with advanced malignancies.” J Clin Oncol 22, no. 14_suppl (July 15, 2004): 2508.Link to Item
-
Kuerer, Henry M., Thomas B. Julian, Eric A. Strom, H Kim Lyerly, Armando E. Giuliano, Eleftherios P. Mamounas, and Frank A. Vicini. “Accelerated partial breast irradiation after conservative surgery for breast cancer.” Ann Surg 239, no. 3 (March 2004): 338–51. https://doi.org/10.1097/01.sla.0000114219.71899.13.Full Text Link to Item
-
Morse, Michael A., Tim Clay, Kirsten Colling, and H Kim Lyerly. “Preparation of peptide-loaded dendritic cells for cancer immunotherapy.” Mol Biotechnol 25, no. 1 (September 2003): 95–99. https://doi.org/10.1385/MB:25:1:95.Full Text Link to Item
-
Morse, Michael A., Smita K. Nair, Paul J. Mosca, Amy C. Hobeika, Timothy M. Clay, Yuping Deng, David Boczkowski, et al. “Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA.” Cancer Invest 21, no. 3 (June 2003): 341–49. https://doi.org/10.1081/cnv-120018224.Full Text Link to Item
-
Morse, Michael A., Timothy M. Clay, Kirsten Colling, Amy Hobeika, Ken Grabstein, Martin A. Cheever, and H Kim Lyerly. “HER2 dendritic cell vaccines.” Clin Breast Cancer 3 Suppl 4 (February 2003): S164–72. https://doi.org/10.3816/cbc.2003.s.007.Full Text Link to Item
-
Mosca, Paul J., H Kim Lyerly, C Denise Ching, Amy C. Hobeika, Timothy M. Clay, and Michael A. Morse. “Proteomics for monitoring immune responses to cancer vaccines.” Curr Opin Mol Ther 5, no. 1 (February 2003): 39–43.Link to Item
-
Morse, Michael A., Steve Chui, Timothy M. Clay, and H Kim Lyerly. “Recent areas of development for dendritic cell vaccines.” Cancer Chemother Biol Response Modif 21 (2003): 339–50. https://doi.org/10.1016/s0921-4410(03)21017-6.Full Text Link to Item
-
Mosca, Paul J., Timothy M. Clay, H. Kim Lyerly, and Michael A. Morse. “Current status of dendritic cell immunotherapy of malignancies.” Int Rev Immunol 22, no. 3–4 (2003): 255–81. https://doi.org/10.1080/08830180305223.Full Text Link to Item
-
Morse, M. A., P. J. Mosca, T. M. Clay, and H. K. Lyerly. “Dendritic cell-based vaccines in cancer: Clinical experience to date.” American Journal of Cancer 1, no. 5 (December 1, 2002): 313–22. https://doi.org/10.2165/00024669-200201050-00002.Full Text
-
Morse, Michael A., Timothy M. Clay, Paul Mosca, and H Kim Lyerly. “Immunoregulatory T cells in cancer immunotherapy.” Expert Opin Biol Ther 2, no. 8 (December 2002): 827–34. https://doi.org/10.1517/14712598.2.8.827.Full Text Link to Item
-
Mosca, Paul J., Amy C. Hobeika, Kirsten Colling, Timothy M. Clay, Elaine K. Thomas, Dania Caron, H Kim Lyerly, and Michael A. Morse. “Multiple signals are required for maturation of human dendritic cells mobilized in vivo with Flt3 ligand.” J Leukoc Biol 72, no. 3 (September 2002): 546–53.Link to Item
-
Morse, Michael A., David Rizzieri, Timothy T. Stenzel, Amy C. Hobeika, James J. Vredenburgh, Nelson J. Chao, Timothy M. Clay, Paul J. Mosca, and H Kim Lyerly. “Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplants.” J Hematother Stem Cell Res 11, no. 4 (August 2002): 659–68. https://doi.org/10.1089/15258160260194802.Full Text Link to Item
-
Morse, Michael A., and H Kim Lyerly. “DNA and RNA modified dendritic cell vaccines.” World J Surg 26, no. 7 (July 2002): 819–25. https://doi.org/10.1007/s00268-002-4058-0.Full Text Link to Item
-
Clay, Timothy M., Michael Morse, and H Kim Lyerly. “Redirecting cytotoxic T lymphocyte responses with T-cell receptor transgenes.” Expert Opin Biol Ther 2, no. 4 (April 2002): 353–60. https://doi.org/10.1517/14712598.2.4.353.Full Text Link to Item
-
Nair, Smita K., Michael Morse, David Boczkowski, R Ian Cumming, Ljiljana Vasovic, Eli Gilboa, and H Kim Lyerly. “Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells.” Ann Surg 235, no. 4 (April 2002): 540–49. https://doi.org/10.1097/00000658-200204000-00013.Full Text Link to Item
-
Morse, Michael A., Timothy M. Clay, and H Kim Lyerly. “Current status of adoptive immunotherapy of malignancies.” Expert Opin Biol Ther 2, no. 3 (March 2002): 237–47. https://doi.org/10.1517/14712598.2.3.237.Full Text Link to Item
-
Keilholz, Ulrich, Jeffrey Weber, James H. Finke, Dmitry I. Gabrilovich, W Martin Kast, Mary L. Disis, John M. Kirkwood, et al. “Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy.” J Immunother 25, no. 2 (2002): 97–138. https://doi.org/10.1097/00002371-200203000-00001.Full Text Link to Item
-
Morse, Michael A., Paul J. Mosca, Timothy M. Clay, and H Kim Lyerly. “Dendritic cell maturation in active immunotherapy strategies.” Expert Opin Biol Ther 2, no. 1 (January 2002): 35–43. https://doi.org/10.1517/14712598.2.1.35.Full Text Link to Item
-
Morse, Michael A., Smita K. Nair, David Boczkowski, Douglas Tyler, Herbert I. Hurwitz, Alan Proia, Timothy M. Clay, Jeffrey Schlom, Eli Gilboa, and H Kim Lyerly. “The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer.” Int J Gastrointest Cancer 32, no. 1 (2002): 1–6. https://doi.org/10.1385/IJGC:32:1:1.Full Text Link to Item
-
Morse, Michael A., Timothy M. Clay, and H Kim Lyerly. “CEA loaded dendritic cell vaccines.” Cancer Chemother Biol Response Modif 20 (2002): 385–90.Link to Item
-
Tokunaga, K., M. L. Greenberg, M. A. Morse, R. I. Cumming, H. K. Lyerly, and B. R. Cullen. “Molecular basis for cell tropism of CXCR4-dependent human immunodeficiency virus type 1 isolates.” J Virol 75, no. 15 (August 2001): 6776–85. https://doi.org/10.1128/JVI.75.15.6776-6785.2001.Full Text Link to Item
-
Clay, T. M., A. C. Hobeika, P. J. Mosca, H. K. Lyerly, and M. A. Morse. “Assays for monitoring cellular immune responses to active immunotherapy of cancer.” Clin Cancer Res 7, no. 5 (May 2001): 1127–35.Link to Item
-
Mosca, P. J., A. C. Hobeika, T. M. Clay, M. A. Morse, and H. K. Lyerly. “Direct detection of cellular immune responses to cancer vaccines.” Surgery 129, no. 3 (March 2001): 248–54. https://doi.org/10.1067/msy.2001.108609.Full Text Link to Item
-
Morse, M. A., T. M. Clay, A. C. Hobeika, P. J. Mosca, and H. K. Lyerly. “Monitoring cellular immune responses to cancer immunotherapy.” Curr Opin Mol Ther 3, no. 1 (February 2001): 45–52.Link to Item
-
Hobeika, A. C., T. M. Clay, P. J. Mosca, H. K. Lyerly, and M. A. Morse. “Quantitating therapeutically relevant T-cell responses to cancer vaccines.” Crit Rev Immunol 21, no. 1–3 (2001): 287–97.Link to Item
-
Morse, M. A., S. Nair, M. Fernandez-Casal, Y. Deng, M. St Peter, R. Williams, A. Hobeika, et al. “Preoperative mobilization of circulating dendritic cells by Flt3 ligand administration to patients with metastatic colon cancer.” J Clin Oncol 18, no. 23 (December 1, 2000): 3883–93. https://doi.org/10.1200/JCO.2000.18.23.3883.Full Text Link to Item
-
Mosca, P. J., A. C. Hobeika, T. M. Clay, S. K. Nair, E. K. Thomas, M. A. Morse, and H. K. Lyerly. “A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-gamma treatment.” Blood 96, no. 10 (November 15, 2000): 3499–3504.Link to Item
-
Rusconi, C. P., A. Yeh, H. K. Lyerly, J. H. Lawson, and B. A. Sullenger. “Blocking the initiation of coagulation by RNA aptamers to factor VIIa.” Thromb Haemost 84, no. 5 (November 2000): 841–48.Link to Item
-
Li, Y., M. Bendandi, Y. Deng, C. Dunbar, N. Munshi, S. Jagannath, L. W. Kwak, and H. K. Lyerly. “Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells.” Blood 96, no. 8 (October 15, 2000): 2828–33.Link to Item
-
Lyerly, H. K., T. Clay, and M. A. Morse. “Optimizing dendritic cell function by genetic modification.” J Natl Cancer Inst 92, no. 15 (August 2, 2000): 1198–99. https://doi.org/10.1093/jnci/92.15.1198.Full Text Link to Item
-
Markert, M. L., C. B. Hicks, J. A. Bartlett, J. L. Harmon, L. P. Hale, M. L. Greenberg, G. Ferrari, et al. “Effect of highly active antiretroviral therapy and thymic transplantation on immunoreconstitution in HIV infection.” Aids Res Hum Retroviruses 16, no. 5 (March 20, 2000): 403–13. https://doi.org/10.1089/088922200309061.Full Text Link to Item
-
Boczkowski, D., S. K. Nair, J. H. Nam, H. K. Lyerly, and E. Gilboa. “Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells.” Cancer Res 60, no. 4 (February 15, 2000): 1028–34.Link to Item
-
Morse, M. A., and H. K. Lyerly. “Clinical applications of dendritic cell vaccines.” Curr Opin Mol Ther 2, no. 1 (February 2000): 20–28.Link to Item
-
Mosca, P. J., M. A. Morse, T. A. D’Amico, J. Crawford, and H. K. Lyerly. “Gene therapy for lung cancer.” Clin Lung Cancer 1, no. 3 (February 2000): 218–26. https://doi.org/10.3816/clc.2000.n.005.Full Text Link to Item
-
Morse, M. A., and H. K. Lyerly. “Dendritic cell-based immunization for cancer therapy.” Adv Exp Med Biol 465 (2000): 335–46. https://doi.org/10.1007/0-306-46817-4_28.Full Text Link to Item
-
Morse, M. A., J. J. Vredenburgh, and H. K. Lyerly. “A comparative study of the generation of dendritic cells from mobilized peripheral blood progenitor cells of patients undergoing high-dose chemotherapy.” J Hematother Stem Cell Res 8, no. 6 (December 1999): 577–84. https://doi.org/10.1089/152581699319731.Full Text Link to Item
-
Morse, M. A., H. K. Lyerly, and Y. Li. “The role of IL-13 in the generation of dendritic cells in vitro.” J Immunother 22, no. 6 (November 1999): 506–13. https://doi.org/10.1097/00002371-199911000-00005.Full Text Link to Item
-
Lyerly, H. K., and M. A. Morse. “Carcinoembryonic antigen peptide-pulsed dendritic cells in patients with metastatic cancer.” Clin Lung Cancer 1, no. 1 (August 1999): 70–72. https://doi.org/10.3816/clc.1999.n.005.Full Text Link to Item
-
Nair, S. K., S. Hull, D. Coleman, E. Gilboa, H. K. Lyerly, and M. A. Morse. “Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA.” Int J Cancer 82, no. 1 (July 2, 1999): 121–24. https://doi.org/10.1002/(sici)1097-0215(19990702)82:1<121::aid-ijc20>3.0.co;2-x.Full Text Link to Item
-
Morse, M. A., Y. Deng, D. Coleman, S. Hull, E. Kitrell-Fisher, S. Nair, J. Schlom, M. E. Ryback, and H. K. Lyerly. “A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen.” Clin Cancer Res 5, no. 6 (June 1999): 1331–38.Link to Item
-
Sullenger, B., C. Rusconi, A. Yeh, J. Lawson, and H. Lyerly. “Isolation of RNA aptamers to block coagulation.” Faseb Journal 13, no. 7 (April 23, 1999): A1320–A1320.Link to Item
-
Morse, M. A., and H. K. Lyerly. “Cellular and biological therapies of gastrointestinal tumors: overview of clinical trials.” Ann Surg Oncol 6, no. 2 (March 1999): 218–23. https://doi.org/10.1007/s10434-999-0218-x.Full Text Link to Item
-
Morse, M. A., R. E. Coleman, G. Akabani, N. Niehaus, D. Coleman, and H. K. Lyerly. “Migration of human dendritic cells after injection in patients with metastatic malignancies.” Cancer Res 59, no. 1 (January 1, 1999): 56–58.Link to Item
-
Morse, M. A., and H. K. Lyerly. “Dendritic cell-based approaches to cancer immunotherapy.” Expert Opin Investig Drugs 7, no. 10 (October 1998): 1617–27. https://doi.org/10.1517/13543784.7.10.1617.Full Text Link to Item
-
Smith, C., S. Lilly, K. P. Mann, E. Livingston, S. Myers, H. K. Lyerly, and G. D. Miralles. “AIDS-related malignancies.” Ann Med 30, no. 4 (August 1998): 323–44. https://doi.org/10.3109/07853899809029932.Full Text Link to Item
-
Wheatley, G. H., K. P. McKinnon, M. Iacobucci, S. Mahon, C. Gelber, and H. K. Lyerly. “Dendritic cells improve the generation of Epstein-Barr virus-specific cytotoxic T lymphocytes for the treatment of posttransplantation lymphoma.” Surgery 124, no. 2 (August 1998): 171–76.Link to Item
-
Morse, M. A., H. K. Lyerly, E. Gilboa, E. Thomas, and S. K. Nair. “Optimization of the sequence of antigen loading and CD40-ligand-induced maturation of dendritic cells.” Cancer Res 58, no. 14 (July 15, 1998): 2965–68.Link to Item
-
Coveney, E., C. R. Weltz, R. Greengrass, J. D. Iglehart, G. S. Leight, S. M. Steele, and H. K. Lyerly. “Use of paravertebral block anesthesia in the surgical management of breast cancer: experience in 156 cases.” Ann Surg 227, no. 4 (April 1998): 496–501. https://doi.org/10.1097/00000658-199804000-00008.Full Text Link to Item
-
Gilboa, E., S. K. Nair, and H. K. Lyerly. “Immunotherapy of cancer with dendritic-cell-based vaccines.” Cancer Immunol Immunother 46, no. 2 (April 1998): 82–87. https://doi.org/10.1007/s002620050465.Full Text Link to Item
-
Nair, S. K., D. Boczkowski, M. Morse, R. I. Cumming, H. K. Lyerly, and E. Gilboa. “Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA.” Nat Biotechnol 16, no. 4 (April 1998): 364–69. https://doi.org/10.1038/nbt0498-364.Full Text Link to Item
-
Morse, M. A., and H. K. Lyerly. “Immunotherapy of cancer using dendritic cells.” Cytokines Cell Mol Ther 4, no. 1 (March 1998): 35–44.Link to Item
-
Clary, B. M., and H. K. Lyerly. “Gene therapy and pancreatic cancer.” Surg Oncol Clin N Am 7, no. 1 (January 1998): 217–49.Link to Item
-
Deng, Y. P., M. St Peter, K. Baseden, E. Thomas, and K. Lyerly. “Activation/maturation of Peripheral blood derived dendritic cells by CD40 ligand.” Journal of Leukocyte Biology, January 1, 1998, 31–31.Link to Item
-
Coveney, E., G. H. Wheatley, and H. K. Lyerly. “Active immunization using dendritic cells mixed with tumor cells inhibits the growth of primary breast cancer.” Surgery 122, no. 2 (August 1997): 228–34. https://doi.org/10.1016/s0039-6060(97)90013-1.Full Text Link to Item
-
Morse, M. A., L. J. Zhou, T. F. Tedder, H. K. Lyerly, and C. Smith. “Generation of dendritic cells in vitro from peripheral blood mononuclear cells with granulocyte-macrophage-colony-stimulating factor, interleukin-4, and tumor necrosis factor-alpha for use in cancer immunotherapy.” Ann Surg 226, no. 1 (July 1997): 6–16. https://doi.org/10.1097/00000658-199707000-00002.Full Text Link to Item
-
Weltz, Christina R., Roy A. Greengrass, and Kim Lyerly. “Letter to the Editor.” Annals of Surgery 225, no. 3 (March 1997): 341–341. https://doi.org/10.1097/00000658-199703000-00019.Full Text
-
Clary, B. M., E. C. Coveney, D. G. Blazer, R. Philip, M. Philip, M. Morse, E. Gilboa, and H. K. Lyerly. “Active immunization with tumor cells transduced by a novel AAV plasmid-based gene delivery system.” J Immunother 20, no. 1 (January 1997): 26–37. https://doi.org/10.1097/00002371-199701000-00003.Full Text Link to Item
-
Clary, B. M., E. C. Coveney, R. Philip, D. G. Blazer, M. Morse, E. Gilboa, and H. K. Lyerly. “Inhibition of established pancreatic cancers following specific active immunotherapy with interleukin-2 gene-transduced tumor cells.” Cancer Gene Ther 4, no. 2 (1997): 97–104.Link to Item
-
Keogan, M. T., V. J. Lowe, M. E. Baker, V. G. McDermott, H. K. Lyerly, and R. E. Coleman. “Local recurrence of rectal cancer: evaluation with F-18 fluorodeoxyglucose PET imaging.” Abdom Imaging 22, no. 3 (1997): 332–37. https://doi.org/10.1007/s002619900202.Full Text Link to Item
-
Clary, B. M., E. C. Coveney, D. G. Blazer, R. Philip, and H. K. Lyerly. “Active immunotherapy of pancreatic cancer with tumor cells genetically engineered to secrete multiple cytokines.” Surgery 120, no. 2 (August 1996): 174–81. https://doi.org/10.1016/s0039-6060(96)80285-6.Full Text Link to Item
-
Coveney, E., B. Clary, M. Iacobucci, R. Philip, and K. Lyerly. “Active immunotherapy with transiently transfected cytokine-secreting tumor cells inhibits breast cancer metastases in tumor-bearing animals.” Surgery 120, no. 2 (August 1996): 265–72. https://doi.org/10.1016/s0039-6060(96)80297-2.Full Text Link to Item
-
Greengrass, R., F. O’Brien, K. Lyerly, D. Hardman, D. Gleason, F. D’Ercole, and S. Steele. “Paravertebral block for breast cancer surgery.” Can J Anaesth 43, no. 8 (August 1996): 858–61. https://doi.org/10.1007/BF03013039.Full Text Link to Item
-
Philip, R., B. Clary, E. Brunette, L. Kilinski, D. Murugesh, M. Sorich, J. Yau, J. Lebkowski, H. K. Lyerly, and M. Philip. “Gene modification of primary tumor cells for active immunotherapy of human breast and ovarian cancer.” Clin Cancer Res 2, no. 1 (January 1996): 59–68.Link to Item
-
Toso, J. F., C. Oei, F. Oshidari, J. Tartaglia, E. Paoletti, H. K. Lyerly, S. Talib, and K. J. Weinhold. “MAGE-1-specific precursor cytotoxic T-lymphocytes present among tumor-infiltrating lymphocytes from a patient with breast cancer: characterization and antigen-specific activation.” Cancer Res 56, no. 1 (January 1, 1996): 16–20.Link to Item
-
DeMatteo, R. P., S. E. Raper, M. Ahn, K. J. Fisher, C. Burke, A. Radu, G. Widera, B. R. Claytor, C. F. Barker, and J. F. Markmann. “Gene transfer to the thymus. A means of abrogating the immune response to recombinant adenovirus.” Ann Surg 222, no. 3 (September 1995): 229–39. https://doi.org/10.1097/00000658-199509000-00002.Full Text Link to Item
-
Weltz, C. R., R. A. Greengrass, and H. K. Lyerly. “Ambulatory surgical management of breast carcinoma using paravertebral block.” Ann Surg 222, no. 1 (July 1995): 19–26. https://doi.org/10.1097/00000658-199507000-00004.Full Text Link to Item
-
LEBKOWSKI, J., M. PHILIP, K. LYERLY, B. CLARY, E. BRUNETTE, L. KILINSKI, D. MURUGESH, E. COVENEY, T. B. OKARMA, and R. PHILIP. “AAV PLASMID - LIPOSOME COMPLEXES FOR THE GENETIC-MODIFICATION OF FRESH PRIMARY TUMOR-CELLS - USE IN TUMOR VACCINATION FOR BREAST-CANCER.” Journal of Cellular Biochemistry, March 10, 1995, 424–424.Link to Item
-
Gilboa, E., H. K. Lyerly, J. Vieweg, and S. Saito. “Immunotherapy of cancer using cytokine gene-modified tumor vaccines.” Semin Cancer Biol 5, no. 6 (December 1994): 409–17.Link to Item
-
Coles, R. E., T. J. Boyle, J. M. DiMaio, K. R. Berend, D. F. Via, and H. K. Lyerly. “T cells or active Epstein-Barr virus infection in the development of lymphoproliferative disease in human B cell-injected severe combined immunodeficient mice.” Ann Surg Oncol 1, no. 5 (September 1994): 405–10. https://doi.org/10.1007/BF02303813.Full Text Link to Item
-
DiMaio, J. M., B. M. Clary, D. F. Via, E. Coveney, T. N. Pappas, and H. K. Lyerly. “Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo.” Surgery 116, no. 2 (August 1994): 205–13.Link to Item
-
Whitman, E. D., K. Tsung, J. Paxson, and J. A. Norton. “In vitro and in vivo kinetics of recombinant vaccinia virus cancer-gene therapy.” Surgery 116, no. 2 (August 1994): 183–88.Link to Item
-
Yoshino, I., P. S. Goedegebuure, G. E. Peoples, A. S. Parikh, J. M. DiMaio, H. K. Lyerly, A. F. Gazdar, and T. J. Eberlein. “HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer.” Cancer Res 54, no. 13 (July 1, 1994): 3387–90.Link to Item
-
Lyerly, H. K., and J. R. Mault. “Laparoscopic ileostomy and colostomy.” Ann Surg 219, no. 3 (March 1994): 317–22. https://doi.org/10.1097/00000658-199403000-00013.Full Text Link to Item
-
GANGAVALLI, R., T. MCCALLISTER, S. NAYAK, R. DILLMAN, J. ROSENBLATT, R. SEEGER, M. BRENNER, et al. “RETROVIRAL VECTOR-MEDIATED GAMMA-IFN GENE-TRANSFER TO TUMOR-CELLS FOR CANCER-THERAPY.” Journal of Cellular Biochemistry, January 1, 1994, 114–114.Link to Item
-
Wax, T. D., L. J. Layfield, S. Zaleski, V. Bhargara, M. Cohen, H. K. Lyerly, and S. R. Fisher. “Cytomegalovirus sialadenitis in patients with the acquired immunodeficiency syndrome: a potential diagnostic pitfall with fine-needle aspiration cytology.” Diagn Cytopathol 10, no. 2 (1994): 169–72. https://doi.org/10.1002/dc.2840100216.Full Text Link to Item
-
Lyerly, H. K., and J. M. DiMaio. “Gene delivery systems in surgery.” Arch Surg 128, no. 11 (November 1993): 1197–1206. https://doi.org/10.1001/archsurg.1993.01420230025004.Full Text Link to Item
-
Berend, K. R., J. U. Jung, T. J. Boyle, J. M. DiMaio, S. A. Mungal, R. C. Desrosiers, and H. K. Lyerly. “Phenotypic and functional consequences of herpesvirus saimiri infection of human CD8+ cytotoxic T lymphocytes.” J Virol 67, no. 10 (October 1993): 6317–21. https://doi.org/10.1128/JVI.67.10.6317-6321.1993.Full Text Link to Item
-
Boyle, T. J., K. R. Berend, J. M. DiMaio, R. E. Coles, D. F. Via, and H. K. Lyerly. “Adoptive transfer of cytotoxic T lymphocytes for the treatment of transplant-associated lymphoma.” Surgery 114, no. 2 (August 1993): 218–25.Link to Item
-
Coles, R. E., T. J. Boyle, J. Kurtzberg, A. Stewart, W. P. Peters, and H. K. Lyerly. “Retroviral gene transduction of circulating progenitor cells in patients with metastatic breast cancer.” Surg Oncol 2, no. 1 (1993): 1–6. https://doi.org/10.1016/0960-7404(93)90038-z.Full Text Link to Item
-
Malim, M. H., W. W. Freimuth, J. Liu, T. J. Boyle, H. K. Lyerly, B. R. Cullen, and G. J. Nabel. “Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication.” J Exp Med 176, no. 4 (October 1, 1992): 1197–1201. https://doi.org/10.1084/jem.176.4.1197.Full Text Link to Item
-
Chen, H., T. J. Boyle, M. H. Malim, B. R. Cullen, and H. K. Lyerly. “Derivation of a biologically contained replication system for human immunodeficiency virus type 1.” Proc Natl Acad Sci U S A 89, no. 16 (August 15, 1992): 7678–82. https://doi.org/10.1073/pnas.89.16.7678.Full Text Link to Item
-
Boyle, T. J., M. Tamburini, K. R. Berend, A. M. Kizilbash, M. J. Borowitz, and H. K. Lyerly. “Human B-cell lymphoma in severe combined immunodeficient mice after active infection with Epstein-Barr virus.” Surgery 112, no. 2 (August 1992): 378–86.Link to Item
-
Hwang, S. S., T. J. Boyle, H. K. Lyerly, and B. R. Cullen. “Identification of envelope V3 loop as the major determinant of CD4 neutralization sensitivity of HIV-1.” Science 257, no. 5069 (July 24, 1992): 535–37. https://doi.org/10.1126/science.1636088.Full Text Link to Item
-
Boyle, T. J., R. E. Coles, A. M. Kizilbash, and H. K. Lyerly. “Effects of cyclosporine on human B-cell lymphoma development in vivo.” Surg Oncol 1, no. 1 (February 1992): 79–86. https://doi.org/10.1016/0960-7404(92)90060-x.Full Text Link to Item
-
Hwang, S. S., T. J. Boyle, H. K. Lyerly, and B. R. Cullen. “Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1.” Science 253, no. 5015 (July 5, 1991): 71–74. https://doi.org/10.1126/science.1905842.Full Text Link to Item
-
Lyerly, H. K., and D. C. Sabiston. “Surgical treatment of chronic pulmonary embolism.” Annu Rev Med 42 (1991): 507–17. https://doi.org/10.1146/annurev.me.42.020191.002451.Full Text Link to Item
-
Shadduck, P. P., D. S. Tyler, H. K. Lyerly, M. W. Sebastian, C. Farnitano, K. T. Fitzpatrick, A. J. Langlois, and J. A. Moylan. “Commercially available surgical gowns do not prevent penetration by HIV-1.” Surgical Forum 41 (December 1, 1990): 77–80.
-
Tyler, D. S., S. D. Stanley, C. A. Nastala, A. A. Austin, J. A. Bartlett, K. C. Stine, H. K. Lyerly, D. P. Bolognesi, and K. J. Weinhold. “Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection. Humoral and cellular defects.” J Immunol 144, no. 9 (May 1, 1990): 3375–84.Link to Item
-
Weinhold, K. J., D. S. Tyler, and H. K. Lyerly. “Measurement of direct and indirect forms of anti-HIV-1 ADCC: implications for other retroviral disease.” Dev Biol Stand 72 (1990): 343–48.Link to Item
-
Weinhold, K. J., H. K. Lyerly, S. D. Stanley, A. A. Austin, T. J. Matthews, and D. P. Bolognesi. “HIV-1 GP120-mediated immune suppression and lymphocyte destruction in the absence of viral infection.” J Immunol 142, no. 9 (May 1, 1989): 3091–97.Link to Item
-
Sheikh, K. H., D. B. Adams, R. McCann, H. K. Lyerly, D. C. Sabiston, and J. Kisslo. “Utility of Doppler color flow imaging for identification of femoral arterial complications of cardiac catheterization.” Am Heart J 117, no. 3 (March 1989): 623–28. https://doi.org/10.1016/0002-8703(89)90737-0.Full Text Link to Item
-
Tyler, D. S., C. L. Nastala, S. D. Stanley, T. J. Matthews, H. K. Lyerly, D. P. Bolognesi, and K. J. Weinhold. “GP120 specific cellular cytotoxicity in HIV-1 seropositive individuals. Evidence for circulating CD16+ effector cells armed in vivo with cytophilic antibody.” J Immunol 142, no. 4 (February 15, 1989): 1177–82.Link to Item
-
Tyler, D. S., H. K. Lyerly, C. L. Nastala, P. P. Shadduck, K. T. Fitzpatrick, A. J. Langlois, and J. A. Moylan. “Barrier protection against the human immunodeficiency virus.” Curr Surg 46, no. 4 (1989): 301–4.Link to Item
-
Ahearne, P. M., T. J. Matthews, H. K. Lyerly, G. C. White, D. P. Bolognesi, and K. J. Weinhold. “Cellular immune response to viral peptides in patients exposed to HIV.” Aids Res Hum Retroviruses 4, no. 4 (August 1988): 259–67. https://doi.org/10.1089/aid.1988.4.259.Full Text Link to Item
-
Skinner, M. A., R. Ting, A. J. Langlois, K. J. Weinhold, H. K. Lyerly, K. Javaherian, and T. J. Matthews. “Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein.” Aids Res Hum Retroviruses 4, no. 3 (June 1988): 187–97. https://doi.org/10.1089/aid.1988.4.187.Full Text Link to Item
-
Weinhold, K. J., H. K. Lyerly, T. J. Matthews, D. S. Tyler, P. M. Ahearne, K. C. Stine, A. J. Langlois, D. T. Durack, and D. P. Bolognesi. “Cellular anti-GP120 cytolytic reactivities in HIV-1 seropositive individuals.” Lancet 1, no. 8591 (April 23, 1988): 902–5. https://doi.org/10.1016/s0140-6736(88)91713-8.Full Text Link to Item
-
Lyerly, H. K., M. A. Skinner, D. S. Tyler, C. L. Nastala, T. J. Matthews, D. P. Bolognesi, and K. J. Weinhold. “Anti-HIV-1 immune cytolysis is independent of viral envelope glycosylation.” Surgical Forum 39 (January 1, 1988): 420–22.
-
Tyler, D. S., C. L. Nastala, H. K. Lyerly, T. J. Matthews, D. P. Bolognesi, and K. J. Weinhold. “Direct antibody-dependent cellular cytotoxicity: Evidence of circulating antibody-armed cytotoxic CD16+ NK/K cells in patients infected with HIV-1.” Surgical Forum 39 (January 1, 1988): 418–20.
-
Rusche, J. R., D. L. Lynn, M. Robert-Guroff, A. J. Langlois, H. K. Lyerly, H. Carson, K. Krohn, A. Ranki, R. C. Gallo, and D. P. Bolognesi. “Humoral immune response to the entire human immunodeficiency virus envelope glycoprotein made in insect cells.” Proc Natl Acad Sci U S A 84, no. 19 (October 1987): 6924–28. https://doi.org/10.1073/pnas.84.19.6924.Full Text Link to Item
-
Matthews, T. J., K. J. Weinhold, H. K. Lyerly, A. J. Langlois, H. Wigzell, and D. P. Bolognesi. “Interaction between the human T-cell lymphotropic virus type IIIB envelope glycoprotein gp120 and the surface antigen CD4: role of carbohydrate in binding and cell fusion.” Proc Natl Acad Sci U S A 84, no. 15 (August 1987): 5424–28. https://doi.org/10.1073/pnas.84.15.5424.Full Text Link to Item
-
Lyerly, H. K., T. J. Matthews, A. J. Langlois, D. P. Bolognesi, and K. J. Weinhold. “Human T-cell lymphotropic virus IIIB glycoprotein (gp120) bound to CD4 determinants on normal lymphocytes and expressed by infected cells serves as target for immune attack.” Proc Natl Acad Sci U S A 84, no. 13 (July 1987): 4601–5. https://doi.org/10.1073/pnas.84.13.4601.Full Text Link to Item
-
Lyerly, H. K., D. L. Reed, T. J. Matthews, A. J. Langlois, P. A. Ahearne, S. R. Petteway, and K. J. Weinhold. “Anti-GP 120 antibodies from HIV seropositive individuals mediate broadly reactive anti-HIV ADCC.” Aids Res Hum Retroviruses 3, no. 4 (1987): 409–22. https://doi.org/10.1089/aid.1987.3.409.Full Text Link to Item
-
Lyerly, H. K., O. J. Cohen, and K. J. Weinhold. “Transmission of HIV by antigen presenting cells during T-cell activation: prevention by 3'-azido-3'-deoxythymidine.” Aids Res Hum Retroviruses 3, no. 1 (1987): 87–94. https://doi.org/10.1089/aid.1987.3.87.Full Text Link to Item
-
Lyerly, H. K., T. J. Matthews, P. M. Aherne, A. J. Langlois, D. P. Bolognesi, and K. J. Weinhold. “Augmentation of anti-HIV ADCC with interleukin-2.” Surgical Forum 38 (January 1, 1987): 425–28.
-
Matthews, T. J., H. K. Lyerly, K. J. Weinhold, A. J. Langlois, J. Rusche, S. D. Putney, R. C. Gallo, and D. P. Bolognesi. “Prospects for development of a vaccine against HTLV-III-related disorders.” Aids Res Hum Retroviruses 3 Suppl 1 (1987): 197–206. https://doi.org/10.1089/aid.1987.3.197.Full Text Link to Item
-
Lyerly, H. K., J. G. Reves, and D. C. Sabiston. “Management of primary sarcomas of the pulmonary artery and reperfusion intrabronchial hemorrhage.” Surg Gynecol Obstet 163, no. 3 (September 1986): 291–301.Link to Item
-
Yarchoan, R., R. W. Klecker, K. J. Weinhold, P. D. Markham, H. K. Lyerly, D. T. Durack, E. Gelmann, S. N. Lehrman, R. M. Blum, and D. W. Barry. “Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex.” Lancet 1, no. 8481 (March 15, 1986): 575–80. https://doi.org/10.1016/s0140-6736(86)92808-4.Full Text Link to Item
-
Woodruff, W. W., B. E. Hoeck, W. R. Chitwood, H. K. Lyerly, D. C. Sabiston, and J. T. Chen. “Radiographic findings in pulmonary hypertension from unresolved embolism.” Ajr Am J Roentgenol 144, no. 4 (April 1985): 681–86. https://doi.org/10.2214/ajr.144.4.681.Full Text Link to Item
-
Chitwood, W. R., H. K. Lyerly, and D. C. Sabiston. “Surgical management of chronic pulmonary embolism.” Ann Surg 201, no. 1 (January 1985): 11–26.Link to Item
-
Baloh, R. W., K. Lyerly, R. D. Yee, and V. Honrubia. “Voluntary control of the human vestibulo-ocular reflex.” Acta Otolaryngol 97, no. 1–2 (1984): 1–6. https://doi.org/10.3109/00016488409130958.Full Text Link to Item
-
-
Book Sections
-
Hsu, D. S., M. Morse, T. Clay, G. Devi, and H. Kim Lyerly. “Immune Cells and the Tumor Microenvironment.” In Genomic and Personalized Medicine, Two-Vol Set, 818–29, 2009. https://doi.org/10.1016/B978-0-12-369420-1.00068-8.Full Text
-
Hsu, D. S., M. Morse, T. Clay, G. Devi, and H. K. Lyerly. “Immune Cells and the Tumor Microenvironment.” In Genomic and Personalized Medicine: V1-2, 818–29, 2008. https://doi.org/10.1016/B978-0-12-369420-1.00068-8.Full Text
-
Morse, M. A., T. M. Clay, and H. K. Lyerly. “Tumor antigens.” In General Principles of Tumor Immunotherapy: Basic and Clinical Applications of Tumor Immunology, 17–31, 2008. https://doi.org/10.1007/978-1-4020-6087-8_2.Full Text
-
Hobeika, A. C., M. A. Morse, T. M. Clay, T. Osada, P. J. Mosca, and H. K. Lyerly. “Intracellular Cytokine Assays.” In Measuring Immunity: Basic Biology and Clinical Assessment, 336–40, 2005. https://doi.org/10.1016/B978-012455900-4/50290-7.Full Text
-
Hobeika, A. C., M. A. Morse, T. M. Clay, T. Osada, P. J. Mosca, and H. K. Lyerly. “Intracellular Cytokine Assays.” In Measuring Immunity: Basic Science and Clinical Practice, 336–40, 2004. https://doi.org/10.1016/B978-012455900-4/50290-7.Full Text
-
-
Other Articles
-
Ginzel, Joshua D., Chaitanya R. Acharya, Veronica Lubkov, Hidetoshi Mori, Peter G. Boone, Lauren K. Rochelle, Wendy L. Roberts, et al. “Supplementary Figure 6 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase,” April 3, 2023. https://doi.org/10.1158/1541-7786.22526387.Full Text
-
Ginzel, Joshua D., Chaitanya R. Acharya, Veronica Lubkov, Hidetoshi Mori, Peter G. Boone, Lauren K. Rochelle, Wendy L. Roberts, et al. “Supplementary Figure 5 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase,” April 3, 2023. https://doi.org/10.1158/1541-7786.22526390.v1.Full Text
-
Ginzel, Joshua D., Chaitanya R. Acharya, Veronica Lubkov, Hidetoshi Mori, Peter G. Boone, Lauren K. Rochelle, Wendy L. Roberts, et al. “Supplementary Figure 1 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase,” April 3, 2023. https://doi.org/10.1158/1541-7786.22526402.Full Text
-
Ginzel, Joshua D., Chaitanya R. Acharya, Veronica Lubkov, Hidetoshi Mori, Peter G. Boone, Lauren K. Rochelle, Wendy L. Roberts, et al. “Movie 1 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase,” April 3, 2023. https://doi.org/10.1158/1541-7786.22526420.Full Text
-
Ginzel, Joshua D., Chaitanya R. Acharya, Veronica Lubkov, Hidetoshi Mori, Peter G. Boone, Lauren K. Rochelle, Wendy L. Roberts, et al. “Movie 3 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase,” April 3, 2023. https://doi.org/10.1158/1541-7786.22526414.Full Text
-
Ginzel, Joshua D., Chaitanya R. Acharya, Veronica Lubkov, Hidetoshi Mori, Peter G. Boone, Lauren K. Rochelle, Wendy L. Roberts, et al. “Supplementary File 1 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase,” April 3, 2023. https://doi.org/10.1158/1541-7786.22526381.v1.Full Text
-
Ginzel, Joshua D., Chaitanya R. Acharya, Veronica Lubkov, Hidetoshi Mori, Peter G. Boone, Lauren K. Rochelle, Wendy L. Roberts, et al. “Movie 4 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase,” April 3, 2023. https://doi.org/10.1158/1541-7786.22526411.v1.Full Text
-
Ginzel, Joshua D., Chaitanya R. Acharya, Veronica Lubkov, Hidetoshi Mori, Peter G. Boone, Lauren K. Rochelle, Wendy L. Roberts, et al. “Supplementary Figure 1 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase,” April 3, 2023. https://doi.org/10.1158/1541-7786.22526402.v1.Full Text
-
Ginzel, Joshua D., Chaitanya R. Acharya, Veronica Lubkov, Hidetoshi Mori, Peter G. Boone, Lauren K. Rochelle, Wendy L. Roberts, et al. “Supplementary Figure 7 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase,” April 3, 2023. https://doi.org/10.1158/1541-7786.22526384.v1.Full Text
-
Ginzel, Joshua D., Chaitanya R. Acharya, Veronica Lubkov, Hidetoshi Mori, Peter G. Boone, Lauren K. Rochelle, Wendy L. Roberts, et al. “Movie 5 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase,” April 3, 2023. https://doi.org/10.1158/1541-7786.22526405.v1.Full Text
-
Ginzel, Joshua D., Chaitanya R. Acharya, Veronica Lubkov, Hidetoshi Mori, Peter G. Boone, Lauren K. Rochelle, Wendy L. Roberts, et al. “Supplementary Figure 7 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase,” April 3, 2023. https://doi.org/10.1158/1541-7786.22526384.Full Text
-
Ginzel, Joshua D., Chaitanya R. Acharya, Veronica Lubkov, Hidetoshi Mori, Peter G. Boone, Lauren K. Rochelle, Wendy L. Roberts, et al. “Supplementary Figure 4 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase,” April 3, 2023. https://doi.org/10.1158/1541-7786.22526393.Full Text
-
Ginzel, Joshua D., Chaitanya R. Acharya, Veronica Lubkov, Hidetoshi Mori, Peter G. Boone, Lauren K. Rochelle, Wendy L. Roberts, et al. “Supplementary Figure 6 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase,” April 3, 2023. https://doi.org/10.1158/1541-7786.22526387.v1.Full Text
-
Ginzel, Joshua D., Chaitanya R. Acharya, Veronica Lubkov, Hidetoshi Mori, Peter G. Boone, Lauren K. Rochelle, Wendy L. Roberts, et al. “Movie 2 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase,” April 3, 2023. https://doi.org/10.1158/1541-7786.22526417.v1.Full Text
-
Ginzel, Joshua D., Chaitanya R. Acharya, Veronica Lubkov, Hidetoshi Mori, Peter G. Boone, Lauren K. Rochelle, Wendy L. Roberts, et al. “Supplementary Figure 2 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase,” April 3, 2023. https://doi.org/10.1158/1541-7786.22526399.Full Text
-
Ginzel, Joshua D., Chaitanya R. Acharya, Veronica Lubkov, Hidetoshi Mori, Peter G. Boone, Lauren K. Rochelle, Wendy L. Roberts, et al. “Supplementary Figure 4 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase,” April 3, 2023. https://doi.org/10.1158/1541-7786.22526393.v1.Full Text
-
Ginzel, Joshua D., Chaitanya R. Acharya, Veronica Lubkov, Hidetoshi Mori, Peter G. Boone, Lauren K. Rochelle, Wendy L. Roberts, et al. “Supplementary Figure 2 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase,” April 3, 2023. https://doi.org/10.1158/1541-7786.22526399.v1.Full Text
-
Ginzel, Joshua D., Chaitanya R. Acharya, Veronica Lubkov, Hidetoshi Mori, Peter G. Boone, Lauren K. Rochelle, Wendy L. Roberts, et al. “Movie 4 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase,” April 3, 2023. https://doi.org/10.1158/1541-7786.22526411.Full Text
-
Ginzel, Joshua D., Chaitanya R. Acharya, Veronica Lubkov, Hidetoshi Mori, Peter G. Boone, Lauren K. Rochelle, Wendy L. Roberts, et al. “Supplementary File 1 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase,” April 3, 2023. https://doi.org/10.1158/1541-7786.22526381.Full Text
-
Ginzel, Joshua D., Chaitanya R. Acharya, Veronica Lubkov, Hidetoshi Mori, Peter G. Boone, Lauren K. Rochelle, Wendy L. Roberts, et al. “Supplementary Figure 3 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase,” April 3, 2023. https://doi.org/10.1158/1541-7786.22526396.Full Text
-
Ginzel, Joshua D., Chaitanya R. Acharya, Veronica Lubkov, Hidetoshi Mori, Peter G. Boone, Lauren K. Rochelle, Wendy L. Roberts, et al. “Supplementary Tables 1-5 for scRNAseq marker genes from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase,” April 3, 2023. https://doi.org/10.1158/1541-7786.22526378.Full Text
-
Ginzel, Joshua D., Chaitanya R. Acharya, Veronica Lubkov, Hidetoshi Mori, Peter G. Boone, Lauren K. Rochelle, Wendy L. Roberts, et al. “Movie 5 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase,” April 3, 2023. https://doi.org/10.1158/1541-7786.22526405.Full Text
-
Ginzel, Joshua D., Chaitanya R. Acharya, Veronica Lubkov, Hidetoshi Mori, Peter G. Boone, Lauren K. Rochelle, Wendy L. Roberts, et al. “Movie 1 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase,” April 3, 2023. https://doi.org/10.1158/1541-7786.22526420.v1.Full Text
-
Ginzel, Joshua D., Chaitanya R. Acharya, Veronica Lubkov, Hidetoshi Mori, Peter G. Boone, Lauren K. Rochelle, Wendy L. Roberts, et al. “Supplementary Figure 5 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase,” April 3, 2023. https://doi.org/10.1158/1541-7786.22526390.Full Text
-
Ginzel, Joshua D., Chaitanya R. Acharya, Veronica Lubkov, Hidetoshi Mori, Peter G. Boone, Lauren K. Rochelle, Wendy L. Roberts, et al. “Data from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase,” April 3, 2023. https://doi.org/10.1158/1541-7786.c.6545072.v1.Full Text
-
Ginzel, Joshua D., Chaitanya R. Acharya, Veronica Lubkov, Hidetoshi Mori, Peter G. Boone, Lauren K. Rochelle, Wendy L. Roberts, et al. “Movie 3 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase,” April 3, 2023. https://doi.org/10.1158/1541-7786.22526414.v1.Full Text
-
Ginzel, Joshua D., Chaitanya R. Acharya, Veronica Lubkov, Hidetoshi Mori, Peter G. Boone, Lauren K. Rochelle, Wendy L. Roberts, et al. “Supplementary Tables 1-5 for scRNAseq marker genes from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase,” April 3, 2023. https://doi.org/10.1158/1541-7786.22526378.v1.Full Text
-
Ginzel, Joshua D., Chaitanya R. Acharya, Veronica Lubkov, Hidetoshi Mori, Peter G. Boone, Lauren K. Rochelle, Wendy L. Roberts, et al. “Supplementary Figure 3 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase,” April 3, 2023. https://doi.org/10.1158/1541-7786.22526396.v1.Full Text
-
Ginzel, Joshua D., Chaitanya R. Acharya, Veronica Lubkov, Hidetoshi Mori, Peter G. Boone, Lauren K. Rochelle, Wendy L. Roberts, et al. “Movie 2 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase,” April 3, 2023. https://doi.org/10.1158/1541-7786.22526417.Full Text
-
Crosby, Erika J., William Gwin, Kimberly Blackwell, Paul K. Marcom, Serena Chang, Holden T. Maecker, Gloria Broadwater, et al. “Figure S3 from Vaccine-Induced Memory CD8<sup>+</sup> T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study,” March 31, 2023. https://doi.org/10.1158/1078-0432.22472856.v1.Full Text
-
Crosby, Erika J., William Gwin, Kimberly Blackwell, Paul K. Marcom, Serena Chang, Holden T. Maecker, Gloria Broadwater, et al. “Figure S4 from Vaccine-Induced Memory CD8<sup>+</sup> T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study,” March 31, 2023. https://doi.org/10.1158/1078-0432.22472853.Full Text
-
Crosby, Erika J., William Gwin, Kimberly Blackwell, Paul K. Marcom, Serena Chang, Holden T. Maecker, Gloria Broadwater, et al. “Figure S1 from Vaccine-Induced Memory CD8<sup>+</sup> T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study,” March 31, 2023. https://doi.org/10.1158/1078-0432.22472862.Full Text
-
Crosby, Erika J., William Gwin, Kimberly Blackwell, Paul K. Marcom, Serena Chang, Holden T. Maecker, Gloria Broadwater, et al. “Table S1 from Vaccine-Induced Memory CD8<sup>+</sup> T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study,” March 31, 2023. https://doi.org/10.1158/1078-0432.22472850.Full Text
-
Crosby, Erika J., William Gwin, Kimberly Blackwell, Paul K. Marcom, Serena Chang, Holden T. Maecker, Gloria Broadwater, et al. “Table S2 from Vaccine-Induced Memory CD8<sup>+</sup> T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study,” March 31, 2023. https://doi.org/10.1158/1078-0432.22472847.Full Text
-
Crosby, Erika J., William Gwin, Kimberly Blackwell, Paul K. Marcom, Serena Chang, Holden T. Maecker, Gloria Broadwater, et al. “Figure S2 from Vaccine-Induced Memory CD8<sup>+</sup> T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study,” March 31, 2023. https://doi.org/10.1158/1078-0432.22472859.v1.Full Text
-
Crosby, Erika J., William Gwin, Kimberly Blackwell, Paul K. Marcom, Serena Chang, Holden T. Maecker, Gloria Broadwater, et al. “Table S1 from Vaccine-Induced Memory CD8<sup>+</sup> T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study,” March 31, 2023. https://doi.org/10.1158/1078-0432.22472850.v1.Full Text
-
Crosby, Erika J., William Gwin, Kimberly Blackwell, Paul K. Marcom, Serena Chang, Holden T. Maecker, Gloria Broadwater, et al. “Data from Vaccine-Induced Memory CD8<sup>+</sup> T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study,” March 31, 2023. https://doi.org/10.1158/1078-0432.c.6528351.v1.Full Text
-
Crosby, Erika J., William Gwin, Kimberly Blackwell, Paul K. Marcom, Serena Chang, Holden T. Maecker, Gloria Broadwater, et al. “Figure S4 from Vaccine-Induced Memory CD8<sup>+</sup> T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study,” March 31, 2023. https://doi.org/10.1158/1078-0432.22472853.v1.Full Text
-
Crosby, Erika J., William Gwin, Kimberly Blackwell, Paul K. Marcom, Serena Chang, Holden T. Maecker, Gloria Broadwater, et al. “Data from Vaccine-Induced Memory CD8<sup>+</sup> T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study,” March 31, 2023. https://doi.org/10.1158/1078-0432.c.6528351.Full Text
-
Crosby, Erika J., William Gwin, Kimberly Blackwell, Paul K. Marcom, Serena Chang, Holden T. Maecker, Gloria Broadwater, et al. “Table S2 from Vaccine-Induced Memory CD8<sup>+</sup> T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study,” March 31, 2023. https://doi.org/10.1158/1078-0432.22472847.v1.Full Text
-
Crosby, Erika J., William Gwin, Kimberly Blackwell, Paul K. Marcom, Serena Chang, Holden T. Maecker, Gloria Broadwater, et al. “Figure S3 from Vaccine-Induced Memory CD8<sup>+</sup> T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study,” March 31, 2023. https://doi.org/10.1158/1078-0432.22472856.Full Text
-
Crosby, Erika J., William Gwin, Kimberly Blackwell, Paul K. Marcom, Serena Chang, Holden T. Maecker, Gloria Broadwater, et al. “Figure S2 from Vaccine-Induced Memory CD8<sup>+</sup> T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study,” March 31, 2023. https://doi.org/10.1158/1078-0432.22472859.Full Text
-
Crosby, Erika J., William Gwin, Kimberly Blackwell, Paul K. Marcom, Serena Chang, Holden T. Maecker, Gloria Broadwater, et al. “Figure S1 from Vaccine-Induced Memory CD8<sup>+</sup> T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study,” March 31, 2023. https://doi.org/10.1158/1078-0432.22472862.v1.Full Text
-
Trotter, Timothy N., Casey W. Shuptrine, Li-Chung Tsao, Robert D. Marek, Chaitanya Acharya, Jun-Ping Wei, Xiao-Yi Yang, et al. “Supplementary Table 3 from IL26, a Noncanonical Mediator of DNA Inflammatory Stimulation, Promotes TNBC Engraftment and Progression in Association with Neutrophils,” March 31, 2023. https://doi.org/10.1158/0008-5472.22423272.v1.Full Text
-
Trotter, Timothy N., Casey W. Shuptrine, Li-Chung Tsao, Robert D. Marek, Chaitanya Acharya, Jun-Ping Wei, Xiao-Yi Yang, et al. “Supplementary Methods from IL26, a Noncanonical Mediator of DNA Inflammatory Stimulation, Promotes TNBC Engraftment and Progression in Association with Neutrophils,” March 31, 2023. https://doi.org/10.1158/0008-5472.22423281.Full Text
-
Trotter, Timothy N., Casey W. Shuptrine, Li-Chung Tsao, Robert D. Marek, Chaitanya Acharya, Jun-Ping Wei, Xiao-Yi Yang, et al. “Supplementary Table 2 from IL26, a Noncanonical Mediator of DNA Inflammatory Stimulation, Promotes TNBC Engraftment and Progression in Association with Neutrophils,” March 31, 2023. https://doi.org/10.1158/0008-5472.22423275.Full Text
-
Trotter, Timothy N., Casey W. Shuptrine, Li-Chung Tsao, Robert D. Marek, Chaitanya Acharya, Jun-Ping Wei, Xiao-Yi Yang, et al. “Supplementary Table 1 from IL26, a Noncanonical Mediator of DNA Inflammatory Stimulation, Promotes TNBC Engraftment and Progression in Association with Neutrophils,” March 31, 2023. https://doi.org/10.1158/0008-5472.22423278.Full Text
-
Trotter, Timothy N., Casey W. Shuptrine, Li-Chung Tsao, Robert D. Marek, Chaitanya Acharya, Jun-Ping Wei, Xiao-Yi Yang, et al. “Supplementary Table 2 from IL26, a Noncanonical Mediator of DNA Inflammatory Stimulation, Promotes TNBC Engraftment and Progression in Association with Neutrophils,” March 31, 2023. https://doi.org/10.1158/0008-5472.22423275.v1.Full Text
-
Trotter, Timothy N., Casey W. Shuptrine, Li-Chung Tsao, Robert D. Marek, Chaitanya Acharya, Jun-Ping Wei, Xiao-Yi Yang, et al. “Supplementary Methods from IL26, a Noncanonical Mediator of DNA Inflammatory Stimulation, Promotes TNBC Engraftment and Progression in Association with Neutrophils,” March 31, 2023. https://doi.org/10.1158/0008-5472.22423281.v1.Full Text
-
Trotter, Timothy N., Casey W. Shuptrine, Li-Chung Tsao, Robert D. Marek, Chaitanya Acharya, Jun-Ping Wei, Xiao-Yi Yang, et al. “Data from IL26, a Noncanonical Mediator of DNA Inflammatory Stimulation, Promotes TNBC Engraftment and Progression in Association with Neutrophils,” March 31, 2023. https://doi.org/10.1158/0008-5472.c.6511455.v1.Full Text
-
Trotter, Timothy N., Casey W. Shuptrine, Li-Chung Tsao, Robert D. Marek, Chaitanya Acharya, Jun-Ping Wei, Xiao-Yi Yang, et al. “Combined Supplementary Figures from IL26, a Noncanonical Mediator of DNA Inflammatory Stimulation, Promotes TNBC Engraftment and Progression in Association with Neutrophils,” March 31, 2023. https://doi.org/10.1158/0008-5472.22423284.v1.Full Text
-
Trotter, Timothy N., Casey W. Shuptrine, Li-Chung Tsao, Robert D. Marek, Chaitanya Acharya, Jun-Ping Wei, Xiao-Yi Yang, et al. “Supplementary Table 1 from IL26, a Noncanonical Mediator of DNA Inflammatory Stimulation, Promotes TNBC Engraftment and Progression in Association with Neutrophils,” March 31, 2023. https://doi.org/10.1158/0008-5472.22423278.v1.Full Text
-
Trotter, Timothy N., Casey W. Shuptrine, Li-Chung Tsao, Robert D. Marek, Chaitanya Acharya, Jun-Ping Wei, Xiao-Yi Yang, et al. “Combined Supplementary Figures from IL26, a Noncanonical Mediator of DNA Inflammatory Stimulation, Promotes TNBC Engraftment and Progression in Association with Neutrophils,” March 31, 2023. https://doi.org/10.1158/0008-5472.22423284.Full Text
-
Trotter, Timothy N., Casey W. Shuptrine, Li-Chung Tsao, Robert D. Marek, Chaitanya Acharya, Jun-Ping Wei, Xiao-Yi Yang, et al. “Supplementary Table 3 from IL26, a Noncanonical Mediator of DNA Inflammatory Stimulation, Promotes TNBC Engraftment and Progression in Association with Neutrophils,” March 31, 2023. https://doi.org/10.1158/0008-5472.22423272.Full Text
-
Hamilton, E., K. Blackwell, A. C. Hobeika, T. M. Clay, G. Broadwater, X. R. Ren, W. Chen, et al. “Correction: phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion.” J Transl Med, 2013. https://doi.org/10.1186/1479-5876-11-82.Full Text Link to Item
-
Abernethy, A. P., J. E. Herndon, A. Coan, T. Staley, J. L. Wheeler, K. Rowe, S. K. Smith, H. Shaw, and H. K. Lyerly. “Erratum: Phase 2 pilot study of Pathfinders: A psychosocial intervention for cancer patients (Support Care Center DOI 10.1007/s00520-010-0823-z).” Supportive Care in Cancer, March 1, 2011. https://doi.org/10.1007/s00520-010-1076-6.Full Text
-
Morse, M. A., H. K. Lyerly, and T. M. Clay. “Immunotherapy of surgical malignancies: Commentary.” Diseases of the Colon and Rectum, January 1, 2005.
-
Lyerly, H Kim. “Tackling T-cell tumors.” Blood. American Society of Hematology, October 1, 2003. https://doi.org/10.1182/blood-2003-07-2579.Full Text
-
Morse, M., B. Clary, and H. Kim Lyerly. “Establishment of a nude mouse model of hepatic metastasis for evaluation of targeted retroviral gene delivery: Commentary.” Journal of Surgical Oncology, February 1, 2003. https://doi.org/10.1002/jso.10169.Full Text
-
Chui, Stephen Y., and H Kim Lyerly. “Disparities in breast carcinoma treatment in Asian/Pacific Islander women. A challenge to the provider.” Cancer, December 1, 2002. https://doi.org/10.1002/cncr.10964.Full Text Link to Item
-
Lyerly, H. K., M. A. Morse, and T. M. Clay. “Surrogate markers of effective anti-tumor immunity.” Ann Surg Oncol, April 2001. https://doi.org/10.1007/s10434-001-0190-6.Full Text Link to Item
-
Morse, M. A., T. M. Clay, A. C. Hobeika, P. J. Mosca, and H. K. Lyerly. “Surrogate markers of response to cancer immunotherapy.” Expert Opin Biol Ther, March 2001. https://doi.org/10.1517/14712598.1.2.153.Full Text Link to Item
-
Beauchamp, R. D., R. D. Edwards, H. K. Lyerly, and W. G. Cance. “End points in the analysis of breast cancer survival: Relapse versus death from tumor - Discussion.” Surgery. MOSBY-YEAR BOOK INC, August 1, 1998.Link to Item
-
Lyerly, H. K. “Gene therapy in surgery.” Ann Surg, February 1996. https://doi.org/10.1097/00000658-199602000-00001.Full Text Link to Item
-
LYERLY, H. K., and J. MAULT. “UNTITLED.” Annals of Surgery. LIPPINCOTT-RAVEN PUBL, February 1, 1995.Link to Item
-
Lyerly, H. K. “Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal carcinomatosis.” Ann Surg, February 1995. https://doi.org/10.1097/00000658-199502000-00001.Full Text Link to Item
-
Lyerly, H. K. “Transmissible agents and the surgeon.” J Am Coll Surg, January 1995.Link to Item
-
Lyerly, H. K. “Survey: Invited commentary (I).” Archives of Surgery, January 1, 1990.
-
Matthews, T. J., H. Kim Lyerly, K. J. Weinhold, A. J. Langlois, S. D. Putney, and D. P. Bolognesi. “Prospects for development of a vaccine against HIV-related disorders.” Clinical Immunology Newsletter, January 1, 1987. https://doi.org/10.1016/0197-1859(87)90033-1.Full Text
-
-
Conference Papers
-
Trotter, Timothy N., Delila Serra, Carina Dagotto, Tao Wang, Xiao Yang, Junping Wei, Gangjun Lei, H Kim Lyerly, and Zachary C. Hartman. “Abstract PR015: Dormant mammary tumors persist long-term despite adaptive immunity by establishing a Treg-dominated niche via DKK3.” In Cancer Research, 83:PR015–PR015. American Association for Cancer Research (AACR), 2023. https://doi.org/10.1158/1538-7445.metastasis22-pr015.Full Text
-
Chen, M., H. Kim, B. Zhang, W. Yang, T. Osada, E. J. Crosby, H. K. Lyerly, and X. Jiang. “Intracorporeal Sonoporation-Induced Drug/Gene Delivery Using a Catheter Ultrasound Transducer.” In Ieee International Ultrasonics Symposium, Ius, Vol. 2022-October, 2022. https://doi.org/10.1109/IUS54386.2022.9958222.Full Text
-
Hwang, Bin-Jin, Li-Chung Tsao, Chaitanya Acharya, Timothy Trotter, Pankaj Agarwal, Tao Wang, Junping Wei, et al. “Sensitizing immune unresponsive colorectal cancers to immune checkpoint inhibitors through MAVS overexpression.” In Cancer Research, Vol. 82, 2022.Link to Item
-
Trotter, Timothy N., Delila Serra, Carina Dagotto, Tao Wang, Xiao Yang, Junping Wei, Gangjun Lei, H Kim Lyerly, and Zachary C. Hartman. “Dormant mammary tumors resist antigen-specific killing and regulate systemic immunity in association with PTN and DKK3.” In Cancer Research, Vol. 82, 2022.Link to Item
-
Crosby, Erika J., Hiroshi Nagata, Melinda L. Telli, Chaitanya R. Acharya, Irene Wapnir, Kaitlin Zablotsky, Erica Browning, et al. “Intratumoral delivery of tavokinogene telseplasmid (plasmid IL-12) and electroporation induces an immune signature that predicts successful combination in patients.” In Cancer Research, Vol. 81, 2021.Link to Item
-
Ginzel, Joshua D., Chaitanya R. Acharya, Ping Wang, Alexis Schmid, Peter G. Boone, Lauren K. Rochelle, Wendy Roberts, et al. “Visualizing Cell Competition and Mechanisms of Occult Tumorigenesis Ex Vivo.” In In Vitro Cellular & Developmental Biology Animal, 57:S10–S10, 2021.Link to Item
-
Nagata, Hiroshi, Takuya Osada, Erika J. Crosby, David A. Canton, Chris G. Twitty, and H Kim Lyerly. “Intratumoral plasmid IL-12 enhanced the systemic anti-tumor effect of anti-PD-1 antibody in triple-negative breast cancer.” In Cancer Research, Vol. 81, 2021.Link to Item
-
Wang, Jie, Michael Morse, Frank Calzone, Hai Yan, Zung Thai, Takuya Osada, and Herbert Lyerly. “Targeting the Glucagon Receptor Signaling Pathway As a Novel Strategy to Counteract PI3K Inhibitor Induced Hyperglycemia While Sustaining Tumor PI3K Inhibition.” In Blood, 136:4–5. American Society of Hematology, 2020. https://doi.org/10.1182/blood-2020-140576.Full Text
-
Crosby, Erika, Hiroshi Nagata, Melinda Telli, Chaitanya Acharya, Irene Wapnir, Kaitlin Zablotsky, Erica Browning, et al. “789 Intratumoral plasmid IL-12 expands CD8+ T cells and induces a clinically validated CXCR3 signature in triple-negative breast cancer.” In Late Breaking Abstracts. BMJ Publishing Group Ltd, 2020. https://doi.org/10.1136/jitc-2020-sitc2020.0789.Full Text
-
Crosby, Erika J., Chaitanya Acharya, Christopher Rabiola, William J. Muller, Lewis A. Chodosh, Gloria Broadwater, Jonathan Shepherd, et al. “Abstract 904: Stimulation and expansion of oncogene-reactive tumor infiltrating T cells through combined Ad-HER2Δ16 vaccination and anti-PD1 enable anti-tumor responses against established HER2 BC.” In Cancer Research, 80:904–904. American Association for Cancer Research (AACR), 2020. https://doi.org/10.1158/1538-7445.am2020-904.Full Text
-
Tsao, Li-Chung, Herbert Kim Lyerly, and Zachary Hartman. “Trastuzumab therapy suppresses HER2+breast tumor growth through inducing ADCP by tumor-associated macrophages and synergizes with CD47 checkpoint blockade.” In Cancer Immunology Research, 8:84–84. AMER ASSOC CANCER RESEARCH, 2020.Link to Item
-
Hwang, Bin-Jin, Li-Chung Tsao, Gabriel DeLeon, Junping Wei, Xiao-Yi Yang, Gangjun Lei, Tao Wang, Michael M. Morse, Herbert Kim Lyerly, and Zachary Conrad Hartman. “Overexpression of MAVS stimulates antitumor immunity and significantly reduces tumor growth of immune-insensitive colorectal cancer in vivo.” In Cancer Immunology Research, 8:24–25. AMER ASSOC CANCER RESEARCH, 2020.Link to Item
-
Hwang, Bin-Jin, Li-Chung Tsao, Gabriel DeLeon, Junping Wei, Xiao-Yi Yang, Gangjun Lei, Tao Wang, Michael M. Morse, Herbert Kim Lyerly, and Zachary Conrad Hartman. “PR2 Overexpression of MAVS stimulates antitumor immunity and significantly reduces tumor growth of immune-insensitive colorectal cancer in vivo.” In Cancer Immunology Research, 8:53–54. AMER ASSOC CANCER RESEARCH, 2020.Link to Item
-
Trotter, Timothy N., Cong-Xiao Liu, Tao Wang, H Kim Lyerly, and Zachary C. Hartman. “Dormant breast tumor cells avoid the adaptive immune system through regulation of the immune and tumor microenvironment.” In Cancer Immunology Research, 8:139–40. AMER ASSOC CANCER RESEARCH, 2020.Link to Item
-
Kim, H., H. Wu, P. Zhong, K. Mahmood, H. K. Lyerly, and X. Jiang. “Small Aperture Ultrasound Transducers for Intracavitary Tissue Ablation.” In Ieee International Ultrasonics Symposium, Ius, 2019-October:1842–45, 2019. https://doi.org/10.1109/ULTSYM.2019.8925925.Full Text
-
Shaia, Kathryn L., Chaitanya R. Acharya, Stephanie Smeltzer, Herbert K. Lyerly, and Kelly S. Acharya. “Non-invasive diagnosis of endometriosis: using machine learning instead of the operating room.” In Fertility and Sterility, 112:e80–e80. Elsevier BV, 2019. https://doi.org/10.1016/j.fertnstert.2019.07.331.Full Text
-
Abe, Shinya, Takuya Osada, Kensuke Kaneko, Pei Zhong, and Herbert K. Lyerly. “Abstract 4071: A novel combination therapy of high intensity focused ultrasound and PDL1 blockades against advanced breast cancer.” In Cancer Research, 79:4071–4071. American Association for Cancer Research (AACR), 2019. https://doi.org/10.1158/1538-7445.am2019-4071.Full Text
-
Kaneko, Kensuke, Takuya Osada, Philip F. Hughes, Timothy A. Haystead, Michael A. Morse, and Herbert K. Lyerly. “Abstract 3731: A novel heat shock protein 90-targeted photosensitizer (HS-201) enables enhanced tumor-specific photodynamic therapy of inflammatory breast cancers.” In Cancer Research, 79:3731–3731. American Association for Cancer Research (AACR), 2019. https://doi.org/10.1158/1538-7445.am2019-3731.Full Text
-
Tsao, Li-Chung, Jun-Ping Wei, Gang-jun Lei, Tao Wang, Xiao-Yi Yang, Cong-Xiao Liu, H Kim Lyerly, and Zachary C. Hartman. “Abstract 3955: Tumor macrophage-mediated antibody dependent cell phagocytosis (ADCP) is theprimary mechanism mediating HER2 mAb (Trastuzumab) anti-tumor responses which can be synergistically enhanced by CD47 innate immune checkpoint blockade.” In Immunology. American Association for Cancer Research, 2019. https://doi.org/10.1158/1538-7445.sabcs18-3955.Full Text
-
Acharya, Chaitanya Ramanuj, and Herbert K. Lyerly. “Effector T-cell cytolytic activity modules derived from CD3+ single cells from human primary triple-negative breast cancer (TNBC) in multiple solid tumors to predict response to immune checkpoint blockade therapy (ICB).” In Journal of Clinical Oncology, 37:1073–1073. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.1073.Full Text
-
Crosby, E. J., W. R. Gwin, S. Chang, H. T. Maecker, V. Lubkov, J. C. Snyder, G. Broadwater, et al. “Abstract P2-09-16: CD8 T cells induced by novel alphaviral vector predict improved progression free survival in advanced HER2+ breast cancer patients.” In Cancer Research, Vol. 79. American Association for Cancer Research (AACR), 2019. https://doi.org/10.1158/1538-7445.sabcs18-p2-09-16.Full Text
-
Crosby, Erika J., Gangjun Lei, Junping Wei, Xiao Yi Yang, Tao Wang, Cong-Xiao Liu, H Kim Lyerly, and Zachary C. Hartman. “Abstract A22: Augmentation of a novel adenoviral vaccine strategy by checkpoint inhibitors.” In Cancer Immunology Research, 6:A22–A22. American Association for Cancer Research (AACR), 2018. https://doi.org/10.1158/2326-6074.tumimm17-a22.Full Text
-
Tsao, Li-Chung, Herbert Kim Lyerly, Zachary Hartman, and Gabriel Deleon. “Abstract B66: Targeted activation of innate immune adaptors MAVS and STING promotes antitumor responses in colorectal cancer models.” In Cancer Immunology Research, 6:B66–B66. American Association for Cancer Research (AACR), 2018. https://doi.org/10.1158/2326-6074.tumimm17-b66.Full Text
-
Stilwell, Jackie L., Amy Hobeida, Ryan T. Birse, Nolan Ericson, Arturo B. Ramirez, Sara Hummel, Darryl Irwin, Eric P. Kaldjian, and H Kim Lyerly. “Detection of mutations in single tumor cells collected by fine needle aspiration in a mouse xenograft breast cancer model using MALDI-TOF.” In Cancer Research, Vol. 78. AMER ASSOC CANCER RESEARCH, 2018.Link to Item
-
Kaneko, Kensuke, Takuya Osada, Timothy A. Haystead, Michael A. Morse, and Herbert K. Lyerly. “Abstract 4709: Induction of enhanced tumor-specific immunity by Hsp90 targeted photodynamic therapy (Hsp90-PDT) combined with immune checkpoint inhibition.” In Cancer Research, 77:4709–4709. American Association for Cancer Research (AACR), 2017. https://doi.org/10.1158/1538-7445.am2017-4709.Full Text
-
Osada, Takuya, Kensuke Kaneko, Zachary Hartman, Amy Hobeika, Philip Hughes, Timothy Haystead, Michael Morse, and H Kim Lyerly. “Abstract 1859: Hsp90 targeted near infrared molecular imaging to detect mammografically occult invasive lobular breast cancer.” In Cancer Research, 77:1859–1859. American Association for Cancer Research (AACR), 2017. https://doi.org/10.1158/1538-7445.am2017-1859.Full Text
-
Crosby, Erika J., Junping Wei, Xiao Yi Yang, Gangjun Lei, Tao Wang, Cong-Xiao Liu, Pankaj Agarwal, H Kim Lyerly, and Zachary C. Hartman. “Abstract A38: Checkpoint blockade elicits unique T cell expansion to promote tumor regression.” In Cancer Immunology Research, 5:A38–A38. American Association for Cancer Research (AACR), 2017. https://doi.org/10.1158/2326-6074.tumimm16-a38.Full Text
-
Kaneko, Kensuke, Takuya Osada, Bruce D. Freimark, and Herbert Kim Lyerly. “Abstract B36: Modulating the tumor microenvironment to enhance cancer immunotherapy by inducing phosphatidylserine expression on the tumor surface.” In Cancer Immunology Research, 5:B36–B36. American Association for Cancer Research (AACR), 2017. https://doi.org/10.1158/2326-6074.tumimm16-b36.Full Text
-
Leon, Gabriel De, Tao Wang, Pankaj Agarwal, H Kim Lyerly, and Zachary Hartman. “Abstract B04: Intralesional vaccination with Ad-MAVS alters the immunosuppressive tumor microenvironment and elicits robust anti-tumor immunity in non-immunogenic cancers.” In Cancer Immunology Research, 5:B04–B04. American Association for Cancer Research (AACR), 2017. https://doi.org/10.1158/2326-6074.tumimm16-b04.Full Text
-
Hartman, Z. C., E. J. Crosby, J. -. P. Wei, X. -. Y. Yang, G. -. J. Lei, T. Wang, C. -. X. Liu, P. Agarwal, M. S. Morse, and H. K. Lyerly. “Abstract P2-04-27: CTLA-4 and PD-1 checkpoint inhibitors enhance individually tailored adaptive anti-tumor immune responses to overcome tumor immunosuppression and effectively treat triple-negative breast cancer.” In Cancer Research, Vol. 77. American Association for Cancer Research (AACR), 2017. https://doi.org/10.1158/1538-7445.sabcs16-p2-04-27.Full Text
-
Song, Qingkun, Jun Ren, Jing Yu, Xiaoli Wang, Xinna Zhou, and Herbert Kim Lyerly. “Abstract 3417: Peripheral CD8+CD28-suppressive T lymphocytes act as a prognosticator among breast cancer patients with adoptive T-cell immunotherapy.” In Cancer Research, 76:3417–3417. American Association for Cancer Research (AACR), 2016. https://doi.org/10.1158/1538-7445.am2016-3417.Full Text
-
Das Roy, L., R. Zhou, L. Dillon, L. J. Moore, R. Puri, J. R. Marks, H. K. Lyerly, and P. Mukherjee. “Abstract P4-09-16: A monoclonal antibody with exceptional specificity across major breast cancer subtypes.” In Cancer Research, Vol. 76. American Association for Cancer Research (AACR), 2016. https://doi.org/10.1158/1538-7445.sabcs15-p4-09-16.Full Text
-
Vaidyanathan, G., D. McDougald, J. Choi, E. Koumarianou, M. Pruszynski, T. Osada, H. Lyerly, T. Lahoutte, and M. R. Zalutsky. “An Anti-HER2 Nanobody Labeled with 18F Using a Residualizing Label for Assessing HER2 Status.” In European Journal of Nuclear Medicine and Molecular Imaging, 42:S102–S102. SPRINGER, 2015.Link to Item
-
Price, Trevor T., Clara H. Lee, Qing Cheng, H Kim Lyerly, William E. Fogler, John L. Magnani, and Dorothy A. Sipkins. “Abstract 3212: Metastatic breast cancer cell communication within a pro-dormancy bone marrow niche.” In Cancer Research, 75:3212–3212. American Association for Cancer Research (AACR), 2015. https://doi.org/10.1158/1538-7445.am2015-3212.Full Text
-
Das Roy, Lopamudra, Ru Zhou, Laura Jeffords Moore, Lloye M. Dillon, Rahul Puri, Kim Lyerly, Jeffrey R. Marks, and Pinku Mukherjee. “Early detection of breast cancer using a unique tumor specific antibody.” In Journal of Clinical Oncology, Vol. 33. AMER SOC CLINICAL ONCOLOGY, 2015.Link to Item
-
Gwin, William Rayford, Amy Hobeika, Takuya Osada, Zachary Hartman, Qing Cheng, Gloria Broadwater, Gretchen Genevieve Kimmick, Kimberly L. Blackwell, Michael Morse, and Kim Lyerly. “Effect of alphavirus vaccine encoding HER2 during concurrent anti-HER2 therapies on induction of oligoclonal T cell and antibody responses against HER2.” In Journal of Clinical Oncology, 33:3081–3081. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.3081.Full Text
-
Burianek, L. E., P. F. Hughes, T. Osada, D. A. Alcorta, A. P. Smith, N. L. Spector, H. K. Lyerly, and T. A. Haystead. “Extracellular Hsp90 is actively trafficked and internalized in aggressive forms of breast cancer.” In Molecular Biology of the Cell, Vol. 26. AMER SOC CELL BIOLOGY, 2015.Link to Item
-
Gabitzsch, Elizabeth Susan, Michael A. Morse, H Kim Lyerly, Joseph Balint, and Frank Jones. “Immunotherapeutic treatment of metastatic colorectal cancer using ETBX-011.” In Journal of Clinical Oncology, 32:3093–3093. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.3093.Full Text
-
Mettu, Niharika B., Joshua M. Uronis, Takuya Osada, Min Lu, Koya Osada, Robert Mook, Wei Chen, et al. “Functional genomic screens and identification of signaling pathways in oxaliplatin-resistance in colorectal cancer.” In Journal of Clinical Oncology, 32:3611–3611. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.3611.Full Text
-
Barrott, Jared J., Aaron P. Smith, Takuya Osada, Nimmi Ramanujam, Michael R. Zalutsky, Kim Lyerly, and Timothy A. J. Haystead. “Abstract C86: Tethered Hsp90 inhibitors carrying optical or radioiodinated probes reveal selective internalization of ectopic Hsp90 in malignant breast tumor cells.” In Molecular Cancer Therapeutics, 12:C86–C86. American Association for Cancer Research (AACR), 2013. https://doi.org/10.1158/1535-7163.targ-13-c86.Full Text
-
Gabitzsch, Elizabeth S., Michael A. Morse, H Kim Lyerly, and Frank Jones. “Abstract LB-164: Treatment of advanced stage colorectal cancer with ETBX-011 immunotherapeutic.” In Cancer Research, Vol. 73. American Association for Cancer Research (AACR), 2013. https://doi.org/10.1158/1538-7445.am2013-lb-164.Full Text
-
Mook, Robert A., Minyong Chen, Jiuyi Lu, Larry S. Barak, H Kim Lyerly, and Wei Chen. “Abstract 5681: Modulation of Wnt/β-catenin signaling by niclosamide and related derivatives.” In Cancer Research, 73:5681–5681. American Association for Cancer Research (AACR), 2013. https://doi.org/10.1158/1538-7445.am2013-5681.Full Text
-
Yu, Jing, Ningning Dong, Ying Yan, Bin Shao, Lijun Di, Guohong Song, Li Che, et al. “Abstract 5298: Two distinctive single nucleotide polymorphisms determine liver metastases responses to docetaxel plus thiotepa for metastatic breast cancer patients.” In Cancer Research, 73:5298–5298. American Association for Cancer Research (AACR), 2013. https://doi.org/10.1158/1538-7445.am2013-5298.Full Text
-
Chen, Minyong, Jiuyi Lu, Jiangbo Wang, Stephen Keir, Min Zhang, Shengli Zhao, Robert Mook, Lawrene Barak, H Kim Lyerly, and Wei Chen. “DEVELOPMENT OF A NOVEL SMALL MOLECULE INHIBITOR OF SMOOTHENED FOR MEDULLOBLASTOMA TREATMENT.” In Neuro Oncology, 15:7–8. OXFORD UNIV PRESS INC, 2013.Link to Item
-
Uronis, Joshua M., Jeffrey Bryan VanDeusen, Michael B. Datto, Joseph Lucas, Michael Morse, Christopher Mantyh, H Kim Lyerly, Bryan M. Clary, and Shiaowen David Hsu. “A molecular profile of colorectal cancer to guide prognosis and therapy after resection of primary or metastatic disease.” In Journal of Clinical Oncology, 31:339–339. American Society of Clinical Oncology (ASCO), 2013. https://doi.org/10.1200/jco.2013.31.4_suppl.339.Full Text
-
Devi, G. R., J. L. Allensworth, S. J. Sauer, M. M. Morse, and H. K. Lyerly. “101 Smac Mimetic Induces Apoptosis and Synergizes with TRAIL in Inflammatory Breast Cancer Cells in an IAP-Dependent and TNF-a-Independent Mechanism.” In European Journal of Cancer, 48:32–32. Elsevier BV, 2012. https://doi.org/10.1016/s0959-8049(12)71899-3.Full Text
-
Gabitzsch, Elizabeth Susan, Michael Morse, Amy Hobeika, Younong Xu, Joseph Balint, Stephanie Balcaitis, H Kim Lyerly, and Frank R. Jones. “Ad5 immunity after multiple safe, homologous immunizations against tumor-associated antigens with new recombinant Ad5 vector.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012. https://doi.org/10.1200/jco.2012.30.30_suppl.85.Full Text Link to Item
-
Hanks, Brent Allen, Alisha Holtzhausen, Petra Gimpel, Rebekah Jamieson, Olivia M. Campbell, Lihong Sun, Christina K. Augustine, et al. “Effect of the loss of the type III TGF beta receptor during tumor progression on tumor microenvironment: Preclinical development of TGF beta inhibition and TGF beta-related biomarkers to enhance immunotherapy efficacy.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.Link to Item
-
Morse, Michael, Amy Hobeika, Arvind Chaudhry, Andrea Amalfitano, Donna Niedzwiecki, Timothy M. Clay, Takuya Osada, et al. “Effect of the vaccine Ad5 [E1-, E2b-]-CEA(6D) on CEA-directed CMI responses in patients with advanced CEA-expressing malignancies in a phase I/II clinical trial.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.Link to Item
-
Lyerly, H. K., A. Hobeika, D. Niedzwiecki, T. Osada, J. Marshall, C. R. Garrett, D. Z. Chang, et al. “A dendritic cell-based vaccine effects on T-cell responses compared with a viral vector vaccine when administered to patients following resection of colorectal metastases in a randomized phase II study.” In Journal of Clinical Oncology, 29:2533–2533. American Society of Clinical Oncology (ASCO), 2011. https://doi.org/10.1200/jco.2011.29.15_suppl.2533.Full Text
-
Morse, M., D. Niedzwiecki, J. Marshall, C. R. Garrett, D. Z. Chang, M. Aklilu, T. S. Crocenzi, et al. “Survival rates among patients vaccinated following resection of colorectal cancer metastases in a phase II randomized study compared with contemporary controls.” In Journal of Clinical Oncology, 29:3557–3557. American Society of Clinical Oncology (ASCO), 2011. https://doi.org/10.1200/jco.2011.29.15_suppl.3557.Full Text
-
Wang, Jiangbo, Robert Mook, H Kim Lyerly, Larry Barak, and Wei Chen. “CANDIDATE HEDGEHOG/SMOOTHENED INHIBITORS FOR PEDIATRIC MEDULLOBLASTOMA.” In Neuro Oncology, 13:I21–I21. OXFORD UNIV PRESS INC, 2011.Link to Item
-
Freedman, J. A., T. Osada, K. A. Tsamis, M. Morse, B. M. Clary, H. K. Lyerly, J. R. Nevins, T. M. Clay, and S. D. Hsu. “Development of an assay to predict oxaliplatin sensitivity from formalin-fixed, paraffin-embedded (FFPE) colorectal cancer tissues.” In Journal of Clinical Oncology, 29:429–429. American Society of Clinical Oncology (ASCO), 2011. https://doi.org/10.1200/jco.2011.29.4_suppl.429.Full Text
-
Lyerly, H. K., Jean Bernard Le Pecq, Zach Hartman, Tim Clay, Alain Delcayre, and Yanal Murad. “Targeting Soluble Tumor Associated Antigens CEA and HER2 to Exosomes Enhances Antigen Specific Immune Reponses.” In Journal of Immunotherapy, 33:879–879. LIPPINCOTT WILLIAMS & WILKINS, 2010.Link to Item
-
Hanks, B. A., J. D. Lee, M. Morse, T. M. Clay, H. K. Lyerly, and G. C. Blobe. “Role of the type III TGF-b receptor in mediating immunosuppression during breast cancer progression.” In Journal of Clinical Oncology, 28:10577–10577. American Society of Clinical Oncology (ASCO), 2010. https://doi.org/10.1200/jco.2010.28.15_suppl.10577.Full Text
-
Morse, M., A. Hobeika, T. Osada, P. Berglund, S. Negri, D. Niedzwiecki, B. Hubby, B. K. Burnett, T. M. Clay, and H. K. Lyerly. “Effect of a novel recombinant alphaviral vector on tolerance to self-antigen in the setting of elevated regulatory T cells.” In Journal of Clinical Oncology, 28:2544–2544. American Society of Clinical Oncology (ASCO), 2010. https://doi.org/10.1200/jco.2010.28.15_suppl.2544.Full Text
-
VanDeusen, J. B., T. Osada, M. Morse, B. M. Clary, H. K. Lyerly, J. R. Nevins, T. M. Clay, P. G. Febbo, and S. D. Hsu. “Use of gene expression signatures to predict in vivo sensitivity of human metastatic colorectal cancer to chemotherapy and to identify novel drug combinations.” In Journal of Clinical Oncology, 28:e14064–e14064. American Society of Clinical Oncology (ASCO), 2010. https://doi.org/10.1200/jco.2010.28.15_suppl.e14064.Full Text
-
Abernethy, A. P., S. Y. Zafar, R. Coeytaux, K. Rowe, J. L. Wheeler, and H. K. Lyerly. “Electronic patient-reported data capture as the foundation of a learning health care system.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.Link to Item
-
Lyerly, H. K., T. Staley, J. E. Herndon, A. Coan, J. L. Wheeler, K. Rowe, B. Horne, and A. P. Abernethy. “Impact of a psychosocial intervention on performance status and coping.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.Link to Item
-
Wang, X., T. Osada, Y. Wang, P. Miyazato, S. Thorne, A. DeLeo, H. K. Lyerly, T. Clay, and S. Ferrone. “Antibody-based immunotherapy: targeting CSPG4 on human basal breast cancer stem cells.” In Cancer Research, 69:314S-315S. AMER ASSOC CANCER RESEARCH, 2009.Link to Item
-
Uronis, H. E., J. E. Herndon, A. Coan, K. Bronson, J. Wheeler, H. K. Lyerly, M. A. Morse, and A. P. Abernethy. “E/Tablets to collect research-quality, patient-reported data.” In Journal of Clinical Oncology, 26:17528–17528. American Society of Clinical Oncology (ASCO), 2008. https://doi.org/10.1200/jco.2008.26.15_suppl.17528.Full Text
-
Clay, T. M., A. Hobeika, T. Osada, D. Serra, D. Niedzwiecki, H. K. Lyerly, and M. A. Morse. “Depletion of human regulatory T cells (Treg) and antigen-specific immune responses to cancer vaccines.” In Journal of Clinical Oncology, Vol. 26, 2008. https://doi.org/10.1200/jco.2008.26.15_suppl.3010.Full Text Link to Item
-
Wang, Jiangbo, Renshui Liu, Michael Bond, Minyong Chen, Simandra Singh, Francis Ali-Osman, Robert J. Lefkowitz, et al. “Targeting hedgehog signaling in medulloblastoma.” In Neuro Oncology, 9:560–61. DUKE UNIV PRESS, 2007.Link to Item
-
Abernethy, A. P., J. Herndon, J. Day, L. Hood, J. Wheeler, M. B. Patwardhan, H. S. Shaw, and H. K. Lyerly. “E-tablets to collect research-quality patient-reported data.” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.Link to Item
-
Baras, Aris I., Ian Cushman, Yiting Cao, Herbert K. Lyerly, Mark Dewhirst, Patrick Casey, and Gayathri R. Devi. “Development of cellular models and small GTPases-targeted therapeutics for inflammatory breast cancer.” In Cancer Research, Vol. 66. AMER ASSOC CANCER RESEARCH, 2006.Link to Item
-
Hobeika, Amy C., Takuya Osada, Teresa Brehm, Xiao Yi Yang, H Kim Lyerly, Michael Morse, and Timothy Clay. “Depletion of regulatory T cells increases the in vivo CEA specific T cell response.” In Cancer Research, Vol. 66. AMER ASSOC CANCER RESEARCH, 2006.Link to Item
-
Osada, Takuya, Heather Labreche, Zachery C. Hartman, Delila Serra, Michael A. Morse, H Kim Lyerly, Andrea Amalfitano, and Timothy M. Clay. “Replication-competent packaging-deficient [E1+, 100k-] adenoviral vector-transduced dendritic cells can efficiently induce antigen-specific immune responses.” In Cancer Research, Vol. 66. AMER ASSOC CANCER RESEARCH, 2006.Link to Item
-
Singh, Simendra, Gamil Antoun, Bartley Adams, Gayathri Devi, Neil Spector, Kim Blackwell, Mark Dewhirst, Herbert K. Lyerly, and Francis Ali-Osman. “Pharmacogenetics, molecular correlates and multiparameter high throughput evaluation of the response of inflamatory breast cancer cells to anticancer agents.” In Cancer Research, Vol. 66. AMER ASSOC CANCER RESEARCH, 2006.Link to Item
-
Morse, M., T. Osada, A. Hobeika, S. Chui, T. Clay, and H. K. Lyerly. “Correlation of clinical outcome with natural killer (NK) response to an anti-cancer, dendritic cell-based vaccine.” In Journal of Clinical Oncology, 23:187S-187S. AMER SOC CLINICAL ONCOLOGY, 2005.Link to Item
-
Disis, M. L., C. dela Rosa, V. Goodell, L. Kuan, J C. C. Chang, K. Kuus-Reichel, T. Clay, et al. “Maximizing the Retention of Antigen Specific Lymphocyte Function after Cryopreservation.” In Journal of Immunotherapy, 27:S40–S40. Ovid Technologies (Wolters Kluwer Health), 2004. https://doi.org/10.1097/00002371-200411000-00145.Full Text
-
Maecker, Holden, James Moon, Sonny Byhatia, Smita Ghanekar, Vernon Maino, Tina Kuus-Reichel, Amanda Summers, et al. “Effect of Cryopreservation on Assays of Antigen-Specific T Cells: Comparison of Tetramer, Cytokine Flow Cytometry, and ELISPOT.” In Journal of Immunotherapy, 27:S42–S42. Ovid Technologies (Wolters Kluwer Health), 2004. https://doi.org/10.1097/00002371-200411000-00153.Full Text
-
Chui, S. Y., M. A. Morse, T. Doldo, T. Osada, T. M. Clay, H. K. Lyerly, S. Khan, A. Gattis, and A. C. Hobeika. “Regulatory and effector T cell subsets and dendritic cells in breast cancer.” In Journal of Clinical Oncology, 22:884S-884S. AMER SOC CLINICAL ONCOLOGY, 2004.Link to Item
-
Kaufman, H. L., R. Dipaola, M. Von Mehren, J. Marshall, H. K. Lyerly, H. Streicher, J. Schlom, D. Panicali, and T. Schuetz. “Safety profile of therapeutic pox virus-based vaccines for cancer.” In Journal of Clinical Oncology, 22:166S-166S. AMER SOC CLINICAL ONCOLOGY, 2004.Link to Item
-
Morse, M., T. Clay, A. Hobeika, T. Osada, D. Panicali, and H. K. Lyerly. “Phase I study of immunization with dendritic cells (DC) modified with recombinant fowlpox encoding carcinoembryonic antigen (CEA) and the triad of costimulatory molecules CD54, CD58, and CD80 (rF-CEA(6D)-TRICOM) in patients with advanced malignancies.” In Journal of Clinical Oncology, 22:165S-165S. AMER SOC CLINICAL ONCOLOGY, 2004.Link to Item
-
Nielsen, K. C., S. M. Steele, R. Pietrobon, M. S. Tucker, S. M. Klein, and H. K. Lyerly. “Thoracic paravertebral blockade for ambulatory breast cancer surgery.” In Breast Cancer Research and Treatment, 88:S135–36. SPRINGER, 2004.Link to Item
-
Lyerly, H. K. “Magnitude and duration of antigen-specific immune response may affect clinical response.” In Cancer Immunology, Immunotherapy, Vol. 52, 2003.
-
Ramakrishna, V., L. Z. He, J. Treml, J. Connolly, X. T. Wang, P. Smith, L. Vitale, et al. “Mannose receptor antibody-mediated antigen presentation by human dendritic cells elicits HLA-restricted antigen-specific anti-tumor immunity.” In Journal of Immunotherapy, 26:S12–S12. LIPPINCOTT WILLIAMS & WILKINS, 2003.Link to Item
-
Osada, T., M. A. Morse, T. M. Clay, A. Shimosaka, and H. K. Lyerly. “Suppression of antigen-specific CTL generation by human NKT cell secretion of TH2 cytokines.” In Faseb Journal, 17:C77–78. FEDERATION AMER SOC EXP BIOL, 2003.Link to Item
-
Venturi, C. B., T. Osada, D. Serraz, Z. Hartman, C. Evelyn, M. A. Morse, T. M. Clay, A. Amalfitano, and H. K. Lyerly. “Comparison of antigen-specific T cell responses induced by transduction of human dendritic cells with E1- and E1-, E2b- adenoviral vectors: Development of adenovirus vectors for DC-based anti-tumor immunotherapy.” In Faseb Journal, 17:C331–C331. FEDERATION AMER SOC EXP BIOL, 2003.Link to Item
-
White, D. C., A. Hamza, K. Nielson, H. K. Lyerly, S. M. Steele, S. K. Pruitt, G. S. Leight, and J. A. Olson. “Thoracic paravertebral blockade for breast sentinel lymph node biopsy: Experience in 137 patients.” In Annals of Surgical Oncology, 9:S56–57. LIPPINCOTT WILLIAMS & WILKINS, 2002.Link to Item
-
Colling, K. L., A. C. Hobeika, P. J. Mosca, T. M. Clay, H. K. Lyerly, and M. A. Morse. “Enumerating functionally mature monocyte-derived dendritic cells for use in cancer immunotherapy.” In Blood, 98:851A-851A. AMER SOC HEMATOLOGY, 2001.Link to Item
-
Hobeika, A. C., S. Peplinski, M. A. Morse, P. J. Mosca, T. C. Clay, and H. K. Lyerly. “Quantitating antigen specific T cell responses in peripheral blood: A comparison of peptide MHC tetramer, ELISpot and intracellular cytokine analysis.” In Blood, 98:23A-23A. AMER SOC HEMATOLOGY, 2001.Link to Item
-
Hobeika, A. C., S. L. Peplinski, T. M. Clay, and H. K. Lyerly. “Quantitating functional CD8+T cell response to viral antigens.” In Faseb Journal, 15:A304–A304. FEDERATION AMER SOC EXP BIOL, 2001.Link to Item
-
Morse, M. A., D. Rizzieri, A. C. Hobeika, N. Chao, and H. Kirn Lyerly. “Dendritic cell (DC) reconstitution after nonmyeloablative allogeneic stem cell transplants.” In Blood, Vol. 96, 2000.
-
Morse, M. A., D. Rizzieri, A. C. Hobeika, N. Chao, and H. K. Lyerly. “Dendritic cell (DC) reconstitution after non-myeloablative allogeneic stem cell transplants.” In Blood, 96:305B-305B. AMER SOC HEMATOLOGY, 2000.Link to Item
-
Mosca, P. J., A. C. Hobeika, T. M. Clay, S. K. Nair, E. K. Thomas, D. A. Caron, H. K. Lyerly, and M. A. Morse. “Multiple signals are required for IL-12 production by Flt-3 ligand mobilized dendritic cells.” In Blood, 96:295A-295A. AMER SOC HEMATOLOGY, 2000.Link to Item
-
Morse, M., S. Nair, M. Fernandez-Castal, D. Caron, A. Proia, and H. K. Lyerly. “FLT3-ligand (FLT3L) mobilization of dendritic cells (DC) in patients with metastatic colon cancer.” In Blood, 94:48A-48A. AMER SOC HEMATOLOGY, 1999.Link to Item
-
Rusconi, C. P., A. Yeh, H. K. Lyerly, J. H. Lawson, and B. A. Sullenger. “RNA aptamers as potential anticoagulants directed against factor VIIa function.” In Thrombosis and Haemostasis, 468–468. F K SCHATTAUER VERLAG GMBH, 1999.Link to Item
-
Clary, B., G. Wheatley, and H. K. Lyerly. “In vivo administration of a suicide gene inhibits tumour progression in breast cancer.” In British Journal of Surgery, 85:1570–1570. BLACKWELL SCIENCE LTD, 1998.Link to Item
-
Gilboa, E., S. K. Nair, M. Morse, D. Boczkowski, Y. Deng, and H. K. Lyerly. “Immunotherapy of cancer with dendritic cell-based tumor vaccines.” In Annals of Oncology, 9:7–7. KLUWER ACADEMIC PUBL, 1998.Link to Item
-
Nair, S. K., M. Morse, D. Boczkowski, H. K. Lyerly, and E. Gilboa. “Cancer immunotherapy with tumor RNA transfected dendritic cell vaccines.” In Journal of Leukocyte Biology, 88–88. FEDERATION AMER SOC EXP BIOL, 1998.Link to Item
-
“Sylvester O'Halloran Surgical Scientific Meeting. March 1997. Abstracts.” In Ir J Med Sci, 167 Suppl 4:1–16, 1998.Link to Item
-
Laughlin, M. J., K. McKinnon, J. Demarest, C. M. Koropchak, K. Weinhold, H. K. Lyerly, E. Gilboa, et al. “Generation of autologous CD4+ T lymphocyte clones specific for precursor-B (pre-B) lymphoblasts via dendritic cell (DC) presentation.” In Blood, 90:826–826. W B SAUNDERS CO, 1997.Link to Item
-
Wheatley, G. H., K. McKinnon, S. Lilly, C. Smith, and H. K. Lyerly. “Adoptive immunotherapy using autologous EBV specific cytotoxic T lymphocytes in an HIV infected patient with refractory Epstein Barr virus expressing B cell lymphoma.” In Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 14:147–147. LIPPINCOTT-RAVEN PUBL, 1997.Link to Item
-
Laughlin, M. J., J. Kurtzberg, K. Weinhold, G. Ferrari, A. Pilgrim, C. Gelber, S. Nair, et al. “Generation of T lymphocyte clones specific for acute lymphoblastic leukemia (ALL) via dendritic cell (DC) presentation.” In Blood, 88:1487–1487. W B SAUNDERS CO, 1996.Link to Item
-
Wheatley, G. H., J. B. Mundorf, R. Philip, and H. K. Lyerly. “Generation of clinically relevant IL-2 cytokine transgene expression in 3 gastrointestinal cancer cell lines using cationic polymer-mediated gene transfer.” In Gastroenterology, 110:A613–A613. W B SAUNDERS CO-ELSEVIER INC, 1996.Link to Item
-
Laughlin, M., J. Kurtzberg, C. A. Smith, H. K. Lyerly, K. Weinhold, L. Martinek, D. Boczkowski, and E. Gilboa. “Liposome-mediated gene-transfection of human precursor-B lymphoblasts.” In Blood, 86:3991–3991. W B SAUNDERS CO, 1995.Link to Item
-
Laughlin, M., J. Kurtzberg, C. A. Smith, H. K. Lyerly, K. Weinhold, L. Martinek, D. Boczkowski, and E. Gilboa. “Gene-transfected leukemia vaccines in acute lymphoblastic leukemia (ALL).” In Blood, 86:16415–16415. W B SAUNDERS CO, 1995.Link to Item
-
Lebkowski, J. S., S. Alters, K. Weinhold, E. Paoletti, W. Cox, J. Tartaglia, D. J. Moody, et al. “Ex vivo generation of antigen specific T cell populations for the treatment of infectious diseases and cancer.” In Blood, 86:1694–1694. W B SAUNDERS CO, 1995.Link to Item
-
Morse, M., L. J. Zhou, T. Tedder, H. K. Lyerly, and C. Smith. “CD83 is a marker for mature dendritic cells (DC) generated from peripheral blood mononuclear cells (PBMC).” In Blood, 86:1279–1279. W B SAUNDERS CO, 1995.Link to Item
-
PHILIP, R., E. BRUNETTE, B. CLARY, L. KILINSKI, D. MURUGESH, M. SORICH, J. YAU, J. LEBKOWSKI, H. K. LYERLY, and M. PHILIP. “GENE MODIFICATION OF PRIMARY TUMOR-CELLS FOR ACTIVE IMMUNOTHERAPY OF HUMAN BREAST AND OVARIAN-CANCER.” In European Journal of Cancer, 31A:77–77. PERGAMON-ELSEVIER SCIENCE LTD, 1995.Link to Item
-
NG, V. L., J. M. DIMAIO, M. H. HURT, C. J. GUNTHEL, H. K. LYERLY, and M. S. MCGRATH. “PATHOGENESIS OF TRANSPLANT-ASSOCIATED B-CELL LYMPHOMAS DIFFERS FROM THOSE ASSOCIATED WITH AIDS.” In Blood, 84:A611–A611. W B SAUNDERS CO, 1994.Link to Item
-
“Sylvester O'Halloran Surgical Scientific Meeting. March 11-12, 1994. Abstracts.” In Ir J Med Sci, 163:517–32, 1994.Link to Item
-
DIMAIO, J. M., A. ISENBERG, P. VANTRIGT, J. W. GAYNOR, R. D. DAVIS, E. COVENEY, B. CLARY, and H. K. LYERLY. “GENERATION OF TUMOR-SPECIFIC CYTOTOXIC T-LYMPHOCYTES FOR THE TREATMENT OF POSTTRANSPLANT LYMPHOMA.” In Circulation, 90:638–638. AMER HEART ASSOC, 1994.Link to Item
-
NABEL, G. J., E. G. NABEL, G. E. PLAUTZ, J. LIU, Z. YANG, C. WOFFENDIN, X. GAO, et al. “DIRECT GENE-TRANSFER AND MOLECULAR INTERVENTIONS FOR AIDS AND CANCER.” In Aids Research and Human Retroviruses, 10:S19–S19. MARY ANN LIEBERT INC PUBL, 1994.Link to Item
-
O’Broin, E., J. Donohoe, K. Mealy, M. Kerin, P. Gillen, W. A. Tanner, F. B. V. Keane, et al. “Seventeenth Sir Peter Freyer memorial lecture and surgical symposium: September 23rd & 24th, 1993.” In Irish Journal of Medical Science, 163:139–67, 1994. https://doi.org/10.1007/BF02967221.Full Text
-
Mealy, K., A. Adeyoju, E. O’Nullain, H. Smyth, F. B. V. Keane, D. Reen, A. Tanner, et al. “Irish society for gastroenterology - Abstracts of Poster Presentations presented at the Irish Society for Gastroenterology, James Connolly Memorial Hospital, Blanchardstown on November 26th and 27th, 1993.” In Irish Journal of Medical Science, 163:37–47, 1994. https://doi.org/10.1007/BF02943012.Full Text
-
MALIM, M. H., W. W. FREIMUTH, J. LIU, T. J. BOYLE, H. K. LYERLY, B. R. CULLEN, and G. J. NABEL. “TRANSDOMINANT REV PROTEIN INHIBITS HIV REPLICATION WITHOUT AFFECTING T-CELL FUNCTION.” In Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 6:669–669. LIPPINCOTT-RAVEN PUBL, 1993.Link to Item
-
NABEL, G. J., E. G. NABEL, G. E. PLAUTZ, J. LIU, Z. YANG, C. WOFFENDIN, X. GAO, et al. “DIRECT GENE-TRANSFER AND MOLECULAR INTERVENTIONS FOR AIDS AND CANCER.” In Journal of Cellular Biochemistry, 185–185. WILEY-LISS, 1993.Link to Item
-
MALIM, M. H., W. W. FREIMUTH, J. LIU, T. J. BOYLE, H. K. LYERLY, B. R. CULLEN, and G. J. NABEL. “TRANSDOMINANT REV PROTEIN INHIBITS HIV REPLICATION WITHOUT AFFECTING T-CELL FUNCTION.” In Clinical Research, 40:A701–A701. SLACK INC, 1992.Link to Item
-
BOYLE, T. J., S. S. HWANG, H. CHEN, M. TAMBURINI, B. R. CULLEN, and H. K. LYERLY. “PH-INDEPENDENT HIV-1 ENTRY INTO MACROPHAGE.” In Aids Research and Human Retroviruses, 8:920–920. MARY ANN LIEBERT INC PUBL, 1992.Link to Item
-
HWANG, S. S., T. J. BOYLE, H. K. LYERLY, and B. R. CULLEN. “THE ENVELOPE V3 LOOP IS THE PRIMARY DETERMINANT OF CELL TROPISM IN HIV-1.” In Aids Research and Human Retroviruses, 8:867–867. MARY ANN LIEBERT INC PUBL, 1992.Link to Item
-
MALIM, M. H., W. W. FREIMUTH, J. LIU, T. J. BOYLE, H. K. LYERLY, B. R. CULLEN, and G. J. NABEL. “TRANSDOMINANT REV PROTEIN INHIBITS HIV REPLICATION WITHOUT AFFECTING T-CELL FUNCTION.” In Clinical Research, 40:A253–A253. SLACK INC, 1992.Link to Item
-
LYERLY, H. K., K. J. WEINHOLD, T. J. MATTHEWS, S. PUTNEY, J. RUSCHE, A. J. LANGLOIS, and D. P. BOLOGNESI. “TYPE SPECIFIC BINDING OF SURFACE EXPRESSED GP120 BY ANTI-GP120 SERUM.” In Journal of Cellular Biochemistry, 73–73. WILEY-LISS, 1987.Link to Item
-
-
- Scholarly, Clinical, & Service Activities
-
Outreach & Engaged Scholarship
Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.
